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ABSTRACT 
SHAN YANG: Development of Peptidase Resistant Reporters for Intracellular Enzymatic 
Activity 
(Under the direction of Nancy L. Allbritton) 
 
There is an increased interest in using peptides with consensus site motifs as 
reporters to assess enzymatic activity in living cells for cancer research.  However, the 
application of these reporters is often challenged by the short lifetimes of these peptides 
due to hydrolysis by peptidases within the cell.  Since the majority of intracellular 
peptidases possess catalytic sites buried deep within a cavity, the linearized peptide can 
access these spaces from the N-terminus and are subsequently degraded.  Here, appending 
a bulky group to the N-terminus of a linear peptide is proposed to overcome this issue.  
This bulky group might block the access of the peptide to sterically hindered peptidase 
catalytic sites and improve the lifetime of peptide within cells.  Previous work 
demonstrated that small folded motifs based on beta hairpins were resistant to peptidases 
in vitro.  These small beta hairpins were termed "protectides" in this work due to their 
ability to resist hydrolysis by peptidases.  Several designs of protectides are presented in 
this work for multiple enzymes.  For Abl kinase, three designs were utilized: two non-
crosslinked beta-bend peptides; two crosslinked beta hairpin peptides; and a FlAsH-
tetracysteine beta hairpin complex.  For Protein Kinase C and the proteasome, a series 
uncrosslinked protectide based on WKWK peptide structures developed by the Waters lab 
were designed and evaluated.  
These protectides are linked to the N-terminus of a kinase substrate peptide via a 
polyethylene glycol (PEG) linker.  Capillary electrophoresis with laser-induced 
fluorescence (CE-LIF) detection was used to quantify peptide breakdown and 
iv 
 
phosphorylation.  The studies also demonstrated that the protectide-peptide constructs 
provided “protection” to the substrate from cytosolic peptidases and they remained 
substrates for the target kinase both in cell lysate and single intact cell assays.  
Additionally, successful development of protectide-peptide constructs to be 
utilized as reporters for other intracellular enzymes was demonstrated.  Substrate reporters 
to measure proteasome activity were designed utilizing the same strategy.  For this 
purpose, it was investigated whether protectide-peptide constructs could be ubiquitinated, 
a critical requirement for recognition by the proteasome.  An S100 lysate was used to test 
the designed reporter’s ability to be ubiquitinated.  It was determined that protectide-
peptide conjugation could be ubiquitinated by S100 lysate assay. 
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Chapter 1: Introduction  
1.1 Protein Kinases in Cancer 
1.1.1 Protein Kinases and Phosphorylation 
A protein kinase is one type of enzyme that helps to transfer phosphoryl group to 
target proteins.  In eukaryotic cells, kinases catalyze the reaction of the addition of the 
phosphoryl group from adenosine-5'-triphosphate (ATP) to a serine, threonine or tyrosine 
residue on substrates.
1-4
  This whole process is known as phosphorylation (Figure 1.1).  In a 
mammalian cell, phosphorylation occurs at some time in almost one third of the proteins.  
Therefore, phosphorylation is one of the most important post-translational modifications.
4-7
 
1.1.2 Phosphorylation in Cell Signal Transduction.  
The importance of phosphorylation in cellular metabolism has been studied for more 
than one hundred years.
8,9
  Over the decades, researchers discovered that protein kinases play 
a key role in regulating biochemical signaling pathways in eukaryotic cells and the signal 
transduction is essential for almost all aspects of cell functions.
10,11
  The signal transduction 
process begins with the binding of extracellular signaling molecules to receptors at the cell 
surface.  These binding actions often induce the activation of kinases.  The organization of 
these activated kinases and their substrates form a phosphorylation cascade.  The 
phosphorylation cascade is involved in controlling the diversity and specificity of signaling
2 
 
pathways in cells and mediating signal transduction.  As a result, phosphorylation cascade 
controls almost all cellular processes including metabolism, cell cycle progression, 
transcription, cytoskeletal rearrangement and cell motility, apoptosis, and differentiation.
11-19
 
The control of signal transduction by phosphorylation occurs by several different 
mechanisms.  First, a change in protein activity can come from the added bulk and charge of 
the phosphate group, or from a conformational change in the protein, or both.
20,21
  For 
example, phosphorylation of a prion protein at serine 43 induces a change of conformation to 
its disease-associated form.22  Second, the change in activity can be caused by the creation of 
a new recognition site in the phosphorylated protein to which another protein can bind.  For 
instance, the phosphorylation-dependent binding of an adaptor molecule, clathrin AP2, to the 
phosphorylated GABAA (γ-aminobutyric acid) receptor regulates the efficiency of synaptic 
transmission.
23
  In general, phosphorylation controls protein activity such as enzymatic 
activity, interaction with other molecules, location in the cell, and propensity for degradation. 
22-26
  By this way, phosphorylation directs cell signal transduction and is deeply involved in 
almost all cellular processes.  
1.1.3 Dysregulation of Kinases in Cancer Cells 
Cancer is a disease known to be characterized by abnormal activities in cellular 
growth, proliferation, and survival pathways.27  Today, cancer represents one of the most 
urgent health challenges.  Cancer is frequently fatal since cell division in cancer is 
uncontrolled. 27-29  Cancer is caused by accumulated genetic mutations yielding a cell with an 
invasve phenotype.  These genetic mutations and amplifications have been found at multiple 
sites in cancer cells and in every type of cancer.  Multiple genetic errors exist in most cancers 
by the time the tumor is clinically apparent.
19,29-32
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To date, approximately 120 known oncogenes which encode for kinases have been 
identified.
33
  In the cell, even a single mutation of a kinase-encoding gene can change the 
expression, conformation, or stability of a kinase.  Since as discussed above, kinases play a 
central role in mediating diverse intracellular signaling pathways, a gene mutation of this sort 
affects the signaling pathway as a whole and can result in the inappropriate regulation of cell 
growth and survival which underlies the cancer phenotype.
30
  For example, the mutated 
oncogenic protein BCR-Abl, which results in the improper activation of the catalytic activity 
of Abelson protein tyrosine kinase (Abl) and leads to the formation of chronic myelogenous 
leukemia (CML) in humans, is a fusion between the Abl kinase and the Breakpoint Cluster 
Region (BCR) protein.
34-36
  In addition, inappropriate kinase activity can also result from 
defects in upstream regulatory proteins.  Many kinases in pathways downstream of activated 
oncogenes are only rarely mutated or overexpressed in tumors, but are critical regulators of 
oncogenic signaling (e.g. protein kinase B (PKB)).37-39 
1.2 Molecularly Targeted Therapy for Cancer (MTTC) 
1.2.1 Molecularly Targeted Therapy 
Molecularly targeted therapy refers to a type of therapy which kills cancer cells by 
interfering with specific molecules involved in tumor growth and progression.
44   
Compared 
to traditional treatments like chemotherapy and radiotherapy, MTTC has been regarded as a 
potential treatment which is more effective and less harmful to normal cells.  Therefore, now 
MTTC is at the forefront of a revolution in cancer therapy.40 
1.2.2 Targeting Protein Kinases for Cancer Therapy 
Because of the fundamental role of kinases in cancer progression, many different 
tyrosine and serine/threonine protein kinases have been selected as candidates for 
4 
 
molecularly targeted therapy in oncology research.  Kinase inhibitors have shown great 
promise in blocking or modulating the activity of select kinases controlling tumor 
progression.  Based on these basic research developments, protein kinases have become a 
very attractive group of drug targets.
41-47
 
Recently, clinical experience with tyrosine kinase inhibitors has demonstrated that the 
inhibition of a dysregulated kinase often brings an effective clinical benefit.  For example, 
imatinib (Gleevec), a molecularly targeted drug inhibiting BCR-Abl, has shown dramatic 
clinical success in treating CML.
48-50
  Such success has initiated extensive efforts to develop 
small molecule inhibitors and monoclonal antibodies against a variety of protein kinases.
49,51-
58
  Since the FDA approved the use of imatinib for CML treatment, six more small-molecule 
kinase inhibitors have been approved.  Currently, multiple therapies targeting receptors for 
tyrosine kinases or intracellular kinases can be found on the market.  As the same time, 
pharmaceutical and biotechnology companies are developing an increasing number of drugs 
targeting kinases and using them in clinical trials for various cancers and other diseases.
40,53-
60
 
Frequently targeted kinases for MTTC include EGFR and VEGFR, both of which are 
transmembrane receptor-kinases.  In the past few years, nuclear and cytoplasmic kinases that 
are dysregulated, overexpressed or located at critical positions in signaling pathways have 
become more attractive and have been pursued as potential new targets of cancer therapy as 
well. 
37,38,61
  Most of the drug developments for these kinases are focused on inhibitors 
including irreversible ATP-binding site competitive inhibitors and monoclonal antibodies.  
This work has opened up new prospects for targeted molecular therapies for cancer patients. 
Thus the measurement of target enzyme activity in primary tumor samples is needed to 
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provide important information for diagnosis and on treatment response.
42 ,43
 
1.3 Challenges in Measurement of Kinase Activity in Clinical Samples 
1.3.1 Requirements for Clinical Measurements 
Because of the above-introduced vast potential clinical benefits of targeting kinases in 
cancer therapies, it is obvious that methods to screen patient samples for the enzymatic 
activity of therapeutic targets would benefit the clinician greatly in diagnosis and treatment.  
However, there are three critical requirements of clinical samples for effective clinical assays.  
First, the assay methods need to provide direct information regarding whether the drug target 
and drug concentration are relevant to treating an individual’s tumor.  Second, the sample 
size from a tumor is usually small (e.g. 5,000 cells in a fine needle aspirate) and within this 
small sample, only a small percentage of these cells are target cells, particularly after therapy 
is performed.  Therefore, it is important that the assay is compatible with very small sample 
sizes, e.g., tens to hundreds, or even single cells.  Third, an ideal method should have the 
ability to monitor the sample heterogeneity since there is tremendous evidence that gene and 
protein alterations have shown significant variability for different patients.39,62-65 Additionally, 
specific abnormal enzyme activity, e.g. cellular drug resistance, in a small number of cells 
may be obscured in bulk assays.  So understanding biochemical heterogeneity is especially 
important in targeting cancer therapy.  This complexity makes it unlikely that any single 
therapy will be effective for all patients.  Therefore, there has been a strong push for the 
individualization of cancer therapy.  This emphasis includes not only the development of 
individual therapeutics targeting critical oncogenic pathways but also identification of 
biologically relevant predictors of treatment response, which allow better selection of 
patients for specific therapies.
66-68
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1.3.2 Limitations of Current Assays 
A number of methods for investigating kinase activity are available, but most of them 
require large numbers of cells, therefore limiting their use in clinical applications.
69
  For 
example, western blotting has been used in clinical trials; however, it provides only a 
qualitative measurement, requires large numbers of cells, and is limited by the availability of 
validated antibodies.
70
  Flow cytometry has been proven powerful for single-cell analysis of 
patient samples, but it also requires large numbers of cells per assay and needs extensive 
optimization to achieve reproducible results.  Flow cytometry is even more limited by 
availability of validated phospho-specific antibodies.
71-73
  Mass spectrometry is another 
powerful tool for analysis of phosphoproteins, but it requires very large numbers of cells and 
is not expected to be applicable in the foreseeable future due to this lack of sensitivity 
70,74
  
Immunohistochemical staining of phospho-proteins in tissue has been used in an analogous 
fashion, but suffers from problems with quantification.
75,76
  Recently, a new technology 
based on isoelectric focusing and chemiluminescence combined with antibody recognition 
may make it possible to generate data equivalent to western blotting from small samples of 
cells, but at present, this method lacks validated targets and has inadequate sensitivity for 
single-cell assays.76,77  Finally, kinase assays based on genetically engineered fluorescent 
protein constructs have been developed, but are not amenable to assays in patient cells.
71
  
Overall, there exists a strong requirement for an assay that measures relevant enzyme activity 
directly and sensitively in primary tumor samples before and after treatment. 
1.4 Microelectrophoretic Techniques for Cellular Kinase Activity Measurements 
1.4.1 Previous Work on Microelectrophoretic Techniques 
  Capillary electrophoresis (CE) was first demonstrated as a powerful separation 
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method by Jorgenson and Lukacs in the 1980s.
78
  CE uses a small internal diameter, fused 
silica capillary filled with an electrolytic buffer. Once the capillary is loaded with sample, 
high voltage is applied across the capillary ends and the components of the sample are 
separated within the capillary based on their different mobilities in an electric field. 
Electroosmotic flow (EOF) arises at the charged capillary wall and works as a mobile “pump” 
to sweep all species in the capillary toward one terminal.  Velocity of migration is 
determined by both the individual sample component’s electrophoretic migration and the 
electroosmotic mobility of the buffer (Figure 1.2). 
CE is a well-established technology for protein and peptide analysis.  This technique 
has been successfully applied to protein and peptide separations in several fields, such as the 
separation of proteolytic fragments and other metabolic products.  Combined with mass 
spectrometry, CE becomes a powerful analytical tool for proteomic studies.
79-81
   More 
recently, this technique has been used to analyze the contents of single cells or small cell 
sample size in the field known as chemical cytometry.  Electrophoretic separation combined 
with laser-induced fluorescence detection (LIF) is one of the most sensitive methods used for 
protein investigation, enabling numerous biochemical studies in single cells.
82-86
  For 
example, by analyzing a fluorescent protein fused to a caspase substrate expressed in cells, 
CE-LIF elucidates caspase activation in apoptosis at the single-cell level.  Fluorescent 
peptides have also been used as reporters to investigate enzymatic activities in vitro.
87-89
  In 
these studies, CE has the capability to separate phosphorylated and non-phosphorylated 
peptide reporters based on the differences in electrophoretic mobilities.  The rate of 
phosphorylation can be calculated and used to assess the activity of the kinase.  This is 
calculated by determining the ratio of the peak areas corresponding to phosphorylated and 
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non-phosphorylated species in an electropherogram.  In addition, CE was also applied to 
successfully separate the degradation products of peptides,
81
 making CE a powerful tool for 
monitoring peptide degradation.
90
 
The Allbritton group has pioneered the development of single-cell assays for 
chemical cytometry and studied new reagents and instrumentation.  To support research on 
signal transduction, particularly kinase assays,
90-97
 a system was developed for single-cell 
assays.  This platform integrates an inverted microscope, a pulsed laser, an LIF detection 
system, and a CE setup to provide several advantages for single cell assays, such as fast cell 
lysis, high sensitivity, the potential for multiplexed measurements of several kinases, and 
monitoring of cells in real-time. 
Chemical cytometry experiments are performed on this instrument as follows:  First, 
cells are loaded with fluorescently labeled substrates, which act as reporters for the activity 
of the target enzymes within the cells.  The substrates can be fluorescent peptides or lipids.  
For protein kinase assays, the substrates contain a serine, threonine or tyrosine residue which 
can be recognized and phosphorylated by target kinases.
96
  After cells were loaded with 
substrates and attached to the sample dish, a nono-second pulsed laser was fired at a position 
close to the cell.  The plasma generated by the laser pulse lysed the cell within tens of micro 
seconds.  Immediately after lysis, the cellular contents were electrokinetically injected into 
the capillary and separated by CE.  The reporters are typically labeled with carboxy 
fluorescein, detected using LIF, and identified by their characteristic migration times.  The 
ratio of the substrate and product peak areas are calculated and used to measure the targeted 
enzymes’ activity.  The ability to load more than one reporter into a cell at the same time 
allows activity measurement of multiple enzymes simultaneously.  Three kinases have been 
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assayed at the same time in single cells so far and substantially greater multiplexing is 
possible due to the very high separation efficiency of micro-electrophoretic methods.
90,92-94,96-
98
 
1.4.2 Cytosolic Degradation as a Limitation of Peptide Reporters for Cell Assays 
Although the peptide reporters have been shown effective, a major pitfall is the 
degradation by intracellular proteases.  This degradation drastically shortens the lifetime of 
the peptides inside the cell, decreasing their utility as reporters.  For example, as the peptide 
reporter degrades, the signals for the phosphorylated and unmodified forms become spread 
out over multiple peaks, making them harder to detect. 
Intracellular proteolysis is a natural process in the cell which controls the turnover of 
proteins and the amount of peptides (antigens) present.  This degradation process typically 
involves the ubiquitin-proteasome system, as well as several aminopeptidases and 
endopeptidases.  In eukaryotic cells, a protein is first degraded by the 26S proteasome into 
oligopeptides that are either the correct size for antigenic peptides or extended on their N-
termini.  Aminopeptidases in the cytosol or ER trim the N-extended precursors into antigenic 
peptides of the correct length.  Proteosome products and other oligopeptides undergo 
degradation by endo- and exopeptidases.  With the effect of the combination of the above 
process, a peptide reporter’s stability within the cell is limited.99-103 
Key cytoplasmic peptidases include tripeptidylpeptidase II (TPPII), thimet 
oligopeptidase (TOP), prolyl oligopeptidase (POP), and leucine aminopeptidase (LAP).  It 
has been found that a common feature of these peptidase structures is a deep cleft or a tunnel 
in which the catalytic site is buried.  Thus, for a peptide to be degraded, it must be threaded 
into a cleft or through a tunnel.  In endopeptidases, such as TOP, the amino terminus of the 
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substrate peptide is buried deep within the cleft.
102,104,105
  This dissertation focuses on 
utilizing this aspect of peptidase structure to slow peptide degradation in cells. 
1.5 Research Goals and Scope of the Dissertation 
1.5.1 Main Goal of This Work 
The overall objective of this research was to develop cytosolic peptidase resistant 
reporters for intracellular kinase activity in a single living cell assay.  This goal is further to 
divided into three sub-goals. First, the designed reporters must have the ability to resist 
cytosolic degradation.  Second, the reporters needed to remain a substrate of the target 
kinase.  Third, the reporters needed to be small and cell membrane permeable.  
1.5.2 Scope of the Dissertation 
This project was completed in collaboration with Dr. Marcey L. Waters’ laboratory.  
In order to prevent degradation of peptide reporters by cytosolic peptidases, it is very 
important to investigate the mechanism by which cytosolic peptidases degrade their 
substrates.  The first step of the work, described in Chapter 2, was a study of the degradation 
mechanisms and structure of cytosolic peptidases.  The unique groove structure of the 
intracellular peptidases guided the novel design of the peptidase resistant reporters using beta 
hairpin “protectides” and linear peptide substrate construction.  Chapter 3 describes the use 
of this strategy to design a series of intracellular BCR-Abl kinase reporters, including the 
details of peptide synthesis, cyclization, purification and mass spectrometry.  The results of 
assays to characterize the reporters both in vitro and in intact cells will be discussed in 
Chapter 4.  During the development and validation of these reporters, a useful assay using 
Pronase E for fast generation of peptide fragments, especially for complicated peptides, was 
developed.  The validation and application of this assay will also be discussed in Chapter 5. 
11 
 
Based on the successful development of peptidase resistant BCR-Abl kinase reporters using 
protectides, protectides were also applied to reporters for protein kinase C and the 
proteasome, as described in Chapters6 and 7.  Assays to validate these reporters will be 
discussed as well. 
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1.6 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  A kinase transfers a phosphoryl group from high-energy donor molecules, 
such as ATP, to specific target molecules (substrate proteins); the process is termed 
phosphorylation. 
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Figure 1.2 Separation of analytes in the capillary by CE. The aqua circles represent the 
negatively charged analytes, the purple circles represent positively charged analytes 
and the white circles represent neutral analytes. 
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Chapter 2: Proposed Design of Peptidase Resistant Reporters Based on the Structural 
Study of Cytosolic Peptidases 
2.1 Introduction 
2.1.1 Intracellular Protein Degradation 
The degradation of reporters by cytosolic peptidases limits the use of peptide 
reporters for the direct measurement of kinase activity in an intact single cell.1,2  In order to 
prevent the degradation of peptide-based reporters in the cytosol, investigating the 
characteristics of intracellular peptidases (i.e. the structure and mechanisms of peptidase 
hydrolysis) is essential. 
In the eukaryotic cell, each protein has a unique rate of degradation under specific 
conditions, a process which is naturally designed for the turnover of normal, unmodified, or 
damaged proteins.  These proteins are degraded to their constituent amino acids, which can 
then be recycled for protein synthesis within the cell.  Since the degradation and synthesis of 
proteins are obviously energy consuming, it is not surprising that all these processes are 
highly regulated within the cell.1-5 
The classification peptidase (proteolytic enzymes or proteases) refers to a large group 
of enzymes that degrade proteins by hydrolyzing the peptide bonds between amino acids in 
proteins or a polypeptide chain.  Chemical reaction of the peptide bond involves making an 
amino acid or water molecule nucleophilic in order to attack the peptide carboxyl group.  
Although the catalytic chemical reaction is essentially the same, different peptidases have 
unique preferences for the various peptide bonds.  These preferences are also highly 
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influenced by the surrounding chemical microenvironment.6 
2.1.2 Classification of Peptidases  
According to the EC system classification, peptidases are members of class 3 
enzymes (the hydrolases) and subclass 3.4 (the peptide hydrolases or peptidases).  This large 
family can be divided into endopeptidases and exopeptidases according to the position at 
which they hydrolyze the peptide chain.  Endopeptidases refer to those peptidases acting 
preferentially in the inner regions of peptide chains, away from the N and C terminus.  
According to the reactive groups at the active site in the catalysis reaction, they can be 
categorized into serine, cysteine, aspartic, and metallo proteinases or endopeptidases.  The 
exopeptidases work only near the N or C terminus of polypeptide chains.  Exopeptidases 
acting at a free N terminus and releasing a single amino acid residue are termed 
aminopeptidases; dipeptide or dipeptidyl- peptidases are those releasing two amino acid 
residues; and tripeptide or tripeptidyl- peptidases are those releasing three amino acid 
residues.  Exopeptidases acting at a free C terminus and liberating a single residue are termed 
carboxypeptidases, and those exopeptidases only liberating dipeptides at C terminus are 
termed peptidyl-dipeptidases.  An additional exopeptidase called omega peptidase removes 
post-translationally modified terminal residues such as substituted, cyclized or linked by 
isopeptide bonds (Figure 2.1).  The carboxypeptidases and endopeptidases are divided into 
sub-classes according to their catalytic mechanisms.  Carboxypeptidases include serine-, 
cysteine- and metallo- type while endopeptidases have the serine-, cysteine-, aspartic- and 
metallo-type (Figure 2.2).6-11 
2.1.3 Cytosolic Peptidases 
The cytoplasm of cells contains only a small number of peptidases.  Among these 
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peptidases are both endopeptidases and exopeptidases.  These endopeptidases are comprised 
of cysteine endopeptidases, serine endopeptidases and metalloendopeptidases.  The cysteine 
endopeptidases include the caspase family.  The serine endopeptidases include the calpain 
family, cathepsins and the prolyl oligopeptidase family.  Finally, the metalloendopeptidase 
include Nardilysin, Thimet oligopeptidase and Neurolysin.  The exopeptidases include 
Tripeptidylpeptidase II and leucine aminopeptidase.12-19  In this work, focus was given to the 
peptidase with less specificity towards peptide degradation.  
2.1.3.1 Prolyl Oligopeptidases (POP) 
A large category of peptidases that hydrolyze after proline residues on proteins and 
peptides have been given much attention recently.  These prolyl peptidases have already been 
found in a broad range of expression forms, tissue distributions, and in various 
compartments.  These peptidases play substantial roles in signal regulation by peptide 
hormones, and have been involved broadly in peptide degradation.20  In cytosol, there are a 
group of prolyl oligopeptidases, also called prolyl endopeptidases, which are a large cytosolic 
prolyl peptidase family that belongs to a class of serine peptidases.  POP hydrolyzes a variety 
of proline-containing peptides by cleaving proline residues and also cleaves alanine residues.  
POP is widely distributed and has been isolated and cloned from many sources, including 
Flavobacterium meningosepticum, porcine brain, and lymphocytes, and has been involved in 
the metabolism of hormonal peptide and neuropeptides. 15,21-23 
2.1.3.2 Thimet Oligopeptidases (TOP) 
Thimet oligopeptidase is one of most important metalloendopeptides related to 
nonspecific degradation in the cytosol.  Metalloendopeptidases represent peptidases 
whichinvolves a metal in catalytic process, in most cases, zinc.8,16  TOP is a metallopeptidase 
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containing zinc that metabolizes a number of bioactive peptides and peptides released from 
the proteasome degradation, therefore limiting antigenic presentation by MHC class I 
molecules.  Studies have shown that TOP is only capable of cleaving 6-17 residues 
peptides.17  TOP is widely distributed in mammalian tissues with the highest expression 
levels in the brain, pituitary gland, and testes.  TOP is present in different subcellular 
locations depending on cell type, with reports of secreted forms found in the cytosol, the 
nucleus, and as a membrane associated protein.4,17,24-26 
2.1.3.3 Leucine Aminopeptidase (LAP) 
The leucine aminopeptidases are cytosolic exopeptidases that catalyze the hydrolysis 
of amino acids from the N terminus of polypeptide chains.  LAPs are widely distributed in 
nature and play crucial roles in several important physiological processes, including protein 
degradation and turnover, protein maturation, metabolism of biologically-active peptides, and 
antigen presentation.  As their name implies, LAPs cleave leucyl substrates, although 
substantial rates of enzymatic cleavage are seen with most amino-terminal amino acids.19,27-30 
2.1.3.4 Tripeptidyl Peptidase II (TPP II). 
In animals, one important intermediate exopeptidase is tripeptidyl peptidase.  It is 
believed to cleave tripeptides from the N termini of longer peptides downstream of the 26S 
proteasome degradation and is implicated in a number of cellular processes. 31,32  This 
aminopeptidase was first identified as a serine peptidase with broad sequence specificity.  In 
addition to exopeptidase activity, TPP II also has endopeptidase activity.  TPP II has been 
implicated in the trimming of proteasomal degradation products for MHC class I antigen 
presentation; unfortunately, the exact role which TPP II plays in antigen processing is still a 
matter of controversy.18,33-36 
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2.1.3.5 Tricone Peptidase (TRI) 
Tricone peptidase is described as the key peptidase of a proteolytic system that is 
unrelated to proteasome activity in cells.  TRI displays a broad collection of multi-catalytic 
activities.37  Studies have shown that TRI can cleave proteins and polypeptides.38  However, 
the rate of cleavage is low in comparison to that of the proteasome.  Furthermore, there is 
evidence showing that the TRI further hydrolyzes oligopeptides generated by the proteasome.  
TRI cleaves the peptide at multiple sites, usually after basic or hydrophobic residues.  Upon 
prolonged exposure to TRI, the majority of degradation products have a size of 3-4 
residues.37,38,39  
2.2 Experimental 
PyMOL was used for the majority of the measurement work and the generation of 
structures presented throughout this chapter, unless otherwise stated.  PyMOL is a powerful 
and comprehensive molecular visualization software package used for rendering and 
animating 3D molecular structures.40  Thus, it can visually investigate and measure the 
distance between any two atoms, thereby giving the precise dimensions of the cavities and 
entrance sizes of the structures of the cytosolic peptidases.  In addition, the software is 
capable of labeling activate sites that are deeply buried in the groove of the peptidases.   
ICM-Pro browser was used to produce images of 3D structures of peptidases as well.  
All structural information was obtained from the Protein Data Bank (PDB), which was also 
used as a 3D investigation database in this chapter.  The PDB archive is a repository of 
atomic coordinates and other information describing proteins and other important biological 
macromolecules.  Structural biologists have used methods such as X-ray crystallography, 
NMR spectroscopy, and cryo-electron microscopy to determine the relative locations of each 
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atom, therefore providing structural information of cytosolic peptidases.41,42 
2.3 Results and Discussion  
In order to understand how hydrolysis occurs, it is necessary to study the structure of 
these proteins, since structure is directly related to function.  Early studies introduced in 
chapter 1 demonstrated that a common feature of peptidase structures is a deep cleft or a 
tunnel in which the catalytic site is buried.16,18  For a peptide to be degraded, it has to be 
threaded into the cleft or tunnel.  Therefore, knowing the entrance size of these degradation 
cavities is critical to the development of degradation resistant peptide reporters.  
Not all structures of cytosolic peptidases are currently available in the PDB data base.  
Here, only available structures of peptidases with broad specificity were investigated and will 
be discussed.  The investigated peptidases include: POP, TOP, LAP, TPPII and TRI.  The 
active site of each peptidase was located and the entrance size of the cavities surrounding the 
active sites was measured.  The results detailing these parameters for each peptidase are 
discussed in the following sections. 
2.3.1 Prolyl Oligopeptidase (POP) Structure 
 Prolyl oligopeptidase is an important cytosolic serine peptidase that is involved in the 
metabolism of peptide hormones and neuropeptides.  Prolyl oligopeptidase sequences from 
different mammalian sources are highly conserved.21  The prolyl oligopeptidase structure has 
a cylindrical shape and contains a catalytic domain and beta propeller domain (Figure 
2.3)(PDB: 1qfm).  The catalytic triad (S554, H680,  A641) of these peptidases is buried in 
the central tunnel whose entrance is covered by an unusual beta propeller domain.  The beta 
propeller domain is based on a 7-fold repeat of four-stranded anti-parallel beta sheets.  The 
sheets are twisted and radially arranged around their central tunnel. Packed face-to-face, this 
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predominantly hydrophobic interaction provides most of the required structural stability and 
causes the narrowing of the tunnel entrance.  The entrance size is about 9 Å and is shown in 
Figure 2.4. This domain causes prolyl oligopeptidases to exclude large structured peptides 
from the active site.  In this way, the propeller protects larger peptide proteins from 
proteolysis in the cytosol. 23 
2.3.2 Thimet Oligopeptidase (TOP) Structure 
 Thimet oligopeptidase is a 77 kDa zinc metalloendopeptidase.  TOP is composed of 
helices and short strands (PDB: 1s4b).  A deep narrow cleft runs the entire length of the 
enzyme body.  It is open at one end but is closed off by helices at the other end.  The deep 
cleft divides the body of the peptidase into two distinct domains, I and II.  The active site of 
TOP contains H473, E474, F475, G476 and H477 sequence motifs that are located at the 
bottom of the cleft, about midway along its length.  The zinc ion is adjacent to the active 
motif, working as co-factor.24  For degradation, peptides must insert into the narrow cleft.  
The entrance of cleft was measured and the size is distributed from 13 -21 Å in width and 
approximately 51 Å in length.  These measurements are shown in Figure 2.5. 
2.3.3 Leucine Aminopeptidase (LAP) Structure 
The LAP is a comma shape hexamer structure (PDB: 1lap).  Each monomer on the 
catalytic site includes two zinc ions and residues KDDDER.  The entrance sizes of the 
degradation clefts of each monomer were measured and are shown in Figure 2.6.  Six active 
sites within the hexamer structure are located in the interior of the hexamer, where they line a 
disk-shaped cavity of radius 15 Å and height 10 Å.  
2.3.4 Tripeptidylpeptidase II (TPPII) structure 
Tripeptidyl peptidase II, a large spindle-shaped complex with a molecular weight of 
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approximately 6 MDa, is the largest known eukaryotic protease.43  Based on the crystal 
structure (PDB: 3xlu.), the TPP II sequence can be divided into three parts.   The first is a 
subtilisin-like domain; the second is a central domain rich in -sheets; and the third is a C-
terminal domain comprising a 12-helix bundle.  The general shape of a monomer is a 
bottomless “bowl” with a handle.43  The active-site residue S462 and catalytic triad are 
located in the “bowl”.  To reach the active sites inside a hollow chamber, substrates can enter 
one of two neighboring entrances through the large openings about 37 Å at either side of 
each of the two close handles and pass through either approximately 16- 24 Å opening 
(Figure 2.7). 
2.3.5 Tricone peptidase (TRI) structure   
The catalytically active complex of TRI is a hexamer of 730 kDa (PDB: 1k32) with a 
very large internal cavity in which the active sites are located.44  The entrance of the cavity is 
covered by propeller domains.  Both the beta 6 propeller for products exiting and the beta 7 
propeller for substrates accessing are connected to the active site of the protein. Structural 
investigation suggests the beta propellers play an important role for substrate access to and 
product exit from the active site.  The opening of beta 6 and beta 7 propeller channels 
represents a gated access to and exit from the catalytic chamber, with the glycines serving as 
hinge residues.  Measured sizes are shown in Figure 2.18. The central pore measured 50 Å in 
diameter at its entrance and 20 Å close to the center of the molecule (Figure 2.8).  
2.4 Conclusion  
These investigations, especially those of the catalytic domain among peptidases, 
clearly show common structural features of these cytosolic peptidases.  Degradation of 
proteins and peptides occur at the catalytic site that is buried in a narrow and deep cavity 
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within the body of proteins. Since it is already known that there are active endopeptidases 
that do not attack proteins, these enzymes must have some mechanisms, as yet not fully 
known, by which they distinguish between large proteins, native or denatured, and 
unstructured peptides consisting of no more than approximately 30 amino acids.  The results 
of the peptidase catalytic cavity entrances are listed in the Table 2.1.  Sizes range from 9 Å to 
50 Å, with most near 20 Å.  These results provide information about how large the blocking 
group should be for preventing peptide insertion into the degradation cavities.  
2.5 Proposed designs of peptidase resistant reporter 
2.5.1 Early generation of the peptide reporters 
To date, the peptide reporters used for enzymatic activity have been designed with a 
fluorescein- labeled N-terminus that is helpful in slowing degradation by amino-terminal 
peptidases.  However, after peptide reporters are loaded into the cells by microinjection or 
via conjugation to the TAT protein transduction domain, degradation can be found if cells are 
damaged during loading or after more than a few minutes of incubation.  Because prolonged 
incubation times are desirable for many applications, peptide breakdown in the presence of 
N- and C-terminal blockage suggests degradation also occurs through the actions of 
endopeptidases, since the typical peptide substrates used to date have been too small for 
degradation by the ubiquitin-proteasome system.  Further investigation will be done by CE-
based studies comparing the peak migration times in cell-based analyses and MS 
spectrometry analysis.  Based on the group’s previous experience, the use of pharmacologic 
inhibitors of peptidases has been met with limited success, partly as a result of the poor 
membrane permeability of many of these reagents and of their toxicity to living cells. 
2.5.2 New strategy for design of reporters 
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The available crystallographic and experimental evidence shows that it is the N-
terminus of the peptide that initially enters into the cavity. 23,24  Yamasaki’s group has 
demonstrated that large N-terminal groups on a peptide can extend the peptide’s lifetime 
when exposed to different proteases.  The peptides, composed of an N-terminal cyclized 10 
amino acid peptide conjugated to C-terminal biologically active linear peptides, were used 
for the degradation assay.  These conjugates displayed an improved stability against 
proteolytic degradation, as well as enhanced biological activity in some cases. The 
conjugated peptides showed up as the majority species even after 4-8 hours, while linearized 
control peptides survived less than 2 hours.45  All these experimental and theoretical 
evidences suggest that the addition of a well-folded N-terminal domain to a linear peptide 
would serve to restrict its access to the peptidase’s catalytic site. 
2.5.3 Beta hairpin structure protectides 
Beta-hairpins are one of the simplest super-secondary structures and the smallest 
isolatable units of a beta-sheet and are widespread in globular proteins.  A beta hairpin is 
defined by four consecutive residues named i, i+1, i+2 and i+3.  A beta hairpin turn includes 
the two most common types: Type 1 and 2 beta hairpins.  The essential difference between 
them is the orientation of the peptide bond between residues at i+1 and i+2.  Glycine is 
always the residue at i+2 for Type 1 and at i+1 for Type 2 turns. Glycine is necessary as any 
other amino acid would cause steric hindrance involving the residue's side chain and the 
main chain. 
Beta hairpins have many features that make them more amenable to biological 
applications than alpha-helical peptides.  The Waters group has been developing well-folded 
beta hairpin peptide structures that show excellent protease resistance.46,47  Therefore, the 
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conjugation of a stably folded beta-hairpin to the N-terminus of a peptide sequence is 
proposed in this work. This structure provides “protection” to that peptide from cytosolic 
peptidases for the reasons discussed above. Therefore, these beta-hairpins are referred to as 
“protectides”. 
There are several advantages of using protectides over other bulky groups to block 
the degradation entrance.  First, since solid phase synthesis of peptides has been well 
established for many years, protectides are easily synthesized using a standard solid phase 
peptide synthesis protocol.  Second, large amounts of work have been completed to develop 
folded peptides, and some have proved well folded and possess good protease resistance 
themselves.  Therefore, it is convenient to append additional amino acid sequences to a 
peptide.  Third, there are limitless possibilities for protectide sequences by fusion of 
nonnative and native amino acids. Fourth, functional groups such as fluorophores or cross-
linked moieties can be easily incorporated with the peptide-based protectide.  Fifth, an 
extensive study was conducted for electrophoretic separations of peptides, thus, CE could be 
a possible technique for characterizing degradation and phosphorylation at the single cell 
level.  Lastly, once the protectide is developed, it can act as an independent unit that can be 
linked to any substrate sequence.  This would greatly simplify the development of kinase 
reporters, since only the substrate sequence needs be optimized for its substrate properties 
(specificity and efficiency).  
2.5.4 General design 
The designed peptide reporters consist of four units (Figure 2.10).  The first 
component is a peptide substrate of the targeting kinase that has a phosphorylation motif and 
possesses a serine/thronine or tyrosine as the phosphoacceptor.  The second portion is a 
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protectide composed of a beta hairpin sequence designed for physically hindering access to 
the peptidase catalytic cleft.  According to the sizes of the entrance cavities shown in Table 
2.1, the main distribution of entrance sizes is about 20 Å.  Protectides were designed at 
different sizes from 10-30 Å.  The different sizes were designed for investigating how 
degradation resistance relates to protectide size.  The third module is a linker to bridge the 
protectide and the substrate peptide as well as to minimize interference for these two parts.  
The final unit is the fluorophore: 6-carboxyfluorescein (6-FAM), enabling detection and 
quantification of the peptides. The design of a new generation of reporters for different 
targets, including BCR- ABl kinase, Protein kinase C and the proteasome, was accomplished 
using this strategy, and more specific details for different reporters will be discussed in the 
following chapters. 
2.5.5 Substrate docking into TOP peptidase 
In order to test the recognition of the peptidase/substrate, a known TOP substrate 
peptide was used as control (ELYEQKPYIL), while Sub-Abl peptide (FAM-
EAIYAAPFAKKK) and one of the designed protectide-abl reporters XBB2 
(K(FAM)KWpGREC (PEG2)2 EAIYAAPFAKKK, cross-linked between the two underlined 
residues) were docked into the TOP degradation pocket by ICM-Pro molecule docking.  The 
substrate ELYEQKPYIL and the Abl peptide docked into the groove within 15 minutes 
(Figure 2.10 A) but the designed reporter XBB2 exhibited difficulty in docking.  The docking 
tests were performed three times and XBB2 only docked into the pocket of the peptidase 
once, after 15 hours (Figure 2.10 B).  The other two tests using XBB2 were run for over 12 
hours, and showed no docking.  These results indicated that the designed protectide cannot 
quickly be recognized by TOP.  In other words, this peptide should not be degraded by TOP 
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as easily as the other two linear peptides.  These result encouraged further experimentation. 
The peptides were made and validated in experiments that will be explained in following 
chapters. 
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2.6 Figures and tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Schematic diagram of peptidases’ hydrolysis position.  Further subdivisions 
of the exoxypeptidases and the endopeptidases have been made on the basis of catalytic 
positions, dark grey ellipses represent amino acid residues and blue ellipses are the 
residues comprising the blocks of one, two, or three terminal amino acids that are 
cleaved off by different peptidases.  The orange hexagons indicate the termini that 
provide substrates for the omega peptidases.  The orange arrows point to the peptide 
bonds which are hydrolyzed by the peptidase. 
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Figure 2.2 Classification of peptidases according to the position at which they hydrolyze 
the peptide chain.  Further categorizations are based on hydrolysis residues. The terms 
are recommended by IUBMB. 
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Figure2.3 The ribbon diagram 3D structure of Prolyl oligopeptidase (POP) (PDB;Iqfm).  
The structure contains a catalytic domain with a large cavity and Beta propeller 
domain in which the degradation entrance is located the center.  The picture was drawn 
with Molsoft ICM-browser (2011 Molsoft LLC.) 
 
 
 
Catalytica domain 
Beta propeller domain 
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Figure 2.4 Close up of degradation entrance of POP in surface model.  The active site 
residues are buried in the tunnel that is covered by the Beta propeller domain and are 
invisible in this case.  The entrance of the catalytic cavity, which is located in the middle 
of the Beta propeller domain, is shown as a yellow solid line in the graph.  The yellow 
dashed lines indicate the diameter measurements (9 Å) of the enzyme and entrance. The 
image and measurements were produced with Pymol 1.1evel.  
 
 
Entrance of catalytic cavity 
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Figure 2.5 Measurement of TOP binding cleft and active site in the surface model. The 
active site residues HEXXH are marked as blue and the entrance of the binding cleft is 
measured and showing in the graphic.  The yellow dashed lines indicate the cleft 
measurements.  The width is approximately 13-21 Å and the length is about 51 Å. The 
graphic and measurements were produced with Pymol 1.1evel. 
 
 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Close up and measurement of LAP monomer binding cleft and active site in 
surface model.  The active site residues are marked as blue and the entrance of binding 
cleft is measured and shown in the graphic.  The yellow dashed lines indicate the cleft 
measurements.  They are 13- 23 Å.  The graphic and measurements were produced with 
Pymol 1.1evel. 
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Figure 2.7 Close up Structure of TPPII in surface model.  The active site residue Ser 462 
is marked as blue.  The yellow dish lines indicate the measurements of the catalytic 
cavity of the enzyme.  The size range is approximately 16-37 Å.  The graphic and 
measurements were produced with Pymol 1.1evel. 
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Figure 2.8 Close up and measurement of TRI central tunnel of biological assembly in 
surface model.  The yellow dashed lines indicate the measurements of tunnel enzyme.  
The central pore measures 50 Å in diameter at its entrance and 25 Å close to the center 
of the molecule.  The graphic and measurements were produced with Pymol 1.1evel. 
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Figure 2.9 General design of protectide-substrate conjugated reporters for kinase 
activity. 
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Figure 2.10 Known TOP substrate peptide ELYEQKPYIL (ball structure in A) and 
XBB2 peptide (ball structure in B) docking to the catalytic cavity of TOP (arrow 
pointed). 
 
A 
B 
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Table 2.1 Dimensions of peptidase catalytic cavities 
 
Peptidase Measurement of active cleft (Å) 
POP  9  
TOP 
Width: 13-25 
Length: ~50 
LAP 
Monomer: 13-24 
Hexamer: 10-15 
TPP II 16-30 
TRI 20-15 
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Chapter 3:Design and Synthesis of Cytosolic Degradation Resistant Reporters for BCR-
ABL Kinase Activity 
3.1 Introduction 
3.1.1 Abl Kinase  
The Abl genes, found in all metazoans, encode cytoplasmic and nuclear protein 
tyrosine kinases, and their structure and function were conserved in early evolution of 
tyrosine kinases.
1,2
  In humans, the c-Abl gene localizes to human chromosome 9.  The c-Abl 
kinase is expressed in two forms, 1a and 1b.   la and lb are different only in their amino-
terminal lengths, which are 26 and 44 amino acids respectively.
3-5
 
The essential feature of c-Abl kinase is its tightly controlled tyrosine kinase activity 
in the cells.  Regulation of c-Abl occurs primarily through auto-inhibition, in which kinase 
function is controlled by intra-molecular interaction among the various domains of the 
protein, such as the catalytic tyrosine kinase, SH3, and SH2 domains and the myristoyl 
group.6-9   Studies have shown that c-Abl has a compact conformation in the inactive 
state.2,3  The SH3 and SH2 units dock onto one side of the catalytic domain and limit its 
conformational flexibility.  The myristoyl group of c-Abl is inserted into the bottom of the 
catalytic domain, which induces a sharp turn in the C-terminal helix of the catalytic domain. 
Also, two additional restrictions keep a compact conformation of the inactive kinase.  One is 
the docking of the SH3 domain into the polyproline helix formed by the SH2-kinase linker.  
The other is a rigid clamp formed by the N-terminal cap.  Studies of the activated kinase 
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howed that all three constraints are removed in the active conformation.10-1314   This result 
revealed that inactive Abl kinase has a closed, compact conformation while the active form 
has an open, elongated one. 
3.1.2 BCR-Abl Kinase 
More than a decade ago, researchers discovered a deletion of the long arm at band q1 
of chromosome 22 in karyotypes of tumor cells from patients diagnosed with chronic 
myelogenous leukemia (CML).15,16  Later, researchers found that this deletion is 
accompanied by breakdown at band q34 of chromosome 9, followed by translocation of the 
Abl gene and fusion to chromosome 22.   This new conjugation of gene, named the 
Philadelphia Chromosome, encodes the BCR-Abl oncogene (Figure 3.1).  This was shown to 
be the primary driver of CML.15  Different BCR–Abl versions can be formed depending on 
how much BCR gene is involved.  So far, three different forms of the Bcr–Abl oncogene 
have been found: p185, p210, and p230.  Each is associated with a different kind of 
leukemia.  p185 is found in 20–30% of acute lymphocytic leukemia (ALL) patients, p210 is 
in 90% of CML patients, and p230 is found in a subset of patients with chronic neutrophilic 
leukemia (CNL). 17-20 
While Abl kinase is tightly regulated in normal cells, the BCR-Abl fusion protein is 
constitutively active. 21  BCR-Abl lacks the N-terminal regulatory cap found in normal Abl 
kinase.  This regulatory cap binds at several regions across the body of the enzyme and 
stabilizes the regulated, inhibited conformation.  Therefore, the common feature for the 
biological effects of the BCR-Abl gene product is its high level of tyrosine kinase activity, 
derived from the catalytic domain in its c-Abl portion.20-23 
3.1.3 Targeting BCR-Abl Kinases in CML 
52 
 
In the early 1990s, realizing that the constitutively activated BCR-Abl kinase had a 
major role in CML,21,24,25 scientists attempted to find drugs that would inhibit the BCR-Abl 
tyrosine kinase activity.21,24,25,28,29   These efforts yielded a phenylaminopyrimidine molecule 
that occupies the ATP binding pocket of the BCR-Abl protein kinase, thereby preventing 
phosphorylation of any substrate.20,26-28   Studies also showed that this molecule was highly 
effective in blocking the tyrosine kinase activity of Abl.29,30  Beginning in 1998, this 
molecule was tested in vast clinical trials for efficacy in treating CML and ALL.  The reports 
of these trials showed the impressive efficacy of the compound, named Gleevec (signal-
transduction inhibitor, STI571 or imatinib).31-34   This molecule, acting as an inhibitor to 
BCR-Abl kinase, can rapidly reverse the clinical and hematologic abnormalities of CML in 
the chronic phase and, in many cases, reduce Philadelphia Chromosome positive cells in the 
bone marrow to low or even zero levels. 35  In 2001, Gleevec was approved by the FDA as 
the first small-molecule kinase inhibitor.  Gleevec has abundant advantages over other 
medical interventions for CML, for example interferon alpha.  It can be administered orally, 
whereas interferon alpha must be injected subcutaneously.30,36-38  Not only does Gleevec have 
fewer unfavorable side effects, but the hematologic responses of Gleevec are more rapid and 
more frequent, and the rate of cytogenetic response is clearly higher than with interferon 
alpha.31.29-34,36-38 
However, Gleevec does have some disadvantages.  Although Gleevec was expected to 
be highly specific for Abl, it has been found to also inhibit the function of two other tyrosine 
kinases: the platelet-derived growth factor receptor and the c-Kit receptor.39  In addition, 
recent work has shown examples of resistance to Gleevec in patients.  There are various 
Gleevec resistance mechanisms that occur.40-43  Because of the clinical implications of these 
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findings, it becomes important to assay kinase activity in clinical samples, and determine 
their sensitivity to Gleevec prior to and during treatment.  
3.1.4 Kinase Reporters for BCR-Abl 
The importance of developing a new cell-based biochemical assay using peptide 
reporters to measure the catalytic activity of oncogenic kinases directly and testing this assay 
in primary cells from cancer patients was discussed in chapter 1.  In this chapter, the peptide 
reporters for the constitutively active kinase BCR-Abl in chronic myelogenous leukemia 
(CML) will be designed. 
3.2 Experimental 
3.2.1 Materials 
All chemical compounds obtained for these procedures were used as shipped with no 
further modification.    All Fmoc-protected amino acids including Fmoc-PEG linker amino 
acid and Fmoc-PAL-PEG-PS resin were bought from EMD biosciences (Darmstadt, 
Germany). (6)-carboxyfluorescein (6-FAM) and Fmoc-Lys (6-FAM) amino acid was 
purchased from Anaspec (Torrence, CA).  Peptide Sub-Abl and TCC (Table 3.1, >75% 
purity) were ordered from Anaspec (Torrence, CA), as well as XBB1, XBB2 (Table 3.1) on 
the resin.  N-hydroxybenzotriazole (HOBT), o-benzotriazole-N,N,N’,N’-tetramethyl- 
uronium-hexafluoro-phosphate (HBTU), N,N-diisopropylethylamine (DIPEA), 
dimethylformamide (DMF), dichloromethane(DCM), dimethyl Sulfoxide (DMSO), tris-HCl, 
bromoacetic acid and diisopropylcarbodiimide for peptide synthesis were purchased from 
Sigma (Carlsbad, CA). Trifluoroacetic acid (TFA), triisopropylsilane(TISP), diethyl ether, 
triethylamine (Et3N), and ethane dithiol (EDT) were from Fisher Scientific (Fair Lawn, 
NJ).   Tris(2-carboxyethyl)phosphine (TCEP), mercaptoethanol (BME), HPLC grade 
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acetonitrile (ACN), methanol (MeOH) and water were purchased from Fisher Scientific as 
well.  FlAsH (Fluorescein Arsenical Hairpin binding) reagent was purchased from Invitrogen 
(Carlsbad, CA). 
3.2.2 Peptide Synthesis  
All synthesis of peptides (Table3.1) was performed on a Creosalus Tetras automated 
peptide synthesizer.  Standard solid phase peptide synthesis (SPPS) protocols were used to 
synthesize all peptides with Fmoc-protected amino acids and Fmoc-PAL-PEG-PS resin (0.07 
mmol scale, 150 mg resin).  The linker Fmoc-(PEG)2-OH (2 e.q) and Fmoc-Lys(6-Fam)-OH 
(2 e.q) were coupled overnight using HOBT/HBTU (4 eq. each) and DIPEA (8 eq.).  The 
peptide Ablnew was deprotected on the N-terminus with 20% piperidine in DMF and 
subsequently labeled with 6-FAM on the free amine of the N-terminus.  Peptides without 
cysteine residues were cleaved and deprotected using a TFA: TIPS: water (95:2.5:2.5) 
mixture to treat resin for 3 hours (Figure 3.2).  The TFA was evaporated by blowing air until 
the peptides were precipitated out.  Then the peptides were spun down in cold diethyl ether.  
All peptides listed inTable 3.1 were dissolved using DI water, and the resulting solution was 
frozen by liquid N2 and lyophilized to produce a yellow solid or powder.  
3.2.3 Cyclization of Peptides  
3.2.3.1 Covalent Crosslinking 
The cyclization reaction was carried out using a modified procedure from a method 
described by Ivanov. 44   First, bromoacetic acid (2 e.q) and diisopropylcarbodiimide (1 e.q) 
were mixed together and reacted at 0 ºC (in an ice and water mixture) for 30 minutes with 
constant stirring, in a glass round bottom flask (Figure 3.3).  The resin with the peptides was 
swelled in DMF for 2-3 hours, and washed by DMF.  Then, a small amount of resin was 
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removed and washed by DCM to dry it, which was followed by a Kaiser test to check for free 
amines.   The result of the Kaiser test was dark blue or purple because the peptides on the 
resin had a free amine at the N- terminus.  Next, DIPEA (4 e.q) and the bromoacetic acid and 
diisopropylcarbodiimide reaction mixture were added to the container with the resin.  When 
the free amine on the peptide’s N‐terminus was bromo‐acetylated, there was no free amine on 
the N-terminus, therefore, no color change was observed in the Kaiser test.  The Kaiser test 
was used for monitoring bromo‐acetylated reaction every 30 minutes till no dark blue or 
purple appeared.  
Next, the peptide-conjugated resin was washed using DMF, Acetic acid and DCM, 3 
times for each, and was shrunk using MeOH.  The peptides were deprotected and cleaved 
using Trifluoroacetic acid (TFA): Triisopropylsilane(TIPS): Water: Ethane dithiol (EDT) 
(95:1.5:2.5:1) with N2 gas on during the entire process.  The cleaving solution was 
evaporated by blowing nitrogen gas until the peptides were isolated, at which time they were 
precipitated out and spun down in cold diethyl ether.  The peptides were dissolved using DI 
water.  The resulting solution was frozen by liquid N2 and lyophilized to produce a yellow 
solid or powder.  The peptides were then redissolved in 10 mL of water with minimal DMSO 
to aid dissolving and 6 equivalents of triethylamine (Et3N) were added for cyclization.  The 
reaction was stirred overnight and lyophilized dry for subsequent purification using HPLC.  
The reaction processes is shown in Figure 3.4. 
3.2.3.2 Tetracysteine-FLAsH Binding 
Making complex for CE analysis, the labeling procedure followed the method 
described previously by Kottegodaet al.(Figure 3.5).45  The FlAsH reagent was dissolved and 
stored in dimethyl sulfoxide (DMSO) with 10X excess EDT.   The final concentration was 
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1μM FlAsH and 10μM EDT.  Tetracysteine motif-containing peptides were dissolved in 
phosphate-buffered saline (PBS, pH 7.2) with TCEP in solution (1 mole of TC-peptide: 25 
moles of TCEP).   The TCEP works as a reducing reagent that was used to prevent oxidation 
of thiol groups in the tetracysteine residues to improve labeling efficiency.  Crosslinking 
reactions (i.e. labeling reactions) were carried out in PBS at pH 7.4.  Peptides containing 
tetracysteine motif were used in 10 to 1000 fold and reacted with the FlAsH-EDT2 reagent 
with incubation for 15 to 30 min at room temperature. The reaction process was monitored 
by CE-LIF to assure complete labeling since the fluorescein emission intensity increased 
dramatically after the peptides were conjugated with FLAsH (Figure 3.6).  The incubation 
period was extended to 90 min to increase yield.  The binding efficiency of the FlAsH 
reagent with the peptide was improved by adding 1 mM BME to the PBS reaction media. 28   
After incubation, the labeled samples were analyzed by CE-LIF in a degradation assay in 
BaF/3 cell lysate.   
To make a preparative-scale tetracysteine motif containing peptides and FlAsH 
complex, another crosslinking method was used.  This method was modified from the 
process described previously by Nathan et al.46  A FlAsH-EDT2 was first diluted in fresh 
TTEE buffer (100 mM Tris-HCl (pH 7.8), 3.5 mM TCEP, 0.1 mM EDT and 1 mM 
EDTA).  This solution was prepared from fresh stock for every reaction. The tetracysteine 
motif containing peptides was diluted in the TTEE buffer as well.   The freshly made solution 
of FlAsH-EDT2 was added to the desired peptides solution.  Final concentrations were 1 mM 
of peptides and 4 mM of FlAsH-EDT2.  Reactions were incubated overnight at room 
temperature and covered by aluminum foil.  After incubation, the labeled samples were 
analyzed and purified by HPLC and MALDI –TOF. 
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3.2.4 Purification 
The peptides were purified using a Waters or Agilent reversed-phase HPLC 
system.  The purification of all peptides was performed using Phenomenex Jupiter 5 µM C18 
300A 250 x 10 mm semiprep column and the various peptides were eluted using optimized 
gradient of standard A (95% water, 5% acetonitrile, 0.1% TFA) and standard B (95% 
acetonitrile, 5% water, 0.1% TFA).   The short peptides were purified using a simple linear 
gradient from 100% standard A to100% B in 30 minutes.  This method was used to purify 
other longer uncrosslinked peptides on reversed phase columns as well.  However, for the 
crosslinked peptides, the purification was more challenging.  Each crosslinked peptide was 
purified by a unique optimized gradient method.  Some peptides were not fully soluble in 
dilute TFA solution, making them difficult to prepare for injection onto an HPLC 
column.  Instead, poorly soluble peptides were dissolved in water with up to 50% 
acetonitrile.  For HPLC analysis, the detection wavelength was 220 nm for peptide bond 
absorption.  Also, fluorescence detection (the excitation was 480 nm and emission was 530 
nm) was used to isolate FAM and FlAsH labeled complexes. 
3.2.5 Mass Spectrometry 
Peptides were analyzed using a Bruker electrospray ionization time of flight mass 
spectrometer (ESI-TOF MS) or Applied Biosystems matrix-assisted laser 
desorption/ionization time of flight mass spectrometer (MALDI-TOF MS) to confirm the 
masses of the peptides. 
3.2.6 Peptide Concentration Determination  
All purified peptides were sent to the University of California, Davis protein analysis 
facility for amino acid analysis.  According to the amino acid analysis results, the moles of 
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peptide in the known volume solutions were determined and the concentrations of the peptide 
solutions were calculated. 
3.3 Results and Discussion  
3.3.1 Components of the Designed BCR-Abl Substrate Reporters 
Using the general design discussed in chapter 2, a series of BCR-Abl kinase substrate 
reporters were designed and synthesized. They are composed of four domains: the substrate 
peptide for Abl kinase, a linker, the beta hairpin-based protectides, and a fluorophore.  
3.3.1.1 Selection of Substrate 
There are a number of peptide substrates for the c-Abl and BCR-Abl kinases that 
have been published (Table 3.1).  These peptides contain favorable amino acids surrounding 
the fixed tyrosine residue which are efficiently phosphorylated by the kinase.  Songyang et 
al. described a number of peptide substrates for Abl/BCR-Abl found by screening a biased 
peptide library that identified a motif providing a predominant substrate motif for the 
kinase.47,48  They published a peptide, EAIYAAPFAKKK, in the table that exhibits an affinity 
(KM) of 64 μM, making this peptide a favorable substrate for Abl or BCR-Abl but a poor 
substrate for Src.  Wu et al. have published a number of substrate peptides for Abl kinase.49  
They showed a shorter peptide “EEIYAEWF” in the table with a better affinity (KM) of 51 
μM while the EAIYAAPF peptide had an affinity of 64 μM.  Both of these peptides also 
showed relatively good Vmax/KM values.  The peptide RRLIEDAIYAARG
50 show the best 
Vmax/KM values, however the KM is much higher than other peptides.  Also, this peptide is 
longer and has negative net charge after label with FAM, and it could be difficult to make 
because if the solubility issue.  Therefore, the peptides EEIYAEWF and EAIYAAPFAKKK 
were chosen as candidates for the design of a reporter substrate. 
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3.3.1.2 Selection of Linker 
A linker was used to join the protectide peptide to the substrate peptide.  The linker 
also permitted the substrate to have flexibility in their relative orientations.   Choosing the 
appropriate type and length of a linker connecting the protectides and substrate peptide is 
challenging.  If the linker is too short, it could hinder the binding of the substrate peptides to 
their catalytic sites.  If the linker is too long, it may inflict an energetic penalty on the ability 
of the whole molecule to bind to the kinase respective.  The linker length should be chosen at 
an appropriate length so that kinase access to the phosphorylatable residue is not sterically 
obstructed by the protectide.   In our work, polyethylene glycol (PEG) was utilized as the 
linker between the substrate and protectide for two main reasons.  First, PEGylated amino 
acids in various lengths are commercially available and covalent linkage to the peptides is 
facile.  Second, the PEG linker is hydrophilic but neutral in charge.  The neutral charge will 
minimize the complexity of the peptide reporters for analysis by capillary zone 
electrophoresis, while hydrophilicity will help for the solubility of the whole molecule.  The 
length of the monomer PEG2 is about 10 Å; two PEG2 were used for the initial design.  
3.3.1.3 Selection of Protectides 
Based on studies, both the turn and strand sequences have been shown to contribute 
to hairpin structure and stability.  The turn sequence is well established to be important for 
beta-hairpin formation.  Each of the peptides was based on the beta hairpin peptide scaffold, 
which contains Glycine (G) and Proline (P) at i+1 and i+2 residues respectively.  The strands 
residues are also crucial to the formation of a stable beta hairpin.  Two elements contribute to 
the role of the strands: the intrinsic beta-sheet propensities of the amino acids in the strands 
and the side chain–side chain interactions across the strands. 51   Different residues that are 
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chosen in the stands can give different folding geometry, which will influence the 
crosslinking yield.  Therefore, in this work, three series of protectides using different beta 
hairpins were designed.51   
D-proline and Glycine were chosen as the turn sequence which leads tightly folded 
structure.  According to the literature, tryptophan can provide more stabilization for the beta 
hairpin structures in the site adjacent to the D-proline than other amino acids.  The first series 
of protectides (series A) includes A1: “K(FAM)pGC”, A2:“K(FAM)WpGRC” and 
A3:“K(FAM)KWpGREC”. There are 4, 6 and 8 amino acid residues in A1, A2 and A3 
respectively.   The underlined residues comprise basic beta turn residues.   
However, if tryptophan is next to lysine that is linked to the FAM on the side chain, 
the fluorescence of the FAM may be quenched by the closed ring structures of 
tryptophan.   Therefore, a second series of protectides were designed (series B), including 
peptides B1: “K(FAM)GpGRC” and B2: “K(FAM)KGpGREC”.   However, the beta hairpin 
structure has a dynamic fold; in order to permanent folding, the crosslinking reaction was 
performed on the beta hairpin structure.  The details of this reaction were discussed in the 
experimental section. 
The other design of beta hairpin structure protectides (series C) C1:  CCPGCC and 
C2: FLNCCPGCCMEP relies on a motif of four cysteines that binds with high affinity to a 
fluorescent dye incorporating two arsenic moieties.  The biarsenical dye FlAsH was used to 
bind the four cysteines, thereby crosslinking the beta hairpin structure and fluorescently 
labeling the peptide at the same time.  Biarsenical dyes were developed by the Tsien group 
for the specific labeling of target peptides or proteins with small fluorescent dyes in 
vivo.52   These designed peptides were synthesized and investigated in different assays to find 
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out the relationship between the resistance of these peptides to degradation by peptidases and 
the folding propensity and how the protectide influences the affinity of the kinase for the 
peptide substrates.     
3.3.1.4 Description of designed BCR-Abl kinase reporters 
A series of peptide reporters with different protectides and substrate peptide 
combinations were synthesized (Table 3.1).  The substrate peptides Abl, Ablmin and Ablnew 
were conjugated to FAM at the N-terminus and work as different control 
peptides.   XBB0new, XBB1new, XBB2new were designed using substrate peptide Ablnew 
and group “A” of protectides.   The UXBB1 and UXBB2 are consisted of Sub-Abl substrate 
peptide and group “A” uncrosslinked protectides.  The XBB1, XBB2 have different 
crosslinked group “A” protectides and substrate peptide Abl.   GlyXBB1 and GlyXBB2 are 
composed of Ablnew substrate peptides and group “B” of protectides.  The peptides TC-abl 
and TCFLN-abl are conjugated to the substrate peptides Abl and group “C” protectides.  
3.3.2 Synthesis, cyclization and purification of the BCR -Abl reporters 
These designed peptides (Table 3.1), including uncrosslinked protectides (dynamic 
folding) and crosslinked protectides (permanent folding), were synthesized for further 
investigation.  First the peptide Ablnew (FAM-EEIYAEWF) was synthesized as a control 
peptide using standard SPPS methods.  Ablnew peptide was found to have low solubility in 
water during the synthesis and purification.  By adding 15% acetonitrile, the peptide could be 
complete dissolved in water and acetonitrile mixture.  The Ablnew has a several hydrophobic 
residues such as A, W, and F.  Often, a peptide with negative net charge and several 
hydrophobic residues may be difficult to dissolve in pure water.  Adding a small amount of 
organic solvent such ACN changed the hydrophobicity of solvent, and therefore the solubility 
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of the peptide was increased.  After purification, the purity of the peptide was greater than 
90% according HPLC and CE analysis results, which is sufficient for future assays.   
In order to test how the stability of the protectide influences the resistance of the 
peptide to hydrolysis by peptidases, the covalent crosslinked reactions were performed on 
designed peptides to achieve permanent fold beta hairpin structure.   The XBB0new, 
XBB1new, XBB2new, GlyXBB1and GlyXBB2 peptides were ordered from Anaspec, which 
were custom-synthesized and shipped on-resin.  The cyclization reactions for all these 
peptides were performed using the protocol described in 3.2.3.   First, all peptides on resin 
were bromo-acetylated on the N-terminus. After this, the peptides were simultaneously 
cleaved from the resin and deprotected.  When peptides were precipitated out from the cold 
ether using water, very little amount of peptides was extracted by the water.   All solutions 
were lyophilized at that time.  However, after lyophilization, the peptides exhibited very poor 
water solubility.  Therefore, DMSO was added to help peptides to dissolve and in order to 
facilitate crosslinking.  After the cyclization reaction, the products were analyzed by RP-
HPLC.  However, the results of HPLC showed that there were many side products.  Since the 
HPLC traces were very complex, the purification was very difficult.  After analyzing the 
products by MALDI, no crosslinked products for XBB0new were found.  We can see from 
the structure (Figure 3.7) that there are only 4 amino acid residues on protectide portion of 
the XBB0new.  The reason of low crosslinking yield is most likely because distance is too 
long between the bromo-acelyated N-terminus and the thiols on side chain of cysteine which 
is located on the other side of turn.   Based on the MALDI result, the cyclyzation of 
XBB1new and XBB2new were successful.  There were 6 and 8 residues on the XBB1new 
and XBB2new protectide portion respectively. The reason of successful crosslinking might 
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be that the bromo-acelyated N-terminus and thiols were close enough to perform the reaction. 
However, low solubility was observed for both peptides.  Up to 50% ACN was added to fully 
dissolve the peptides before HPLC purification.   HPLC results were very complex. The 
purity of the peptides was still less than 60% even after two rounds of purification. The 
HPLC and CE analysis are shown in Figure 3.8 (A) and Figure 3.8 (B). This purity is 
acceptable for initial investigational experiments; however, the purity has to be increased for 
the quantitative characterization assays in the future.  Since low solubility for these peptides 
was found during the experiments, it may lead to difficulties for not only the cyclization but 
also the purification.  Increasing the solubility of the peptide might improve the yield of 
crosslinking and help the purification. 
In order to increase the solubility of the peptide, a lysine residue can be added to the 
peptide to increase polarity of the peptides.   The other substrate peptide for Abl kinase 
“EAIYAAPFAKKK” was chosen as the substrate motif of the reporter because it is not only 
one of the currently known substrates with relatively good affinity (Table 3.1), but is also the 
substrate with three lysines on the C-terminus, which dramatically increases the solubility of 
the peptides.   Then, another series of reporters using Sub-Abl peptide including two 
uncrosslinked reporters (UXBB1 and UXBB2) and four crosslinked reporters (XBB, XBB2, 
TC-abl and TCFLN-abl ) were designed, synthesized and crosslinked. 
For the uncrosslinked reporters UXBB1 and UXBB2, the protectides are not 
crosslinked to the beta hairpin, which remains dynamically folded.  The synthesis was 
performed using the process described in 3.2.3.  The purification was done by RP-
HPLC.   After one round purification, the purity of the peptides was greater than 85% (Figure 
3.9).   The crosslinking reaction of reporters XBB1 and XBB2 were done according the 
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process in 3.2.2 as well.  These two peptides showed a good solubility in water during each 
step of the reaction.  However, according to the HPLC analysis, the products were 
complicated before crosslinking and more complicated after the cyclization.   Normally, 
Fmoc SPPS can give a satisfactory yield if the synthesized peptide is less than 10-15 amino 
acid residues.  There are 20 -22 amino acid residues in the XBB1 and XBB2 peptides, 
including some nonnative amino acid residues. Normally the yield is not very good for 
peptides with over 20 residues. After two rounds of purification, the peptides were analyzed 
by CE-LIF and multiple peaks were seen.  The phosphorylation reaction showed that all 
peptides, including impurities, can be phosphorylated.   In this case, the peptides cannot be 
used for further quantification characterization. Therefore, the new process was used to make 
the XBB1 and XBB2 peptide reporters. After the bromo‐acetylated reaction on the N-
terminus, peptides were purified before crosslinking. Then, the crosslinking reactions were 
performed as described previously.  According to the HPLC analysis results, the yield of 
crosslinking was about 50%.   After HPLC purification, the crosslinked products of XBB1 
and XBB2 had purity greater than 85%, according to CE analysis (Figure 3.10).  
Use of the substrate EAIYAAPFAKKK made the reporter more soluble which 
allowed for the crosslinking reaction to give a better yield.  In the crosslinking reactions, it 
was noted that the solubility of the reporter was dramatically increased when this substrate 
was utilized.  This increased solubility allowed for pre-purification to remove excess 
impurities, which resulted in a final purification step that was much less complicated because 
of the elimination of possible side reactions.  Based on the HPLC results, it was concluded 
that good solubility is an important parameter in reporter selection. 
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 The crosslinking reaction of reporter TCC was done according to the process in 
3.2.2.  The short peptide sequence C-C-X- X-C-C, where amino acid X is a noncysteine 
amino acid, was first recognized binding to FlAsH. Affinities in vitro and detection limits in 
living cells are optimized with X-X = P-G, suggesting that the preferred peptide 
conformation is a hairpin.  The TC-abl peptide is non-fluorescent.  FlAsH is used as a non-
fluorescent complex with ethanedithiol (EDT) and it becomes fluorescent on binding to the 
tetracysteine amino acid sequence in the beta hairpin motif of the TC-abl peptide.  Therefore, 
the beta hairpin of TC-abl was crosslinked and generated fluorescence at the same time by 
this method.  The reaction was performed as described in 3.2.3.2. After a 30 min incubation 
at room temperature the products gave strong fluorescence.  Subsequently, TCC-binding 
sequences were optimized, and in particular, the 12-amino-acid motif FLNCCPGCCMEP52 
was introduced.  These residues surrounding the tetracysteines binding motif display 20-fold 
higher fluorescence quantum yields and improved binding in the presence of dithiols.  Also, 
this structure gave a larger size with more residues.  These characteristics provide a better 
candidate for the protectide.  Therefore, the FLNCCPGCCMEP beta hairpin motif was used 
as a protectide attaching to substrate peptide.  The TCFLN-Abl peptide was crosslinked and 
labeled with FlAsH.  A prep scale TCFLN-Abl- FlAsH complex (TCC-FlAsH) was made as 
descripted in 3.3.2 and purified by RP-HPLC.  According to HPLC analysis results, the yield 
of TCC-FlAsH was over 80% (Figure 3.11).  After purification, all reporters were 
characterized by MALDI or ESI mass spectrometry (Table 3.3).  The expected molecular 
weights of the crosslinked peptides were observed in the mass spectra, indicating that the 
peptides were synthesized correctly.  In order to determine the relationship between 
protectide structure and size and the resistance of degradation to the peptidase, the 3D 
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structure of each peptide was generated using Chemdraw and Chem3D (Figure 3.13 and 3.14) 
and the dimensions of each protectide were measured (Table 3.5).  The size of protectides 
was distributed from 10 – 25 Å and was used for future reference.   
3.4 Conclusion  
A series of beta hairpin-peptide conjugates to be utilized as BCR-Abl kinase reporters 
were designed and synthesized using standard SPPS. Two strategies of crosslinking were 
used for peptides based on different sequences of the betahairpin protectide. The products of 
this crosslinking were characterized by ESI or MALDI, and the proper molecular weight was 
found.   These reporters were purified by RP-HPLC using an ACN: water: TFA gradient, and 
the purities are over 80% for all finalized peptides.   
 
 
. 
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3.5 Figures and Tables  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1Philadelphia translocation.  A piece of chromosome 9 and a piece of 
chromosome 22 break off and trade places. The BCR-Abl gene is formed on 
chromosome 22 where the piece of chromosome 9 attaches. The changed chromosome 
22 is called the Philadelphia chromosome. 
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1: Coupling Fmoc-protected amino acids using HOBt, 
HBTU, and DIPEA (standard protocol) 
2: Deprotecting Fmoc using 20% piperidine in DMF 
3: Adding amino acid one after another by repeating steps A and B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Synthesis of the linear Protectide-PEG-Abl reporters 
 
 
 
(PEG2)2 Abl substrate peptide 
(PEG2)2 Abl substrate peptide 
FAM 
FAM 
4: Synthesizing peptides on 
resin 
5: Cleaving peptide from resin and 
deprotecting amino acid side chains 
using TFA  
6: Purifying peptides by HPLC 
Purified peptides  
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Figure 3.3 Synthesis of the bromoacetic anhydride.  
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Figure 3.5 Covalent cyclization reactions of the reporters 
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Figure 3.5 Labeling reactions of TCFLN-abl and FlAsH.  TCFLN-abl used in excess 
was reacted with the FlAsH-EDT2 and incubated for 30 min at room temperature. The 
FlAsH reagent was dissolved in DMSO and TCFLN-abl in 1 x PBS pH7.4. 
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TCC-FlAsH FlAsH-EDT2 
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Fig. 3.6 CE-based analysis of biarsenical binding to the TC-abl.Shown are 
electropherograms of 3 nM FlAsH (red), 300nMTC-abl (black), and the TC-FlAsH 
complex (blue). Run buffer is composed of 1 mM DTT, 1% SDS, and 0.1 M borate 
buffer, pH8.5. 
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Figure 3.7 Backbone structures of uncrosslinked XBB0new, XBB1new and XBB2new.  
There are different numbers of amino acids in the beta hairpin motif. 
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Figure 3.8 Purified XBB2new peptide (indicated with arrow) is shown in RP-HPLC (A) 
and CE-LIF (B) results.  Other peaks in the electropherogram represent impurities.  
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Figure 3.9 Electropherogram of purified UXBB1 (A) and UXBB2(B).  The purity of 
both peptides is more than 90%. 
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Figure 3.10 Electropherogram of purified XBB1 (A) and XBB2 (B). The purity of both 
peptides is more than 90%. 
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Figure 3.11 HPLC purification trace of TCC-FlAsH complex.  A is the trace with 
fluorescence (excitation: 480 nm and emission: 530 nm) detection and B with 
absorbance (220 nm). 
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Figure 3.12 Backbone structures of Abl, UXBB1 and UXBB2.  The structures include 4 
units: protectides (Red), linker (blue), substrate (black) and FAM (green). Residues 
which can be phosphorylated are marked as pink. 
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Figure 3.13 Backbone structures of XBB1, XBB2 and TCC-FlAsH. The structures 
include 4 units: protectides (Red), linker (blue), substrate (black) and FAM (green).  
Residues which can be phosphorylated are marked as pink. 
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Table 3.1 Partial list of published peptide substrates for BCR-Abl 
 
Substrate KM (µM)* Vmax*pmol/min Vmax/KM* 
EAIYAAPFAKKK
47
 64 0.8 0.013 
EEIYAEWF
49
 51 0.7 0.014 
EEIYDYAY
49
 134 1 0.007 
ERIYARTK
53
 121 5.1 0.04 
KKSRGDYATMZIG
54
 400 2.5X10
3
 6.25 
RRLIEDAIYAARG
50
 670 7.3X10
4
 109 
 
*kinetic values taken from individual papers and should not be directly compared due to the 
different assay conditions utilized. 
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Table 3.2 Designed peptide reporters for BCR-Abl kinase 
 
 
 
Peptides 
Amino acid sequence 
Protectide Linker Substrate 
Sub-Abl   EAIYAAPFAKKK 
UXBB1 K(FAM)WpGR (PEG2)2 EAIYAAPFAKKK 
UXBB2 K(FAM)KWpGRE (PEG2)2 EAIYAAPFAKKK 
XBB1 K(FAM)WpGRC (PEG2)2 EAIYAAPFAKKK 
XBB2 K(FAM)KWpGREC (PEG2)2 EAIYAAPFAKKK 
TCFLN-abl FLNCCPGCCMEP (PEG2)2 EAIYAAPFAKKK 
TC-abl CCPGCC (PEG2)2 EAIYAAPFAKKK 
Ablmin   EAIYAAPF 
Ablnew   EEIYAEWF 
GlyXBB1 K(FAM)GpGRC (PEG2)2 EEIYAEWF 
GlyXBB2 K(FAM)KGpGREC (PEG2)2 EEIYAEWF 
XBB0new K(FAM)pGC (PEG2)2 EEIYAEWF 
XBB1new K(FAM)WpGRC (PEG2)2 EEIYAEWF 
XBB2new K(FAM)KWpGREC (PEG2)2 EEIYAEWF 
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Table 3.3 MALDI results of designed reporters 
 
Peptide Theoretical MW (Da) Detected MW (Da) 
Sub-Abl 1691.5 1692.3 
UXBB1 2723.3 2723.4 
UXBB2 2981.5 2981.4 
XBB1 2866.4 2867.3 
XBB2 3123.5 3124.2 
TCC 3403.4 3401.3 
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Table 3.4   Dimensions of different beta hairpin protectides 
 
Peptide Beta hairpin size (Å) 
Sub-Abl N/A 
UXBB1 10x16 
UXBB2 14x16 
XBB1 14x16 
XBB2 17x22 
TCC-FlAsH 18x25 
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Chapter 4: Characterization of BCR-Abl Kinase Reporters in vitro and in Intact Living 
Cells 
4.1 Introduction 
The design and synthesis of BCR-Abl kinase reporters has been described in Chapter 
3.  The research presented in this chapter is a compilation of experimental observations made 
while investigations were performed to validate these reporters in additional assays.  First, 
the resistance of the peptide reporters to proteolysis was investigated using pure 
endopeptidase POP and a cell lysate assay screen.  Specifically, the role that protectides 
played in degradation resistance was studied by changing the sizes and altering the structures 
via crosslinkages within the protectides.  POP is widely distributed and is the only 
commercially available cytosolic peptidase and was chosen as one method to assess 
degradation.  Cell lysate assays are a convenient method for screening proteolysis resistance 
because they are relatively inexpensive, easily and fast to generate.  Also, in a cell lysate, 
there are not only cytosolic peptidases but also all intracellular proteases.  Furthermore, while 
the activity of peptidases is highly regulated in living cells this regulation is lost in a cell 
lysate when intracellular compartments are lysed in the lysis process.  Thus, a lysate assay 
may be a more stringent test of the reporter’s ability to resist degradation.  After the 
degradation screen, traditional steady-state kinetic analysis was done for the reporters using 
pure commercialized Abl kinase.  The aim of the kinetics analysis was to quantitatively test 
the ability of the reporters to remain as substrates of Abl kinase.  At the conclusion of these 
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screens, the reporters which had the longest lifetime in the cell lysate and remained the 
best substrate for Abl were used to assess BCR-Abl kinase activity in BaF3 cell lysates. 
The aim of this assay was to determine if the reporter could be phosphorylated by BCR-
Abl in an environment that more closely represents that of an intact cell.  In addition to 
investigating in vitro phosphorylation by active kinase in a cell lysate, BCR-Abl activity 
and reporter resistance to degradation in single cells was also probed.  This single-cell 
assay could be valuable in biochemical studies of chronic myelogenous leukemia (CML) 
cells by having the capacity to provide information about BCR-Abl kinase activity.  
These studies may demonstrate the fundamentals for a new paradigm for the direct 
measurement of signal transducing kinase activity in patient cells.  Such assays are 
expected to have applications in cancer research in general, as they could provide greater 
understanding of the abnormal regulation of signal transduction proteins which fuel the 
oncogenic state. 
The main technique utilized for this work was capillary electrophoresis with laser 
induced fluorescence detection (CE-LIF).  The CE method required optimization in order 
to separate unmodified peptides, phosphorylated product, and any degradation fragments 
from one another.  The benefits of CE-LIF for single cell analysis are discussed in more 
detail in Chapter 1. 
4.2 Experimental 
4.2.1 Material 
All materials were used as shipped without further modification. Sodium 
hydroxide solution (NaOH), hydrochloric acid (HCl), sodium chloride (NaCl), 1,1,1-
tris(hydroxymethyl)-methanamine (Tris) and 3-[(3-cholamidopropyl)dimethylammonio] 
90 
 
propanesulfonic acid (Tricine), sodium citrate, sodium dodecyl sulfate (SDS), N-
cyclohexyl-3-aminopropanesulfonic acid (CAPS) and borax were all obtained from 
Sigma (St. Louis, MO).  Fluorescamine, fluorescein free acid (fluorescein) and Oregon 
Green 488 carboxylic acid 6-isomer (Oregon Green) were purchased from Molecular 
Probe (Eugene, OR).  Bovine serum albumin (BSA) and tissue culture materials were 
obtained from Gibco BRL (Gaithersburg, MD).  All other reagents were purchased from 
Fisher Scientific (Pittsburgh, PA).  A  physiologic extracellular buffer (ECB) was 
composed of 135 mM NaCl, 5 mM KCl, 10 mM HEPES, 2 mM MgCl2, and 2 mM CaCl2 
and adjusted to pH 7.4 with NaOH.  Phosphatase inhibitor mixture 1 and phosphatase 
inhibitor mixture 2 and protease inhibitor cocktail were bought from Sigma (St. Louis, 
MO).  Prolyl oligopeptidase (POP) was obtained from Biomol (Farmingdale, NY).  Abl 1 
kinase was obtained from Invitrogen (Carlsbad, CA). 
4.2.2 CE-LIF Setup 
A capillary electrophoresis with laser induced fluorescence detection system (CE-
LIF) was set up as the detection system for the in vitro assay of this project.  There were 
three principle units in this system: an electrophoresis unit, an optical unit and an 
electronic unit.  The detailed set up of each unit is described separately below.  The 
diagram of the CE-LIF system is shown in Figure 4.1 
4.2.2.1 Electrophoresis Setup 
Capillary electrophoresis was performed in an untreated fused silica capillary 
(PolymicroTechnologies, Phoenix, AZ) 40 cm in length.  Capillaries were 50/360 (50 μm 
i.d./360 μm o.d.).  The capillary was housed on a custom-made polycarbonate holder 
machined in the mechanical shop of the University of North Carolina at Chapel Hill.  The 
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holder was 3” x 8” x 1/2” (w x l x h).  A round shaped window was open at the back of 
the holder which faced toward the objective for light emission collection.  A slot 20 mm 
long and 4 mm wide was centered on the top of the holder.  This slot was for exposing 
the detection window of the capillary to the excitation laser beam.  The holder was 
mounted on the “L” shaped stage which was fixed on an X-Y translational stage.  Two 
small holes were drilled on the sides of the holder in order to thread the capillary into the 
holder.  The inlet reservoir and outlet reservoir were mounted on translational stages 
which could move on the metal trail, allowing the two reservoirs to have adjustable 
height.  The levels of electrophoretic buffer in the two reservoirs were the same height 
during CE running.  
During the CE experimental process, the inlet was maintained at ground and the 
outlet was connected to the output of a high voltage power supply.  The high voltage 
power was supplied by high voltage output modules (CZE1000R, Spellman, Plainview, 
NY)  and across two ends of capillary, i.e., between two reservoirs.  Platinum wires were 
used to apply the voltages to two fluid reservoirs (inlet and outlet).  The voltages were 
controlled by a custom program written in Test Point (Measurement Computing 
Corporation, Norton, MA).  A washing system was connected to the outlet reservoir.  The 
N2 gas was connected to the outlet reservoir which was well sealed.  When the N2 was 
turned on, the positive pressure drove the solution from the reservoir into the 
capillary.  This method was a convenient way to use different solutions such as NaOH, 
water and CE running buffer to wash the capillary between each CE separation 
experiment.  This washing proved to be important for reproducibility of CE experiments. 
4.2.2.2 Optical Setup 
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The CE system used laser induced fluorescence detection (LIF).  The optical set up 
in this system included an excitation and an emission unit, which had orthogonal optical 
geometry.  The excitation laser was a diode pumped solid-state laser (BML- 473-
10F0A1FC9, Lasermate Group, Inc, Pomona, CA).  This blue laser consisted of the laser 
head and the AC power supply.  The input voltage was provided by power supply with a 
turnkey switch (90-240 V, AC).  The wavelength of the laser was 473 nm and output 
power was 10 mW.  The custom-made optical fiber was coupled to the laser head with a 
FC connecter (diameter: 9 mm).  The fiber was LPF-04-473-3.5/125-s-9.5-39-3.9AS-40-
3AF-3-2 (Oz Optics, Ottawa, ON, Canada). The fiber had a 3.5 micron fiber core.  The 
laser was aligned through the fiber and focused in 30 microns diameter beam which was 
smaller than the capillary lumen diameter by focusing lens (singlet lens).  This single lens 
was connected at the end of the fiber.  The laser beam output power was adjusted to 2 
mW and focused on the on-column detection window (the region of the capillary with 
polyimide coating removed) perpendicularly.  The “on-column” window was used in a 
lot of CE instruments because of its several advantages including good sensitivity, 
simplicity of setup and low cost.
1
  However, it can cause reflected/scattered light which 
can come from the air/glass interface, glass/buffer interface, curved glass surfaces and 
glass impurities.  Several strategies were used in this work to eliminate these issues.  First, 
visible wavelength fluorophores such as fluorescein or Oregon Green were used for 
detection.  Second, the laser beam was focused to a size smaller than the lumen diameter 
of the focusing lens which helped eliminate side-wall scatter.  Since fluorescence is 
isotropic i.e. emitted in all directions, after the excitation, the emission light (induced 
fluorescence) was collected at a right angle to the excitation light.  This maximized the 
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collection of fluorescent light and minimized background light.  The open space 
excitation pathway included an objective, spatial filter, spectral filters and a detector. 
An objective (40, 0.75 N.A., Plan Fluor, Nikon, Melville, NY) was used to collect 
the emission light.  A band pass filter (535DF50, Omega Optical, Brattleboro, VT) and 
long-pass filters were used as spectral filters.  The band pass filter transmitted ~510-560 
nm, 488 nm and Raman.  This filter had high transmission (>70%) in selected regions.  
However, due to a high intensity of scattering light, spectral filtering alone was 
insufficient for a high S/N.  Therefore an orthogonal optical geometry obscuration bar 
was used as a spatial filter.  The distance between the objective and the lumen was 
carefully chosen so that it could make the tightest scatter line and broadest fluorescent 
spot at the bar. 
The filtered fluorescence light was measured with a photomultiplier tube (PMT, 
R3896, Bridgewater, NJ).  The emission light spot was adjusted aperture of photocathode 
1 which was 8 x 24 mm
2
.  Detection using a PMT provided advantages such as a wide 
dynamic range, high sensitivity and low cost. 
4.2.2.3 Electronic Setup 
After the emission light was collected by the PMT and converted into current, the 
current was amplified and converted to positive voltage with an advanced research 
instrument preamplifier (Model PMT-5, DL Instruments, Dryden, NY).  The preamplifier 
adjusted the voltage to the range of the A/D board.  The preamplifier was placed as close 
as possible to the PMT to minimize the background noise and loss of signal.  This 
prevented noise from being amplified as the signal traveled to the computer.  The signal 
was digitized by a data acquisition board (KPCI-3100 Series, Keithly Metrabyte, Taunton, 
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MA) in a personal computer from Dell.  The Test Point software controlled all 
experimental processes. 
4.2.3 Capillary Electrophoresis 
CE was performed in a 40 cm long fused silica capillary at different voltages 
depending on different buffer systems.  Generally plastic vials served as the inlet and 
outlet reservoirs where the electrodes were inserted.  The CE running buffers were 
different depending on the peptide.  As the fluorescent analytes migrated through the 
capillary the fluorescence was measured 21 cm from the outlet end of the capillary.  After 
each run, the capillary was washed with ~10 column volumes of water, NaOH (0.1 N), 
water and then running buffer.  Despite the wash protocol, the performance of the 
capillary deteriorated over time.  Capillaries lasted anywhere from one day to about one 
month.  This was due to an increasing adsorption of analytes onto the capillary 
walls.  Typical symptoms of capillary fouling were peak broadening, loss of separation, 
irreproducible migration time, and loss of sensitivity.  
For the actual CE separation of peptides, peptide standard samples were prepared 
daily by dilution in CE running buffer.  The standards were injected into the capillary by 
gravity loading.  The volume of the peptide standards loaded into the capillary was 
estimated from Pouiselle’s equation.2   
4.2.4 Cytosolic Peptidase Degradation Assay 
Commercially available POP cytosolic proteases were purchased for the 
degradation assay.  The assay condition was recommended by supplier (Biomol, 
Farmingdale, NY). POP was diluted in the reaction buffer (100 mM Tris-HCl) (pH 7.2) 
containing 0.05% sodium azide and 0.1 mM CaCl2.  Different peptides (5 µM to 60 µM) 
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were incubated individually in the peptidase solution at 37°C. The final concentration of 
peptidase was 3 ng/mL for POP.  Aliquots of the reaction mixtures were removed at 
various time points. The reaction was stopped by heating at 95°C for 4 minutes.  Each 
aliquot was diluted 10-120 times to achieve appropriate concentrations for CE 
analysis.  The sample was analyzed by the PA800 CE–LIF system (Beckman Coulter, 
CA).  The intact peptide was identified by spiking with a standard and comparison of its 
migration time with that of a standard.  Peaks appearing at migration times differing from 
the intact peptide were identified as degradation products.  The percentage of non-
degraded peptides at each time point was determined from the ratio of the peak area of 
the intact peptide to that of the sum of all peaks. 
4.2.5 Cell Lysate Degradation Assay 
4.2.5.1 Cell Culture and Cell Lysate Preparation 
BaF3 BCR-Abl positive cells were used for all experiments.  The cell culture was 
maintained at 37ºC and 5% CO2 in RPMI 1640 1X medium (Gibco BRL, Gaithersburg, 
MD) supplemented with 10% (v/v) FBS and 100 g/mL penicillin.  The cells were grown 
in 25 mL polystyrene culture flasks (Nalge Nunc International, Rochester, NY) to 
densities of approximately 1x10
6
/mL before passage. 
To prepare a BaF3 cell lysate for the cell lysate degradation assay, two 25 mL 
flasks of cells were collected and spun down at 0.8 x g for 2 minutes.  The supernatant 
was removed and the cell pellet was resuspended with 10 mL of ice-cold ECB.  This 
process was repeated 3-4 times by pelleting and resuspending with ECB.  The final cell 
pellets was resuspended in 200 µL of ECB buffer and was frozen in liquid N2 and 
defrosted in a 37 º C water baths.  By this quick freeze/thaw method, cells were lysed.
3
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The whole process was monitored by microscopy to confirm the breakdown of the cell 
membrane. Then, the mixture was centrifuged at 4
o
C for 5 minutes at 0.8 x g and the 
supernatant was aliquoted and put on ice for further use. 
4.2.5.2 Measuring Protein Concentration 
Bovine serum albumin (BSA) stock solution was made at 1 mg/mL in 1X 
phosphate buffered saline (PBS) buffer.  Fluorescamine was dissolved in acetone (HPLC 
grade) at 3 mg/mL.  According to the literature, when fluorescamine reacts with free 
amines on proteins it becomes fluorescent.  At protein concentrations below 500 mg/mL, 
the intensity of fluorescence is proportional to concentration.
4
 
A BSA standard calibration curve was made as follows: the BSA solution was 
diluted into concentrations ranging from 0 to 500 mg/mL from the stock solution.  30 µL 
of each solution at different concentrations was added to a 96 well microplate (Molecular 
Devices, CA) along with 10 µL of fluorecamine/acetone solution to each of the vials and 
was incubated for 5 minutes.  After incubation, fluorescence intensity was read from the 
top of the plate using a Molecular Devices Spectramax M5 reader.  The endpoint 
excitation was 390 nm and emission was 475 nm and the cutoff was 450 nm.  A 
calibration curve was created by plotting of the fluorescence intensity against the 
concentration of BSA and linear regression analysis was performed.  
Then cell lysate, which was prepared as described in 4.2.5.1, was diluted 100 
times.  30 µl of lysate solution and 10 µL of fluorescamine solution in acetone were 
added to the microplate and incubated for 5 minutes.  The fluorescence intensity of this 
solution was determined and recorded and the concentration of protein in the cell lysate 
was calculated using the BSA standard calibration curve. 
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4.2.5.3 Cell Lysate Degradation Assay 
A series of experiments was performed in triplicate in order to assess the degradation 
of protectide-linked kinase (Table 1).  A lysate of BaF3 cells were prepared as described 
above.  2 μM of each peptide was incubated individually in the previously described 
lysate at 37°C in ECB buffer.  Aliquots of the reaction mixture were removed at various 
time points.  The reaction was stopped by the addition of 200 mM HCl and heating at 
95°C for 4 minutes.  Each aliquot was diluted 20-50 times to achieve appropriate 
concentration for CE analysis.  Each sample was analyzed by the CE-LIF system.  The 
intact peptide was identified by spiking with a standard and comparison of its migration 
time with that of a standard.  Peaks appearing at migration times that differed from the 
intact peptide were identified as degradation products.  The percentage of non-degraded 
peptides at each time point was determined from the ratio of the peak area of the intact 
peptide to that of the sum of all peaks. Therefore the lifetime of each peptide was defined 
in the cell lysate before it was completely degraded. 
4.2.6 Abl Kinase Assay 
Abl1 kinase 10 µg was diluted and aliquoted into 100 ng/µL and stored in -20
o
C 
for the future use.  An Abl kinase assay was used for making the phosphorylated reporter 
standard.  The kinase assay was performed at 30°C in an assay buffer of 50 mM Tris, 5 
mM MgCl2, 2 mM DTT, 1 mM ATP.  The final concentration of each reporter was 30 
µM.  The 200 ng Abl1 kinase was used for each reaction.  The reaction process was 
monitored by CE and the assay was performed until peptide was phosphorylated 
completely.  The reaction mixtures were incubated at 95°C for 4 minutes to stop reaction.   
The molecular weight of each peptide was determined by MALDI to confirm reporter  
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phosphorylation. 
4.2.7 Kinetic Properties of the Designed Reporters for Abl Kinase  
4.2.7.1 in vitro Kinase Assay 
The kinase assay was performed at 30°C in assay buffer of 50 mM Tris, 5 mM 
MgCl2, 2 mM DTT, and 1 mM ATP.  The kinase was used 0.5 ng for each assay.  The 
kinase assay was performed at 5, 10, 20, 30, 45, and 60 µM concentrations of each 
peptide.  The total volume was 40 µL and 10 µL of the mixture was taken out at time 
points 5, 10, 15 and 20 minutes and the reaction mixtures were incubated at 95
o
C for 4 
minutes to stop the reactions. 
4.2.7.2 Phosphorylation Measured by IMAP 
The Immobilized Metal Ion Affinity-Based Fluorescence Polarization (IMAP) 
assay kit (Molecular Devices, Sunnyvale, CA) was used to measure the amount of 
phosphorylated peptide in each reaction mixture.
5
 The method was modified based on the 
protocols from supplier.  
A calibration curve of percentage phosphorylation was created by measuring the 
anisotropy of solutions with known ratios of phosphorylated to nonphosphorylated.  The 
standards of 100% phosphorylated peptides were prepared using Abl1 kinase with the 
condition mentioned above and the phosphorylation percentage was verified by capillary 
electrophoresis. The samples were diluted in to a final concentration of 100 nM using 
working buffer (10 mM Tris-HCl, 10 mM MgCl2, 0.01% Tween 20).    
After incubated with the metal nanoparticle solution, anisotropy was measured 
using a fluorescence plate reader (SpectraMax M5, Molecular Devices) with an excitation 
of 485 nm (bandwidth of 9 nm) and emission of 530 nm (bandwidth of 15 nm). 
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4.2.8 Cell Lysate Kinase Assay 
4.2.8.1 Cell Lysate Preparation for Kinase Assay 
BaF3 cells were cultured and passed in the same way as described in 4.2.4.1.  The 
medium was removed prior to lysis by washing the cells three times with 10 ml of ice-
cold PBS.  The cells were then resuspended in Mammalian Protein Extraction Reagent 
from Thermo Fisher Scientific (Waltham, MA) containing 1:100 dilution of phosphatase 
and protease inhibitor cocktail from Thermo Fisher Scientific (Waltham, MA).  The 
excess membranes were separated from the lysate by centrifugation at 14,000 x g at 4 °C 
for 10 min, and the concentration of protein in the supernatant was determined using the 
BSA-fluorescamine calibration curve.  A 1:100 dilution of the cell lysate was labeled 
with fluorescamine.  After 5 minute incubation, the fluorescence intensity (excitation, 
390 nm; emission, 475) was monitored with the fluorescence plate reader. 
A mammalian cell lysis buffer from Thermo Fisher Scientific (Rockford, IL) was 
used to lyse the cells.  Normally 2-3 million cells were washed 3-4 times with PBS buffer 
and 450 µL of lysis buffer and 50 µl of protease and phosphatase inhibitors cocktails 
were added.  The lysates were clarified by centrifugation at 4 °C for 10 min at 14,000 x g.  
The supernatant was obtained and the protein concentration of the supernatant was 
determined by the protein-fluorescamine method described in 4.2.5.2. 
4.2.8.2Abl Peptide Reporters Assay 
BaF3 cells were cultured and passed same as described in 4.2.4.1.  Then medium 
was removed prior to lysis by washing the cells three times with 10 ml of ice-cold 
PBS.  The cells were resuspended in a cell lysis buffer (Thermo Fisher Scientific, MA) 
and diluted 10 times in a phosphatase inhibitor and protease inhibitor cocktail.  The 
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lysates were clarified by centrifugation at 4 °C for 10 min at 14,000 x G, and the 
concentration of the supernatant was determined using the BSA-Fluorescamine 
calibration curve described as in 4.2.5.2. 
Then the cell lysate kinase assay was performed using selected reporters including 
Abl, XBB2 and TCC.  The kinase assay was performed at 30°C in assay buffer of 50 mM 
Tris, 5 mM MgCl2, 2 mM DTT, 1mM ATP.  The cell lysate protein concentration was 3 
mg/ mL for each reaction.  The final concentration of peptides was 10 µM.  The reactions 
were stopped at time points 10, 20, 30, 45 and 60 minutes.  The reaction mixtures were 
incubated at 95
o
C for 4 minutes to stop reaction.  Then each reaction was diluted 20x and 
tested by CE-LIF. 
4.2.9 Loading Peptide into Living Cells (BaF3) 
4.2.9.1 Light and Fluorescence Microscopy 
The cells were examined with bright field and fluorescence microscopy before 
and after loading dye or reporters into the cells.  Microscopy was performed with using a 
Nikon Eclipse TE2000-U.  Cell fluorescence was observed by excitation with an Arc 
lamp.  The emission light was filtered through a Semrock Brightline GFP-3035B-NTE 
filter (Rochester, NY).  During the experiment, the cell chamber was placed on the stage 
of a Nikon Eclipse microscope and cells were observed using a CoolSNAP video camera 
that was mounted onto the side of the microscope. 
4.2.9.2 Pinocytic Loading 
The pinocytic loading method was modified from a procedure provided by 
Molecular Probe (Carlsbad, CA).  A kit from Molecular Probe was used for the pinocytic 
loading experiment. 30 μL of the hypertonic loading medium containing the compound to 
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be loaded, 3 mL of the hypotonic lysis medium and 2 mL of the recovery medium were 
pre-warmed to 37°C.  HeLa cells were cultured on the glass bottom of the cell chamber 
first.  The dye or peptide reporters were mixed with hypertonic loading medium.  The 
final concentration of the dye or peptide reporters was 20 µM in the hypertonic loading 
medium. Before the loading experiment, cells attached on the glassed were washed by the 
pre-warmed medium and the cell culture medium was removed as much as possible to 
minimize dilution of the hypertonic loading medium. 
BaF3 cells were suspended in a 1 mL volume of fresh medium so that the cell 
density was not higher than 1 × 10
6
 cells/mL.  The cell suspension was transferred to a 
sterile 1.5 mL microfuge tube.  The cells were pelleted by centrifugation in a microfuge 
for 1 minute at 2000 x g.  The supernatant solution was removed carefully.  The 
supernatant solution was removed as much as possible to minimize dilution of the 
hypertonic loading medium.  Hypertonic loading medium was pre-warmed before the 
loading experiment.  Hypertonic loading medium contained the dye Oregon Green from 
Invitrogen.  The cells were resuspended and incubated at 37°C for 10 minutes.  1 mL of 
the hypotonic lysis medium was added to the cell suspension right after incubation and 
the solution was transferred to a separate 5 mL tube containing 2 mL of hypotonic lysis 
medium.  The cell suspension was incubated for 1.5 minutes at 37°C and divided into two 
1.5 mL microfuge tubes.  The cells were pelleted by centrifugation in a microfuge for 1 
minute at 2000 x g.  The supernatant was removed.  At least 1 mL of the recovery 
medium was added to each microfuge tube and the cells were resuspended.  The cells 
were allowed to recover for at least 10 minutes before observation and plating onto fresh 
coverslips for future examination. 
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4.2.9.3 Microinjection 
BaF3 cells were maintained as described in 4.2.1.  Before the experiment, 
homemade cell chambers were made using a grid glass slide (Eppendorf, NY) and PDMS 
ring which was suitable for both the microinjector and the microscope platform.  The 
glass was cleaned by washing with water and plasma treatment.  The glass bottom of the 
cell chambers was coated with the Cell TAK (BD bioscience, MA) before loading the 
cells. 
After the cells were loaded into the chamber, they were incubated 20 minutes to 
permit adhesion to the glass surface.  After the cells were fully attached, cells were 
microinjected using a commercial microinjection system (Transjector 5246, Eppendorf, 
NY).  The concentrations of the peptide substrates tested ranged from 1 to 500 µM.  After 
microinjection, the cell chamber was put into the incubator (37
o
C) for 5-60 
minutes.  Immediately before the start of the CE experiments, the medium in the cell 
chamber was exchanged for ECB buffer which was pre-warmed to 37
o
C. The 
experiments were conducted in the ECB buffer which was pre-warmed at 37
o
C for 
washing and surrounding the cells.  
4.2.10 Single cell Assay 
4.2.10.1 Experimental Setup 
The peptides used for each experiment either were synthesized by Anaspec Inc 
(CA) or in the lab using standard Fmoc-solid phase peptide synthesis (SPPS).  Phospho-
peptides used for standards were phosphorylated in vitro with the Abl1 kinase and the 
characterized by MALDI.  N-terminally labeled fluorescent peptides were prepared as 
described in chapter 3.  All single cell experiments were performed using a custom-built 
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CE-LIF system for single cell analysis. The capillary inlet was mounted perpendicularly 
to the cell chamber on a micromanipulator (World Precision Instruments, Sarasota, 
FL).  The micromanipulator enabled precise positioning of the capillary lumen over the 
cell selected for analysis.  
4.2.10.2 Single Cell Experiments 
The microscopy system used for single cell experiments was similar to that 
described in chapter 1.   A frequency-doubled Q-switched Nd:YAG laser (Surelite I, 
Continuum, Santa Clara, CA) was used to generate a single laser pulse (10-100 µJ, 5-ns 
pulse width, 532 nm) directed into the microscope (Nikon). The pulse was focused with a 
microscope objective within the cover slip adjacent to its interface with the buffer.  The 
cell to be lysed was positioned 20-30 nm away from to the focal point of the laser pulse 
so that no direct interaction of the laser beam with the cell occurred.  A CCD video 
camera system (ZVS-47E, Optronics Engineering, Goleta, CA) recorded the real-time 
bright-field image of the cell.  Briefly, the single cell analysis experiment was performed 
as follow.  First, cells were microinjected with Sub-Abl peptide.  After 0 to 30 minutes of 
loading reporter into the cell with incubation at 37
o
C, the cell was washed 10x using pre-
warmed ECB buffer and then lysed within 10 μs by a focused 5 ns laser pulse.  Right 
after lysis, the cellular contents were immediately electrokinetically injected into the 
capillary located above and separated by CE. 
CE was performed in a 43-cm-long fused-silica capillary. The cell chamber 
served as the inlet reservoir and was maintained at ground.  The CE running buffer was 
Tris/tricine (100 mM), EOTrol
TM
 (Targetdiscovery, CA) HR (5%).  Physiological buffer 
surrounded the cell.  The fluorescence of the analyte bands migrating through the 
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capillary was measured 19.5 cm from the outlet end of the capillary.  After each run the 
capillary was washed with ~10 column volumes of water, NaOH (0.1 N), water and then 
the running buffer. Peptide standards were prepared by preparing fresh dilutions of 
known concentration in CE running buffer each day. To estimate the intracellular 
concentration of peptide, the fluorescent peak area from the cell was compared to that of 
standards. 1 pL cell volume and 100% peptide recovery were assumed. 
4.3 Results and Discussion 
4.3.1 CE-LIF Instrument Optimization 
A custom-made CE-LIF system was built and used for separation and detection of 
reporter peptides.  Prior to running experimental samples, performance of the CE-LIF 
instrument was adjusted and checked.  Reproducibility of this instrument was verified to 
ensure proper system set up and optimal performance.  The limit of detection (LOD) was 
tested in order to ensure the desired sensitivity could be achieved.  Even though this 
specific CE-LIF system was not designed for single cell studies, it was important that it 
be equally sensitive for ease of comparison to single cell work.  Therefore, the required 
LOD was at least 10
-18
-10
-19
 moles.  Known concentrations of fluorescein were prepared, 
hydrodynamically injected into the capillary and run on the CE with a 100 mM 
Tris/Tricine buffer, pH 8.2.  Approximately 1 nL of a 2x10
-10 
M solution of fluorescein 
was injected into capillary (Figure 4.2).  The total amount injected was 2x10
-19 
mole with 
a signal to noise ratio of 23.  Fluorescence intensity is proportional to number of 
molecules and the LOD is defined as having a signal to noise ratio of 3.  From this, the 
LOD of this system was determined to be 3x10
-20
 moles.  Peak area, height, and 
migration time were measured for six replicates and all three parameters were highly 
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reproducible (Table 4.1).  Therefore, it was determined that the custom-made system was 
sufficiently sensitive and reproducible. 
4.3.2 Determination of Separation Buffers 
The choice of a separation buffer is critical in obtaining successful CE separation 
of the analytes.
6
  Once the optimal wavelength for detection has been chosen, a buffer 
must be selected with the ability to detect the analytes of interest, maintain solubility of 
the analytes, maintain buffering capacity throughout the analysis and enable the desired 
separation.  In this work, peptides were linked with carboxyfluorescein (Fam); therefore, 
the excitation wavelength was 473nm and signal was collected at 530+/-25 nm. The 
choice of actual separation buffers are covered in more detail in the following section. 
Buffer systems play a key role in capillary electrophoresis and any technique that 
is electrokinetically driven.
6
  Within the buffer, the differential migration of analytes 
allows for analyte separation and the buffer plays the selectivity-determining role of both 
the mobile and stationary phases in the capillary.  By these means, the buffer has an 
essential influence on the efficiency and resolution of the separation.  The buffer is also a 
major factor in the strength and direction of electroosmotic flow (EOF).  There have been 
numerous investigations on the effect of ionic strength, pH value, concentration, and 
additives to obtain useful CE separations.
7,8
   It has been found that small changes in pH 
can influence electroosmostic mobility; however, it is not to the same degree in every 
buffer and not the same in the same buffer at different ionic strengths.
8
  The mechanisms 
by which pH influences the separations are extremely complex and not fully understood.  
However, it remains that the role of buffer systems in capillary electrophoresis is 
extremely important. 
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Based on the literature to date, zwitterionic buffers such as tris, tricine, and CAPS 
have been the buffers of choice for many research groups investigating separations of 
proteins and peptides because of their low conductivity at high concentrations.
9-12
  The 
buffer concentration plays an important role in the separation; at high buffer 
concentration, the buffer can improve peak shape, wall interactions and increase the 
sample stacking; however, the production of excess heat may require the use of lower 
field strengths.  Low concentration buffers usually provide faster separations because the 
solute mobility and EOF are inversely proportional to the square root of the buffer 
concentration.  However, interactions of the analytes of interest with the capillary wall in 
low concentration buffers are a common issue, especially for biomolecules.  For proteins 
and peptides, which may contain highly charged regions, CE separations are often more 
difficult due the adsorption of the analytes to the capillary wall.  The zwitterionic buffer 
systems are often the best to use because they can be used at high concentrations, yet due 
to the low mobility ions, which tend to minimize buffer conductivity, a higher electric 
field can also be used, enabling both faster and better separations.
10,13
 
A tris/tricine buffer is one type of zwitterionic buffer which has been used 
successfully for peptides separation and has an appropriate buffering range of pH 7.4-8.8; 
6,14
 therefore, it was the first buffer tested.  In this work, the separation buffer must have 
the ability to separatea peptide and its phosphorylatedcounrtpart. For the peptides Sub-
Abl and phosphorylated Sub-Abl, a separation in 100 mM tris/tricine buffer, pH 8.2, was 
obtained, although there was obvious peak tailing (Figure 4.3 A).  However, TCC-FlAsH 
and phosphorylated -TCC-FlAsH could be separated very well in the same buffer (Figure 
4.3 B).This better separation could have resulted from net charge and conformational 
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differences of the TCC-FlAsH compared to sub-Abl.  It is probable that this less to less 
wall interactions in this particular buffer. 
However, when the same tris/tricine system was used for the other reporters 
UXBB1, UXBB2, XBB1 and XBB2, the electropherograms show an uninformative 
smear of peaks.  The reason for this is probably due to the following: at pH 8.2 the 
capillary wall is negatively charged and the net charge of peptides is positive.  
Furthermore, at this pH value, there are three positively charged lysine residues at the C-
teminus of the peptides.  Thus, it is likely that there is a strong interaction between the 
peptides and the capillary wall, causing severe peak tailing.  Also, these peptides have a 
flexible PEG linker and a secondary structure which is either an open or cross-linked beta 
hairpin.  These subsections might lead to a completely different 3D structure than that of 
a linear peptide and these structures might dominate the separation.  Additional strategies 
were tested for optimizing the separation buffer. One possibility is to add additives to 
eliminate wall effects.  The other is to change the pH value of the buffer to alter the net 
charge of peptide and wall surface.  
A borate/SDS buffer system commonly used in the Allbritton lab was tested next.  
Concentration of the borate was varied from 50mM to 100mM by 10mM increments, and 
SDS concentration was varied from 1mM to 10mM by 1mM increments and from 10mM 
to 100mM by 10mM increments. For 100mM borate, the migration time of the non-
phosphorylated/phosphorylated peptide mixture increased as the SDS concentration was 
increased. However, there was no separation of the two analytes.A50 mM borate buffer 
showed the same trend in migration time and still no separation was observed.  Figure 4.4 
shows one example for peptide UXBB1and its phosphorylation product (A) and XBB1 
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and its phosphorylated product (B) tested in a100 mM borate/10mM SDS buffer, pH 8.5.  
In each case, there is one peak for the mixture with no observed separation in this buffer. 
Additionally, the acid buffer sodium citrate (20mM at pH 3) was tested and it was 
found that the UXBB1 and phosphorylated UXBB1 were successfully separated in this 
buffer (Figure 4.5).  The capillary wall is positively charged at this pH and the net charge 
of the peptide is positive, allowing for a decrease in the wall interactions.  However, the 
peptides were labeled with FAM, which is highly sensitive to pH.  The fluorescence 
intensity of FAM is dramatically decreased in a low pH buffer and the sensitivity of CE-
LIF detection drops to about 10
-17
 moles.  In this case, the buffer cannot be used for a 
single cell assay which requires an LOD between 10
-19
 -10
-21 
moles.  Based on these 
results, it was decided that the focus would remain on a high pH buffer.  
As the tris/tricine buffer system proved to give adequate separation of the TCC-
FlAsH non-phosphorylated/phosphorylated pair, this was used as a base for further 
separations.  The detergent additives sodium dodecyl sulfate (SDS), sodium deoxycholate 
(SDC), cetrimonium bromide (CTAB) and dodecyl trimethyl ammonium bromide 
(DTAB) were tested below and above their critical micelle concentrations (CMC) in an 
attempt to improve the separation.  However, there were still no separations of 
phosphorylated and parent pair in the presence or absence of these detergents.  These 
additives did help in that they seemed to limit the wall interactions, resulting in 
anelectropherogramwith sharper peaks.  However, although these buffer systems were 
tested in both positive and negative polarity mode, only one peak was ever detected for 
the phosphorylated/non phosphorylated pair mixture.  These results showed the non-
phosphorylated/phosphorylated pair cannot be separated utilizing these additives. 
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Finally, a dynamic coating was tested.  EOTrol is a commercially available class 
of linear polyacrylamide, N-substituted acrylamide copolymers that can be used in CE or 
microfluidic applications for control of electroosmotic flow (EOF).Based on the different 
formulations of EOTrol, changes to EOF direction and mobility occur.  Both EOTrol HR 
(high reverse) and LR (low reverse) were used in the tris/tricine buffer system to test for 
separation.  The differences between the HR and LR formulations are that dynamic 
coating totally reverses the EOF direction while leaving the EOF mobility relatively high 
in buffer with HR and the mobility of EOF stays relatively low in LR.  In the buffer with 
EOTrol LR, only one peak of non-phosphorylated/phosphorylated pairs was detected 
under both negative and positive polarity.  This might be because no separation was 
achieved or only that only one of the peaks would migrate to the detection window under 
each voltage. In these conditions, the negative peptide was moving in the same direction 
as the EOF, which is opposite the detection window and thus the peptide will not migrate 
past the window.  Therefore, the LR buffer was not a sufficient separation buffer for 
these peptides. 
However, in the tris/tricine buffer with EOTrol HR, the separations were detected 
for every designed reporters phosphorylated and non phosphrylated pair.  This is might 
be the dynamic coating in the buffer eliminated the wall effects and the two peptides 
were separated.  Furthermore, when positive polarity was applied in this buffer, the EOF 
was highly reversed; the mobility of the EOF was much greater than the mobility of the 
peptide, acting to sweep all analytes toward the detection window.  Then separation was 
achieved and detected (Figure 4.6).  Therefore, the 100 mM tris/tricine (pH 8.2) with 5% 
EOTrol HR was used for CE analysis of the beta bend Abl peptides.  Remaining CE 
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separations were performed in this buffer system. 
4.3.3 Endopeptidase assay 
In Chapter 2, some cytosolic endopeptidases were introduced in detail.  POP is 
one of the important cytosolic peptidases and commercially available. Therefore it was 
used for studying the degradation of the designed reporters. The control peptide Sub-Abl 
was incubated with POP and the result showed that Sub-Abl peptide is a substrate of POP.  
The XBB1, XBB2 and TCC-FlAsH peptides showed no degradation within 30 minutes 
under the same conditions.  The result shows the peptides conjugated with a protectide 
are more resistant to POP degradation than the un-conjugated peptide.  
4.3.4 Degradation of Peptides in a Cell Lysate  
The resistance of the kinase reporters to degradation was initially tested in Ba/F3 
cell lysates using the degradation assay described in section 4.2.3.  After lysing, the 
intracellular contents were released and dissolved into the ECB buffer.  The lysis buffer 
lysed not only the plasma membrane of the cell but also the membranes of the cellular 
organelles.  Intracellular peptidases, which are normally confined in the organelles and 
are tightly regulated in living cells, were also released using this lysis buffer.  
Comparison of the peptidase conditions in cell lysates and in intact cells is listed in Table 
4.2.  As discussed previously, the cell lysate may be a more stringent test of the reporter’s 
ability to resist degradation; however, it is a fast and easy method for testing the 
resistance of the reporter to peptidase degradation and is very important for defining the 
lifetime of the reporters in viable cells to confirm that they remain intact for the period of 
the assay.  
The cell lysate was prepared by using freeze/thaw cycles.  In this method, the cell 
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membrane is broken and all cellular contents, including cytosolic peptidases, are released 
into the lysis buffer.  The initial cell lysate tests were performed for Ablmin peptide and 
the two cross-linked protectide versions of reporters XBB1 and XBB2 using the cell 
lysate without further dilution.  The linear peptide Ablmin totally disappeared within 1 
minute (Figure 4.7), which was the shortest time point taken in this assay.  The XBB1 
and XBB2 peptides showed longer lifetimes for 15 minute and 25 minute in these 
conditions (Figures 4.8-4.9).  However, because the lifetime of the control peptide was 
less than 1 minute, the exact lifetime of the reporters could not be compared.  Thus, the 
concentration of cell lysate used in this assay needed to be optimized. 
The first step was to make sure that the amount of peptidases used in the assay 
could be quantified.  The assumption was that the peptidase concentration is proportional 
to the total protein concentration in the lysate.  By measuring the total protein 
concentration in the lysate and using this same concentration in all assays, a similar 
peptidase concentration can be assumed for each assay.  In the initial assay, the cell 
number was counted before lysis; however, this method gave a large variety in the final 
protein concentration in the lysate.  Fluorescamine, a heterocyclic dione, reacts with 
primary amines and forms fluorescent products.  The fluorescence intensity is 
proportional to the quantity of free amine groups present in the solution.  This formed the 
basis of a fluorescent protein assay and showed good reproducibility.  After measuring 
the protein concentration by this method, the cell lysate was diluted to various 
concentrations for the optimization assays.  The final protein concentration of 3 mg/mL 
was chosen for the degradation and lysate kinase assays based on the fact that the control 
Ablmin peptide was completely degraded within 5 minutes.  
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The hydrolytic stability of all peptides was initially measured by incubation in a 
cell lysate with 3 mg/mL total protein concentration, followed by analysis using CE.  
Survival in a cell lysate is thought to be a harsh test of resistance to breakdown, since 
tightly-regulated proteolysis enzymes normally located in the organelles are released in 
the lysate and can act on the peptides with fewer restrictions than normal.  In these 
experiments, the peptides were added to the lysate to a final concentration of 2 μM and 
incubated at 37°C for varying times.  Protease inhibitors were not used.  In the 
electropherograms of the degradation assay samples, the presence of multiple peaks with 
migration times differing from the parent peptide peak is typically due to peptide 
degradation within the lysate.  The amount of breakdown was quantified by comparing 
the peak areas on the CE trace of the degradation products to that of the intact reporter at 
different time points.  Fluorescently labeled substrates without protectides served as 
controls (Figure 4.10) in order to quantify the relative protection conferred by the 
protectides.  The different time points of the assay, including 1, 3, and 5 minutes are 
shown in Figure 4.10 B, C and D.  The degradation of the peptide over time is clearly 
demonstrated.  Degradation of the cyclized peptides was also evaluated in a cell lysate.  
The selective electropherograms of the cyclized peptide TCC-FlAsH at different time 
points are shown in Figure 4.11.   The degradation data for all reporters tested are showed 
in Figure 4.12.  According to these data, the control peptide Sub-Abl was 90% degraded 
within 1 minute and completely degraded within 3 minutes.  The non-cyclized, 
betahairpin-containing compounds displayed increased lifetimes, with 90% degradation 
seen after 10 minutes incubation.  The lifetimes of the cross-linked versions of these 
compounds were even more extended, particularly XBB2, which required greater than 40 
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minutes to be fully degraded.  The TCC-FlAsHcomplex showed the longest lifetime, with 
complete degradation requiring about 50 minutes.  
These results show that the lifetime of the peptides with the protectide is 
increased compared with the linear control.  Also observed was that the satablizing the 
peptide by corssling the beta hairpin protectide further increased the lifetime of the 
reporter.  This is probably due to the fact that the uncross-linked peptides contain an open 
beta hairpin that is not folded 100 percent of the time and the peptide can still access the 
active site in grooves of the peptidase.  However, the cross-linked protectides remain 
permanently folded; making it is less likely to insert into the cleft where the active site is 
located.  The t1/2 of each peptide in cell lysate degradation and the sizes of each protectide 
are listed in the Table 4.3.  The results indicate that larger protectides and cross-linked 
protectides possessed longer lifetimes than their smaller, linear counterparts. 
4.3.5 Kinetic Properties of the Designed Reporters for Abl Kinase 
In order to determine if protectide-substrate conjugated peptides remain substrates 
of Abl kinase. A kinase assay using a pure Abl kinase was performed (conditions 
described in section 4.2).  This assay was used two control experiments, one using the 
Abl inhibitor Gleevec and one using no ATP were performed simultaneously.  The results 
showed that the phosphorylation of the Sub-Abl peptide peak increased over time (Figure 
4.13), while in the control experiments, neither CE nor MALDI results showed 
phosphorylation.  It was concluded that Sub-Abl peptide can be phosphorylated under 
this condition and this kinase assay could be used for assay for all designed reporters 
phosphorylation. 
In order to quantitatively evaluate the designed peptides as a substrate of Abl 
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kinase, a commercially available immobilized metal ion affinity-based fluorescence 
polarization (IMAP) assay (Molecular Devices, CA) was used to measure the amount of 
phosphorylated peptide in reaction mixtures, also previously described.  This assay 
provides a thoroughly validated platform for high-throughput kinase screens, 
approximately 100 samples/hour.
5
  The IMAP assay measures the change in anisotropy 
when a fluorescently labeled phosphorylated peptide selectively binds to a metal 
nanoparticle (Figure 4.14.).  Binding of the large metal III-containing nanoparticle to the 
phosphorylated peptide slows down the rotation of the peptide, thereby increasing its 
anisotropy over the non-phosphorylated peptide.
15
  Anisotropy of the fluorescently 
labeled peptide was calculated using the following equation: 

r 
Ill  I
Ill  2I
 
Where r is the anisotropy, Ill is the fluorescence intensity parallel to the excitation plane 
and I⊥is the fluorescence intensity perpendicular to the excitation plane. 
The assay conditions had to be optimized for each substrate used.
16
  After 
determining optimized buffer combinations and incubation times for each peptide, the 
calibration curves were made for each peptide.  For the calibration buffer, the same 
reaction buffer used in thenormal kinase assay with all additives normallyused in the 
assay ensures the calibration curve will mimic as closely as possible the conditions of the 
assay.  
After kinase assay were performed for all reporters described in 4.2.8, 
phosphorylation percentage of each peptide at different time point were measured and 
initial velocity were calculated out.  The phosphorylation of peptide substrates by Abl 
kinase obeys Michaelis-Menten kinetics.17 So this model was used to measure the KM , 
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Vmax and Kcat of the various protectide-substrates and the substrates alone. Michaelis-
Menten curves of each substrate were plotted as reaction velocity as a function of initial 
substrate concentration.  Results for all peptides are shown in Figures 4.15-4.17.  The KM, 
Vmax and Kcat values were calculated and are listed in Table 4.4.  Some samples were also 
screened via CE-based separation of the substrate and product to check the percentage of 
phosphorylation as well.  The amount of phosphorylated peptide in reaction mixtures as 
measured by CE was similar with the results of the IMAP assay. .   
According to the results, the reporters with the designed protectide show slightly 
different KM (ranging from 61 ± 9 µM to 95 ± 9 µM) and Vmax values, but they are the 
same order of magnitude.  The turnover numbers are also moderately different (ranging 
from 1.04 ± 0.09 to 1.58 ± 0.3 x 10
4
/min), although they remain the same magnitude.  
The most likely reason for these differences in the reaction constants is due to the 
conformational changes instigated by the protectide.  This could alter the access of the 
substrate region to the kinase catalytic site.  It is possible that variation of the length of 
the PEG linker between the protectide and the susbtrate region might reduce or eliminate 
this influence.  This can be further investigated in the future.  
4.3.6 Cell Lysate Kinase Assay in a BCR-Abl BaF3 Cell Line 
In order to determine if the peptides can be phosphorylated by the BCR-abl 
positive Ba/F3 cell line, a cell lysate kinase assay was performed for the control peptide 
Sub-Abl and two designed reporters, XBB2 and TCC-FlAsH.  The rationale behind 
choosing XBB2 and TCC-FlAsH to perform this assay is because they had the longest 
lifetime of the designed reporters in the cell lysates.  In addition to increased stability, 
XBB2 and TCC gave even better turnover numbers for the kinase than the control peptide 
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in the purified kinase assay.  Thus, these two peptides were used for the cell lysate kinase 
assay. 
The assay was performed as described in 4.2.9, and control experiments with 
Gleevec were done simultaneously for all there peptides.  The different time points of 
each peptide were analyzed by CE.  All peptides show both degradation and 
phosphorylation at varying degrees over time (Figure 4.18).  The results show successful 
phosphorylation of the peptide by this Ba/F3 cell lysate, indicating the presence of active 
Abl and/or BCR-Abl kinases in the cell lysate.  While XBB2 showed less resistance to 
degradation than TCC-FlAsH, it was more resistant than the control.  It was 
phosphorylated better than the other peptides on a reasonable time scale (between 10 – 40 
min) (Figure 4.19)  with peak phosphorylation (10 ± 0.2 %) occurred at 20-25 minutes in 
the lysate Based on these favorable properties, XBB2 was chosen to as the substrate in 
the intact single cell assay. 
4.3.7 Loading Methods 
The importance of single cells assay has been discussed in chapter1. In order to 
evaluate designed reporters in intact cells, the reporter needs to be loaded into a living 
cell. There are several methods for loading peptide into living cells, including: pinocytic 
loading, electroporation, Chariot delivery, myristoylation and microinjection.  All of 
these methods have been previously used in the Allbritton lab to load different cell types.  
Pinocytic loading is based on a phenomenon from cell biology called pinocytosis. 
It is a form of endocytosis in which small particles in a surrounding solution are non-
specifically brought into the cell.  This provides a convenient, rapid and simple procedure 
for loading water-solublematerials into live cells. However, pinocytosis does not work for 
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all cell lines.  Pinocytosis was tested for loading the small fluorescent dye Oregon green 
into HeLa and Ba/F3 cells.  However, this work showed that while the dye could be 
successfully loaded into HeLa cells using pinocytosis.  It could not be loaded into Ba/F3 
cells by this method (Figure 4.20).  Some literature shows that pinocytosis does not work 
very well for lymphoid cell lines because these cell lines do not undergo pinocytosis.
18,19
 
Ba/F3 cells are one type of a lymphoid cell line that doesn’t load well via this method; 
therefore, pinocytosis was not a good choice for loading Ba/F3 cells  
Microinjection is a powerful and versatile technique for introducing exogenous 
material into cells.  It uses a glass micropipette to inject any solution into a single cell.  It 
has been successfully used to load peptide reporter into single living cells to monitor 
kinase activity.  However, it is non-trivial to microinject cells, especially non-adherent 
cells such as Ba/F3.  Despite this, it is a reliable method and seems to disturb the cell 
Therefore, microinjection was chosen as the loading method to introduce Abl and XBB2 
peptides into single cells for this work.  
4.3.8 Single Cell Assay 
Assays in single living cells are important for validation of the designed reporters.  
Single cells provide a complete environment in which the peptidases and kinases are 
sequestered and regulated.  The intact cell provides a more realistic environment than a 
lysate for investigation of phosphorylation and degradation of the reporters.  Therefore, it 
was key to determine how the designed reporters behaved in this single cell environment. 
The single cell say were performed as described as in 4.2.7 using peptide Sub-Abl 
as control and peptide XBB2.  Several control experiments were performed prior to 
single cell assays.  To determine the migration time of the phosphorylated and non-
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phosphorylated standards, a cell was lysed by the pulsed laser and loaded into the 
capillary.  Immediately after loading the cell into the capillary, either the non-
phosphorylated or phosphorylated peptide was immediately loaded into the capillary and 
electrophoresis commenced.  This allowed for the identification of the migration time of 
the analytes in the presence of cell debris. 
A second control, “sham” microinjection, was performed to examine non-specific 
adsorption of the fluorescent peptide to the cell.  A sham microinjection was performed 
by injecting the peptide into the space beside the cell instead of into the cell.  The same 
washing procedure used for other cells was then applied.  The peptide solution inside the 
microinjector tip is hundreds of micromolar and there was a high probability of 
extracellular adsorption.  However, after the sham microinjection and washing 8 times 
with 1X PBS buffer, either no peak or a very small peak that migrates at the same time as 
the parent standard was seen.  This indicated that washing 8 times with 0.5 mL solution 
per rinse was sufficient to remove adsorbed peptide from the cell surface.  
The single cell assay was performed by microinjecting either the control peptide 
Sub-Abl or the designed reporter XBB2 into single BaF3 cells.  CE was performed after 
incubation of the peptide in the cell for different times.  After a 20 minute incubation, the 
control peptide Sub-Abl was completely consumed and no phosphorylated product was 
detected (Figure 4.21B).  However, the XBB2 peptide showed a much longer lifetime and 
phosphorylation of the peptide was detected.  The amount of intact, non-phosphorylated 
XBB2 was 41.20 ± 17.14% while the amount of intact, phosphorylated peptide was 8.04 
± 7.39 % (Figure 4.22B).  An additional control experiment was performed where the 
cells were incubated withthe BCR-Abl kinase inhibitor Gleevec prior to peptide 
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microinjection.  Again, this assay demonstrated that the non-modified peptide Sub-Abl 
completely disappeared within 20 minutes (Figure 4.21C).When the cells pre-incubated 
with Gleevec were microinjected with the XBB2 peptide, 60.4 ± 12.0%of the non-
phosphorylated parent remained and no phosphorylated product was detected after 20 
minutes (Figure 4.22C).  It was determined that phosphorylated peptide XBB2 was 
detected in living cells.  Although XBB2 degradation was also detected, the rate of XBB2 
degradation was much slower than degradation of the control Sub-Abl.   
4.4 Conclusions and Future Work 
This study utilized in vitro experiments to demonstrate that conjugation of protein 
kinase substrates with β-hairpin structures can increase resistance to proteolytic 
degradation.  Both covalent cross-linking and FlAsH binding were shown to stabilize the 
beta hairpin.  The stabilized beta hairpin structures showed more resistance to 
degradation than the open beta hairpin structures and further increased the lifetime of the 
peptides in cell lysates.  Additionally, while the XBB2 peptide was more resistant than 
XBB1, the TCC-FlAsH complex showed more resistance than either XBB1 or XBB2.   
All three of these peptides have a rigid beta hairpin stabilized by cross-linking, but they 
are different sizes.  It appears that the larger protectide gives more stability to the peptide 
and imparts more resistance to degradation.  Although these peptides did not completely 
block degradation, phosphorylation of the reporters was seen in a single cell assay.  This 
assay demonstrated that the designed peptide was resistant enough to enable 
phosphorylation, while the control peptide was completely degraded.  Future changes to 
these peptides could include the use of unnatural amino acids, which may provide even 
greater resistance to degradation by peptidases.  
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The kinetics investigation showed there was not a surprising difference between 
the protectide-substrate conjugations and the control.  This means our design showed 
increased resistance to peptidase degradation and did not significantly decrease the 
affinity to the target kinase.  It is likely that there was little influence on the substrate 
because the protectide was held separate from the substrate via a PEG linker.  Details of 
how the length of the linker will influence the kinetics could be the further investigated in 
the future. 
In summary, the design and validation of intracellular peptidase-resistant reporters 
for Abl kinase activity was performed.  The application for utilization as a BCR-Abl 
kinase reporter in single living cells was demonstrated.  Significantly, the strategy of 
attaching a beta hairpin structure to the substrate peptide was shown to prolong the 
lifetime of linear peptides.  Therefore, it is hopeful that this novel tool can help deepen 
the understanding of kinase activity in cancer cells, and the application of this tool to 
other intracellular peptide-based probes and drugs for peptidase/protease resistance will 
be further investigated and reported in the future. 
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4.5 Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 The diagram of CE-LIF system set up. The system includes capillary 
electrophoresis section, optical section and electrical section. 
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Figure 4.2 Limit of detection of the homemade CE-LIF system.  The signal to noise 
is 23.  The injection concentration of fluorescein was 2 x 10
-10
M and limit of 
detection is about 3 x 10
-20
mole. 
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Figure 4.3 Separation of Abl and TCC-FlAsH and their phosphorylated products  
A) Sub-Abl and phosphorylated Sub-Abl (Pho-Sub-Abl) can be separated in 100 
mM tris/tricine pH 8.2 buffer There are peak tailing for both peptides. B) TCC and 
phosphorylated TCC-FlAsH (Pho- TCC-FlAsH) could be separated in same buffer 
without peak tailing. 
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Figure 4.4 Electrophagram of UXBB1 and phosphorylated UXBB1 mixture (A) and 
XBB1 and phosphorylated XBB1 mixture (B) in buffer 100mM borate 10mM SDS 
pH 8.5 are showing no separation for the substrate peptides and phosphorylated 
ones. 
 
 
Time (S) 
A 
Time (S) 
B 
R
FU
 
R
FU
 
125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Electropherogram are showing separation of the substrate 
peptideUXBB1(A) and XBB1(B) pointed by blue arrow and phosphorylated one 
(Pho-) pointed by red arrow in 20mM sodiumcitratepH 3.0. 
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Figure 4.6 Electropherogram showing separation of the substrate peptide XBB2and 
phosphorylated XBB2 in 100mM tris/tricine 5% Eotrol HR pH 7.7 
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Figure 4.7 Electrophorgrams of cell lysate degradation for Abl min. The standard 
Abl min peak is showing in A and there is no Abl min left within 1 minute in B.  
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Figure 4.8 Electrophorgrams of cell lysate degradation for XBB1. The result of 1min 
is showing in A and XBB1 was pointed by the arrow. The 3 minutes assay is showing 
in B and 5 minutes showing in C in which there is no XBB1 left. 
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Figure 4.9 Electrophorgrams of cell lysate degradation for XBB2. The 1min is 
showing in A and XBB1 was pointed by the arrow. The 5 minutes assay is showing 
in B and 10 minutes showing in C in which there is few XBB2 left. 
 
 
 
C 
B 
A 
R
FU
 
Time (s) 
XBB2 
XBB2 
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 The electrophorgrams of BaF3 cell lysate degradation for Sub-Abl 
peptide. The standard Sub-Abl peptide is pointed by the arrow. The 3 minutes and 5 
minutes assay are showing in which there is a 10% and no Abl peptide left. 
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Figure 4.11 Electrophorgrams of BaF3 cell lysate degradation for TCC-FlAsH.  The 
standard peptide is showed in A and pointed by the arrow. The 3 minutes assay is 
showing in B and 5 minutes showing in C in which there is no parent peptide left. 
Other peaks represent degradation products. 
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Figure 4.12 Degradation all designed peptide reporters in BaF3 cell lysate over the 
time.  
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Figure 4.13 Electropherograms of the Sub-Abl peptide in pure Abl1 kinase assay at 
5(A), 10(B), 15(C) minutes respectively. The peak of phosphorylation product 
(Pho-Sub-Abl) is increased over the time. 
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Figure 4.14 Molecular devices IMAP® assay.Binding of the large metal III 
containing nanoparticle to the phosphorylated peptide slows down the rotation 
of the peptide, thereby increasing its anisotropy over the non-phosphorylated 
peptide. 
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Figure 4.15 The rates of phosphorylation of the designed reporters by 
Abl kinase fit to an equation of the form v = Vmax[ S]/ (KM+ [S]) 
where [S] is the concentration of the substrate peptide. A is the v vs. substrate 
concentration ([S]) curve for Sub-Abl and B is UXBB1 peptide.  The solid lines 
represent the fits to the Michaelis-Menten equation.   
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Figure 4.16 The rates of phosphorylation of the designed reporters by 
Abl kinase fit to an equation of the form v = Vmax[ S]/ (KM+ [S]) 
where [S] is the concentration of the substrate peptide. A is the v vs. substrate 
concentration ([S]) curve for UXBB2 and B is XBB1 peptide.  The solid lines 
represent the fits to the Michaelis-Menten equation.   
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Figure 4.17 The rates of phosphorylation of the designed reporters by 
Abl kinase fit to an equation of the form v = Vmax[ S]/ (KM+ [S]) 
where [S] is the concentration of the substrate peptide. A is the v vs. substrate 
concentration ([S]) curve for XBB2 and B is TCC-FlAsH peptide.  The solid lines 
represent the fits to the Michaelis-Menten equation.  
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Figure 4.19 Cell lysate kinase assay of Sub-ABL, XBB2 and TCC-FlAsH peptide 
The peptide XBB2 shows the most phosphorylation within 40 minutes. 
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Figure 4.19 Cell lysate kinase assay of XBB2 peptide. A as control is cell lysate assay 
with inhibitor Gleevec at 10 minutes and B is the assay at 10 minutes without 
inhibitor. The parent peptide XBB2 and Phosphorylated XBB2 (Pho-XBB2) are 
pointed by arrow. Other peaks represent the degradation products in cell lysate 
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Figure 4.20 Pinocytosis loading the Oregon green to BaF3 cell line. The transparent 
light image is A and Fluorescent light image (B) shows that no fluorescent dye was 
loaded into BaF3 cell by this method. 
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Figure 4.21 Electropherograms of peptide Sub-Abl single cell assay using 
microinjection loading method. A is standard mixture of Sub-Abl and 
phosphorylated XBB2 (Pho-Sub-Abl). B is assayat 20 minuts and c is assay with the 
single cell pre-incubated by inhibiter Gleevec. The results are showing that no 
phosphorylation of the Abl peptide and fully degradation was detected in this 
condition.  
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Figure 4.22 Electropherograms of peptide XBB2 single cell assay using 
microinjection loading method. A is standard mixture of XBB2 and phosphorylated 
XBB2 (Pho-XBB2). B is assay at 20 minuts and C is assay with the single cell pre-
incubated by inhibiter Gleevec. The results are showing that phosphorylation of the 
XBB2 peptide in 20 minutes assay was detected in this condition.  
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Figure 4.23 Phosphorylation percentage of XBB2 reporter in 10 single cell assays 
with 20 minutes incubation. 
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Table 4.1 Reproducibility of the custom-built CE system 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Peak area Migration time (s) Peak height 
f1 13.31 283.79 6.44 
f2 12.92 281.93 6.36 
f3 13.25 283.37 6.42 
f4 14.19 281.78 6.74 
f5 13.77 282.14 6.66 
f6 13.89 282.65 6.64 
Stdev 0.47 0.82 0.15 
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Table 4.2 Comparison of peptidase attributes in intact cells vs cell lysates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intact cell Lysed cell 
Concentrated enzymes Diluted enzymes 
Regulated protease activity Poor regulation 
Intact organelles Broken organelles with protease 
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Table 4.3 Degradation t1/2 and protectide size of reporters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide t1/2 (min) protectide size (Å) 
Sub-Abl 0.5±0.1 NA 
UXBB1 4.8±0.4 10x16 
UXBB2 5.3±0.7 14x16 
XBB1 9.2±1.2 14x16 
XBB2 20.3±1.7 17x22 
TCC-FlAsH 24.6±1.0 18x25 
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Table 4.4 Kinetics parameters of all reporters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide KM (μM) Vmax (pmole/min) Kcat (10
4/min) 
Sub-Abl 61 ± 9 83.4 ± 7.3 1.04±0.09 
UXBB1 62 ± 6 81.1 ± 4.6 1.01±0.06 
UXBB2 90 ± 8 120.2 ± 7.3 1.50±0.09 
XBB1 62 ± 15 94.5 ±14.1 1.18±0.17 
XBB2 74±23 125.8 ± 24.3 1.58±0.30 
TCC-FlAsH 95 ± 21 107.5 ± 16.4 1.35±0.20 
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Chapter 5: Fast Generation of Peptide Fragment Standards by Pronase E Assay 
5.1Introduction 
CE-LIF, as described in chapter 1, is a highly sensitive method which has been 
applied successfully for analyses of both single cells and cell lysates.
1-3
  CE-LIF is 
sensitive enough to combine analyses of kinase activity by measuring a substrate and its 
phosphorylated counterpart and also investigating peptidase activity by analyzing the 
hydrolytic breakdown of the substrate into its constituent proteolytic fragments.  The 
peak capacity of CE-LIF is large enough to provide the ability to quantify these varied 
and distinct products.
4-7
  The advantages of using peptide reporter for measuring the 
enzymatic activity have been discussed in chapter 1.  
However, although CE can provide a good resolution for separating peptides even 
with differentiation of a single amino acid, the determination of metabolic products in a 
cell is still challenging because it is hard to achieve a full set of potential enzymatic 
products as standards particularly proteolytic fragments.  Additionally, co-migration of 
some metabolic products with the parent peptide may occur.  These possibilities bring 
further challenges for identifying specific products.
8,9
 
In this work, fluorescently labeled peptide substrates were used to measure kinase 
activities in cell lysates and single cells. CE-LIF quantifies the result by separating 
fluorescent degradation fragments and the unmodified peptide from phosphorylation 
products.  Thus, all fluorescent degradation fragments were needed for use as CE 
standards. By knowing where all of the degradation fragments migrate in CE, it can be
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determined if any of these fragments are co-migrating with the unmodified peptide or the 
phosphorylated products.  In order to accomplish this, all possible fluorescent fragments 
need to be synthesized utilizing SPPS.  For short peptide sequences, this is a minor task.  
However, for longer peptides, this can be extremely time consuming and labor intensive.   
Furthermore, for the cross-linked peptides used in this work, the cross-linking reactions 
need to be performed for every fragment, costing more time and money.  Therefore, the 
development of an assay which can generate fragments in a faster and more cost-effective 
manner is necessary.  
5.2Experimental 
5.2.1 Reagents 
The FAM-labeled peptides (Table 5.1) were synthesized by SPPS or custom 
synthesized by Anaspec (Fremont, CA).  All chemicals were purchased from Sigma (St. 
Louis, MO) unless otherwise specified.  Physiologic buffer was composed of Hank’s 
balanced salt solution from  (Carlsbad, CA) supplemented with 20 mM HEPES, 100 mM 
CaCl2, and 100 lM MgCl2 adjusted to pH 7.4 
5.2.1 Pronase E Assay 
Pronase E from Streptomyces griseus (EC 3.4.24.31) came as a solid and was 
dissolved in 1 x PBS buffer to approximately 0.01 mg/mL. The solution was diluted 100 
X further.  1-10 μL for every 100 μL reaction was used depending on the different 
substrate peptides.  These values were based on the amount of enzyme that could not only 
degrade the peptide completely within 10 minutes but could also generate all 
possiblepeptide fragments of each reporter peptide over that time. 
For each reaction, 10 μM of peptide was reacted with the appropriate concentration of
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enzyme in the PBS buffer or Hepes buffer at 37°C.  A 5 μL aliquot was removed after 3, 5, 
10, 20, 30,40, and 60 minute time points, and the reaction was quenched with 5 μL 
hydrochloric acid and heat inactivated at 95°C  for 4 minutes.  Eachtime point aliquot was 
diluted 20 times and analyzed using CE-LIF (PA800), using 100  
mM tris/trcine, pH 8.8 with Eotrol HR 5% as the separation buffer. 
5.2.2 LC/MS and MALDI Assay 
Some pronase E degradation samples were analyzed by LC/MS and MALDI to 
confirm their molecular weights. The degradation samples at different time points were 
analyzed by a UPLC/MS system (Waters). The samples were injected 10uL at 100uM 
peptide concentration. The samples at the same concentration were analyzed by 
MALDI.  The laser intensity was between 3890 and 4950 µJ depending on the peptide.  Both 
positive and negative ion modes were used to analyze the sample. The signal to noise was 3  
5.3 Discussion 
In order to generate all possible degradation fragments as standards, assays utilizing 
Pronase E have been developed for use here.  Pronase E is a non-specific peptidase cocktail. 
As is well known, peptidases hydrolyze peptide bounds.  The implication for this work is that 
this non-specific peptidase can be used to hydrolyze the peptide bonds of the designed 
reporters and can generate all potential degradation fluorescence fragments of the peptides.  
The following series of experiments were performed to test this strategy. The peptides used 
for this assay are listed in Table 5.1 
First, a 12-residue Abl kinase substrate (FAM-GGAYAAPFKKKA-NH2) was used 
for evaluation of this method.  The FAM is linked to the N-terminal residue, so hydrolysis of 
all the peptide bonds should lead to formation of the 11 fluorescent fragments listed in Table 
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5.1.  All of these fragments were synthesized via SPPS, purified by HPLC and the molecular 
weights were verified by MALDI-MS or ESI-MSby collaborators in the Lawrence lab.  The 
fragments and parent peptide were analyzed by CE and the migration time of each fragment 
standard was determined (Figure 6.1A).  Then the parent peptide was incubated in the 
Pronase E solution.  Aliquots were removed from the mixture at various time points and 
analyzed by CE.  These samples were also analyzed by MALDI-MS to determine the 
degradation products.  After only 10 minutes of incubation with Pronase E solution, all 
expected molecular weight of each fluorescent fragments were found in this sample utilizing 
MALDI-MS.  This sample was analyzed by CE and the migration time of all peaks was 
determined.  According to the result, there were 12 peaks (S/N>3) in the mixture and their 
migration lined up the standards in Figure 5.1A very well.  Every peak in the reaction 
mixture was identified by spiking synthesized fragment standard (Figure 5.1B).  It was 
determined that all potential degradation fragments for this peptidewere found in this sample. 
Ideally, all of the possible degradation products can be detected by MALDI-MS, but only 
fragments linked with FAM can be detected by CE-LIF.  According to the results, both 
MALDI–MS and CE were able to detect all of the fluorescent fragments (Table 5.1).  
Therefore, the Pronase E assay was determined to be successful for generation of all possible 
fluorescent peptide fragments. 
In order to further evaluate this assay, additional peptides were used to test hydrolysis 
by Pronase E.  The peptide Her2-1 (FAM-RHHEEIYHFFFAKKK-NH2), which is a substrate 
peptide of Her-2 kinase, was incubated with Pronase E.  Her-2 kinase is a popular target for 
cancer research and substrate peptides are under intensive investigation for her-2 kinase.
10
  
Using the same conditions and experimental process discussed above, the assay mixture was 
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sampled at different time points and analyzed by MALDI-MS (Figure 5.2).  The results 
showed different fragments appearing over time.  All fluorescent fragments were seen in 
varying amounts in the 5, 10, and 15 minute samples. The MALDI spectrum for reaction 
mixture at 10 minute is shown in Figure 5.2 with 15 fluorescent fragments appearing.  The 
calculated molecular weights and the observed molecular weights of the fluorescent 
fragments are listed in Table 5.2. These samples were also analyzed by CE so that the 
migration times of all the fragment standards could be obtained.  This sample could be 
reliably used as a CE or HPLC separation standard.  
Additionally, an epidermal growth factor receptor (EGFR) kinase substrate peptide 
EGFR-1 (FAM-LEDDYEDD-Nle-NH2) was used to test for fragment formation by 
incubating with a Pronase E solution.  Nle represents Norleucine which is an isomer 
of Leucine and a nonnative amino acid.  EGFR kinase is another popular target for cancer 
research and this substrate peptide is one of the best substrates for EGFR to date. 
11
  
Therefore, generating the fragments of this substrate will provide a set of degradation 
standards so that proteolytic products can be distinguished from phosphorylated products in 
cell assays.    The samples of the assay mixture were analyzed by MALDI-MS to verify the 
presence of the fluorescent fragments.  All expected molecular weights and the observed 
molecular weights of the fluorescent fragments are listed in Table 5.3.  In the result, the 
fragment FAM-LEDDYEDD-COOH was found in the reaction mixture. This means the 
Pronase E even can hydrolyze the peptide bond between the native amino acid, D, and 
nonnative amino acid, Nle.   
Development of peptides that can resist hydrolysis is attractive for researchers not 
only for drug discovery but also for peptide-based intracellular probes.  Multiple works exist 
 155 
 
that focus on development of well-folded or cross-linked peptides that can resist 
degradation.
12,13
  In these works, peptide degradation was monitored based on separation.  
Normally, only the parent peptide is monitored to calculate the lifetime.  However, 
quantification using this method is not accurate if any of the fragments co-migrate with the 
parent.  Thus, it would be useful to generate fragments for those folded peptides to use as 
standards.  In this way, it is easy to know if co-migration is occurring and what the migration 
times of all fragments are used to test this application.  In this work, the Pronase E assay was 
used to determine if fragments of a peptide with a more stable secondary structure could be 
generated.  A well-folded beta hairpin peptide Tripzip 2 (FAM-PEG6-SWTWENGKWTWK-
NH2)was used for this applications.14 Following the same assay procedure as described 
above, different time points were sampled and tested by MALDI-MS.  All fluorescent 
fragments were seen at the 10 minute time point and all expected molecular weights and the 
observed molecular weights of the fluorescent fragments are listed in Table 5.4. 
Another strategy for preventing degradation is the cross-linking of peptides. 
Therefore, a cross-linked peptide, XBB1, was also used to test fragmenting by the Pronase E 
assay.  Peptide XBB1 is a cross-linked reporter for Abl kinase that shows more resistance to 
degradation than a regular Abl reporter described in chapter 4.  The preparation and 
purification of XBB1 is discussed in Chapter 3.   Note that manual preparation and 
purification of the degradation fragments of XBB1 would be an extraordinary amount of 
work.  However, by using the newly developed Pronase E assay, different time points were 
sampled and analyzed by MALDI-MS.  All possible fluorescent fragments were found in the 
sample after a 20 minute incubation with Pronase E (Figure 5. 3).  All expected molecular 
weights and the observed molecular weights of the fluorescent fragments are listed in Table 
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5.5.  In this way, all potential degradation fragments up to a crosslinked protectide were 
obtained by this simple and fast assay. 
5.4 Conclusion 
All the results discussed above show that the Pronase E assay is a fast, convenient, 
and relatively cheap method that can be used to generate fragment standards for many types 
of peptides.  This method proved exceptionally useful for the generation of fragments of 
cross-linked substrates, which would ordinarily be extremely difficult to prepare utilizing 
standard SPPS method. 
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5.5 Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Electropherogram of standards of all possible fluorescent fragments formed 
from 67B (A) and that generated from PronaseE incubation with 67B (B). All 
fluorescent fragments present in (A) can also be identified in (B).  
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Figure 5.3 Electropherogram of the XBB1 fragments generated upon incubation with 
Pronase E. A peak with the m/z for each possible fluorescent fragment of this peptide 
was identified when the sample was analyzed by MALDI (Table 5.5). The parent 
peptide XBB1 (arrow) and the fragments (other peaks) are shown here. 
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Table 5.1 67B peptide expected and observed MW of all fluorescent fragments 
 
 
 
 
 
 
 
Peak  Fragment 
MW 
(Da) 
Detected MW  
(Da) 
1 FAM-G-OH 432.0 434.0 
2 FAM-GG-OH 489.1 491.1 
3 FAM-GGA-OH 506.1 508.2 
4 FAM-GGAY-OH 723.3 724.3 
5 FAM-GGAYA-OH 794.4 796.4 
6 FAM-GGAYAA-OH 865.5 867.5 
7 FAM-GGAYAAP-OH 926.4 928.4 
8 FAM-GGAYAAPF-OH 1109.8 1111.7 
9 FAM-GGAYAAPFK-OH 1237.9 1239.9 
10 FAM-GGAYAAPFKK-OH 1366.1 1368.1 
11 FAM-GGAYAAPFKKK-OH 1494.3 1497.3 
12 FAM-GGAYAAPFKKKA-NH2 1565.4 1568.4 
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Table 5.2 Her-2 peptide expected and observed MW of all fluorescent fragments 
 
Peak Fragments 
MW 
( Da) 
Detected, MW 
(Da) 
1 FAM-R-OH 531.2 533.1 
2 FAM-RA-OH 602.3 604.3 
3 FAM-RAH-OH 739.4 741.4 
4 FAM-RAHE-OH 868.5 871.4 
5 FAM-RAHEE-OH 997.6 999.6 
6 FAM-RAHEEI-OH 1110.8 1113.8 
7 FAM-RAHEEIY-OH 1273.9 1275.6 
8 FAM-RAHEEIYH-OH 1411.1 1413.2 
9 FAM-RAHEEIYHF-OH 1558.3 1558.4 
10 FAM-RAHEEIYHFF-OH 1705.4 1707.4 
11 FAM-RAHEEIYHFFF-OH 1852.6 1852.6 
12 FAM-RAHEEIYHFFFA-OH 1923.7 1925.6 
13 FAM-RAHEEIYHFFFAK-OH 2051.9 2053.9 
14 FAM-RAHEEIYHFFFAKK-OH 2180.0 2182.0 
15 FAM-RAHEEIYHFFFAKKK-NH2 2308.3 2308.3 
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Table 5.3 EGFR-1 peptide expected and observed MW of all fluorescent fragments 
 
 
 
Fragments 
MW 
(Da) 
DetectedMW 
(Da) 
FAM-L-OH 489.1 487.1 
FAM-LE-OH 618.2 616.2 
FAM-LED-OH 733.3 731.3 
FAM-LEDD-OH 848.4 846.4 
FAM-LEDDY-OH 1011.6 1009.6 
FAM-LEDDYE-OH 1140.7 1138.7 
FAM-LEDDYED-OH 1255.8 1253 
FAM-LEDDYEDD-OH 1370.9 1368.6 
FAM-LEDDYEDD-Nle-NH2 1483.0 1481.0 
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Table 5.4 Expected and observed MW of Fluorescent fragments of Trpzip 2 peptide 
 
 
 
 
Fragments 
MW 
(Da) 
Detected MW 
(Da) 
FAM-PEG6-S-OH 798.1 799.2 
FAM-PEG6-SW-OH 984.3 985.0 
FAM-PEG6-SWT-OH 1085.5 1086.6 
FAM-PEG6-SWTW-OH 1271.6 1272.7 
FAM-PEG6-SWTWE-OH 1400.0 1401.0 
FAM-PEG6-SWTWEN-OH 1514.2 1515.3 
FAM-PEG6-SWTWENG-OH 1571.1 1572.1 
FAM-PEG6-SWTWENGK-OH 1699.2 1670.1 
FAM-PEG6-SWTWENGKW-OH 1885.3 1886.4 
FAM-PEG6-SWTWENGKWT-OH 1986.7 1987.4 
FAM-PEG6-SWTWENGKWTW-OH 2172.6 2173.6 
FAM-PEG6-SWTWENGKWTWK-NH2 2302.3 2303.3 
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Table 5.5 Expected and observed MW of Fluorescent fragments of XBB1 peptide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fragments 
MW 
(Da) 
DetectedMW 
(Da) 
K(FAM)WpGRC(PEG2)2E-OH 1554.5 1553.4 
K(FAM)WpGRC(PEG2)2EA-OH 1625.3 1625.4 
K(FAM)WpGRC(PEG2)2EAI-OH 1738.2 1736.2 
K(FAM)WpGRC(PEG2)2EAIY-OH 1910.5 1908.6 
K(FAM)WpGRC(PEG2)2EAIYA-OH 1981.6 1979.6 
K(FAM)WpGRC(PEG2)2EAIYAA-OH 2052.7 2050.6 
K(FAM)WpGRC(PEG2)2EAIYAAP-OH 2149.8 2147.8 
K(FAM)WpGRC(PEG2)2EAIYAAPF-OH 2296.9 2294.8 
K(FAM)WpGRC(PEG2)2EAIYAAPFA-OH 2368.0 2366.0 
K(FAM)WpGRC(PEG2)2EAIYAAPFAK-OH 2495.1 2496.1 
K(FAM)WpGRC(PEG2)2EAIYAAPFAKK-OH 2623.2 2623.2 
K(FAM)WpGRC(PEG2)2EAIYAAPFAKKK-NH2 2751.1 2752.3 
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Chapter 6: Applications of “Protectides” to Design Reporters for Protein Kinase C 
(PKC) in Multiple Myeloma (MM) 
6.1 Introduction  
6.1.1 Protein Kinase C (PKC)  
PKC is a family of serine/threonine kinases which play critical roles in controlling 
cell responses to extracellular stmuli.1,2  Protein kinase C consists of 12 isozymes, grouped 
into conventional (cPKCs), novel (nPKCs), and atypical (aPKCs) isozymes based on 
structure differences, cofactor requirements and substrate specificity.  All PKC isozymes 
have a conserved catalytic domain responsible for substrate phosphorylation located on the 
carboxy terminus and a variable regulatory domain located on amino terminus.  These two 
domains are linked by a flexible connecting region.  The conventional isoforms (cPKCs) 
include PKCα, PKCβI, PKCβII and PKCγ and are activated by phosphatidylserine (PS), 
diacylglycerol (DAG) and Ca
2+
.  The cPKCs have two C1 domains that bind DAG and PS 
and a C2 domain responsible for binding anionic lipid cofactors in the presence of Ca
2+
.  The 
nPKCs include PKCδ, PKCε, PKCε and PKCζ and require PS and DAG for activation, but 
not Ca
2+
.   The nPKCs include two C1 domains that bind DAG and PS and a C2-like domain 
that lacks the residues required to bind Ca
2+
.  However, the nPKCs bind DAG with an 
affinity two orders of magnitude greater than the aPKCs.  The aPKCs include PKCδ and 
PKCλ and require only PS for activation and include a variant of the C1 domain that binds 
lipid or ceramide (Figure 6.1). 
3-6
  The recent discovery of the conserved catalytic domains of 
PKCµ and PKCѵ have caused them to be added as new members of the PKC family but have 
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not yet been characterized any further.
4,7,8
  Overall, PKC isozymes are implicated in all 
cellular biological functions including cell proliferation, differentiation, apoptosis and 
transformation.  However, the way in which PKC isozymes specifically work in vivo remains 
unclear because of the complexity of isozyme expression and activation in cells and/or 
tissues.
5,6,9
 6.1.2 Role of PKC in Cancer 
For many years, it has been known that the phorbol esters phorbol-12-myristate-13-
acetate (PMA) and 12-O-tetradecanoylphorbol 13-acetate (TPA) are powerful tumor 
promotors.  PKC was discovered as the “receptor” of phorbol esters, and therefore became an 
attractive target for discovery of the kinase’s contribution to tumorigenesis and tumor 
progression.  Overall, PKC function in cancer is complicated and studies indicate its 
participation regulates many signaling pathways involved in multiple cellular 
processes.
4,8,10,11
  Particularly, PKC regulates proliferation and/or cellular survival, and 
overexpression of PKC has been found to be associated with malignant transformation in 
various cancers including breast, lung and gastric carcinomas.
12,13
 
6.1.3 Targeting PKC in Multiple Myeloma (MM) 
Multiple myeloma is the second most abundant blood cancer with roughly 50,000 
MM patients in the United States and approximately 16,000 new individuals diagnosed each 
year.
14
   MM is characterized by proliferation of malignant plasma cells in the bone marrow.  
Additionally, high levels of monoclonal protein (M protein) have been found to be associated 
with the blood and/or serum of MM patients.
15
  All three categories of PKC isozymes have 
been found to be expressed in MM cells and have been involved in MM tumor progression.
10
   
For example, PKCα, β, and μ are involved in MM cell migration, PKCδ is implicated in 
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apoptosis of MM cells and PKC δ, ε, ε, are involved in receptor regulation.8,6  Therefore, 
PKCs have become an attractive candidate for molecularly targeted therapy in MM.  PKC 
inhibitors not targeting a single isozyme have demonstrated notable activity in pre‐clinical 
investigations of MM.  Results show that Enzastaurin (in phase I‐III clinical trials) only 
inhibits PKCβ at low concentrations, but inhibits others (PKCα, γ, δ, ζ, ξ, ε) at high 
concentrations.  Other promising inhibitors in phase I-II clinical trials are Midostaurin (PKC‐
412), which inhibits PKCα, β, γ, δ, ε, ε, and UCN‐01, which inhibits both c and nPKC 
isozymes.
10,16-10,17,18
 
The discussion about the need for developing a new cell-based biochemical assay has 
been fully discussed in chapters 1 and 3.  Peptide reporters can be used to measure catalytic 
activity of an oncogenic kinase directly and eventually can be used to test primary cells from 
cancer patients.  In this chapter, design and characterization of a peptide reporter for PKC is 
presented.  The rationale behind these assays is discussed in chapter 4. 
6.2 Experimental 
6.2.1 Materials 
All chemicals were purchased from Sigma (St. Louis, MO) unless specifically 
indicated.  Protein kinase Cα was obtained from Invitrogen (Carlsbad, CA). 
6.2.2 Synthesis and Purification of PKC Reporters 
A series of 6-FAM labeled PKC reporters were synthesized by collaborators from the 
Waters’ lab (University of North Carolina, Chapel Hill) using the method described in 
chapter 3.2.2.  Purifications were performed on anAtlantis Prep OBD dC-18 semi-preparative 
column in an RP-HPLC system (Waters Corporation, Milford, MA) using a simple linear 
gradient from 100% standard A (95% water, 5% acetonitrile, 0.1% TFA) to 100% B (95% 
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acetonitrile, 5% water, 0.1% TFA) in 60 minutes.   
6.2.3 Fragment Standards Generated by Trypsin and Pronase E  
Trypsin and pronase E were used to generate fragment standards of the PKC peptide 
reporters.  Trypsin from bovine pancreas was dissolved in 10 mM HEPES buffer to 
approximately 0.001 mg/mL.   Pronase E from Streptomyces griseus was dissolved in 10 mM 
Hepes buffer to approximately 0.002 mg/mL.  100 μM peptide was incubated with 10-50 
μg/mL Trypsin or 20-100 μg/mL Pronase E in a final reaction volume of 100 μL at 37°C.  10 
μL aliquots were removed after 3, 5, 10, 20, 30, 40, and 60 min time and the reaction was 
halted by heat inactivation at 95°C for 4 min.  Each aliquot was diluted and analyzed with 
CE-LIF (ProteomeLab PA800, Beckman Coulter, CA) and MALDI-TOF (Applied 
Biosystems 4800, CA). 
6.2.4 Separation of PKC Reporters and Phosphorylated Products by CE 
A wide range of electrophoretic buffers from pH 1.5 to pH 11 were screened for 
separation of PKC reporters.  Buffers utilized included: CAPS (pH 11) with and without SDS; 
Sodium borate buffer (pH 8.5) with and without SDS;  tris/tricine (pH 7-8.2) with and 
without dynamic coating and detergents including PEG (polyethylene glycol), PVP 
(polyvinylpyrrolidon), coating reagent 3 (Caliper Life Sciences, Hopkinton, MA), EOTrol 
(Target Discovery, Palo Alto, CA),SDS,SDC, CTAB and DTAB; Tris-HCl (pH 6-7); 
NaH2PO4 (pH 7); Sodium citrate (pH 3-3.5); Sodium phosphate (pH 2-3) with and without 
the additives SDC, SDS, α- cyclodextrin and β-cyclodextrin; and phosphoric acid with and 
without α- cyclodextrin and β-cyclodextrin.  An optimum separation was achieved in 250 
mM phosphoric acid (pH 1.5).  For electrophoresis performed on the PA800 system, 
capillary length was 30 cm with an effective length of 20 cm and a voltage of -10 kV (30 μm 
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id) or -6 kV (50 μm id) was applied to the outlet.  For electrophoresis performed on the 
custom-built system, capillary length was 42 cm with an effective length of 21 cm and a 
voltage of -8 kV (30 μm id) or -5.5 kV (50 μm id) was applied to the outlet. 
6.2.5 Cell Lysate Degradation of the PKC Reporter 
6.2.5.1 Lysate Preparation 
The OPM2 cells were maintained and lysate was prepared as described in chapter 4.2. 
6.2.5.2Protein Concentration Measurement 
Protein concentration of the OPM-2 cell lysate was measured using the 
fluorescamine-BSA standard curve method described in chapter 4.2.   
6.2.5.3 Degradation Assay 
OPM-2 cytosolic lysates were utilized to assess degradation of designed PKC 
reporters (sequences are listed in Table 6.2).  Each peptide (50 μM) was incubated 
individually in the lysate at 37°C in ECB buffer and aliquots were removed at various time 
points.  The reaction was stopped by heating at 95°C for 4 minutes.  Each aliquot was 
analyzed by CE‐LIF.  The method used for integrating the results was same as described in 
chapter 4.3. 
6.2.6 Kinase Assay 
1 µM peptide (Table 6.2) was incubated at 30°Cin assay buffer (20 mM HEPES, 100 
mM MgCl2, 1 mM CaCl2), 1 mM ATP, 1X lipid activator (100 µg/ml phosphatidylserine, 10 
µg/ml diacylglycerol, 10 mM DTT and 0.03% Triton X100) and 20 ng PKCα in a total 
reaction volume of 100 µL.  Aliquots were removed at various timepoints and the reaction 
halted by incubation at 95
o
C for 4 min.   
6.2.7 Cell Lysate Kinase Assay 
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6.2.7.1 Activation of PKC in the OPM-2 Cells 
 OPM-2 cells were maintained in culture as described above.  Cell activation was 
achieved by introducing 0.2 µM Phorbol 12-Myristate 13-Acetate (PMA) solution into the 
culture medium for 10 minutes and removed prior to lysis.  
6.2.7.2 Cell Lysate Kinase for PKC Reporters. 
After pre-exposure to PMA and subsequent rinses in ECB, the OPM-2 pellet was 
suspended in 100 µL ofprotein extraction buffer (Thermo scientific, MA) with 10 µL 
protease and phosphatase inhibitor cocktails (Thermo scientific, MA).  The lysates were 
clarified by centrifugation at 4 °C for 10 min at 14,000 x g.  The supernatant was obtained 
and its protein concentration determined by the protein-fluorescamine method described in 
4.2.5.2.  
The cell lysate kinase assays were performed utilizing the selected reporters Scram-
PKC as a control and WKpG-PKC as the peptide which has the longest lifetime in the lysate.  
The kinase assays were performed at 30°C using the conditions described in the above 
Kinase assay section with the following exceptions: Peptide concentration was 50 µM and 
total protein concentration was 3 mg/mL.   Aliquots were removed at 0, 10, 20, 30, 45 and 60 
min and halted by incubation at 95
o
C for 4min.   
6.2.8 Loading Reporters into Intact Cells  
Approximately 2x10
6 
OPM-2 cells were collected and centrifuged at 0.8 x g for 2 min.  
The supernatant was removed and the cell pellet was washed 3-4 times with 10 mL ice-cold 
ECB.  The cell pellet was resuspended in 100 µL ECB buffer containing 30 µM PKC 
reporters.   The mixture was incubated in a humidified incubator at 37ºC with 5% CO2.  After 
20 minute incubation, the cell pellet was washed with 10 mL ECB and incubated with 0.05% 
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trypsin for 5 minutes to eliminate extracellular peptide binding to the cell surface.  Finally, 
the cells were washed 3 times with 10 mL ECB. 
6.3 Results and Discussion 
6.3.1 Design of Protein Kinase C Reporters 
6.3.1.1 Selection of Substrate Sequence for PKC Reporters 
Since MM cells probably recruit multiple PKC isozymes to support tumor cell growth, 
most of the PKC inhibitors in clinical trials are not specific to a certain isozyme.  So a 
reporter designed to assess the activity of PKC in MM cells should not be specific to a single 
PKC isozyme.  Thus, peptide sequences which are not isozyme specific were utilized as the 
substrate component for the designed PKC reporters.  A substrate RFRRFQTLKIKAKA for 
PKC has been utilized by the Newton and Tsien Labs for prior analyses.
19
  This substrate has 
been shown to measure PKC activation in cells and possesses excellent affinity and 
specificity for PKC.  Additionally, it is not isozyme specific.  Based on these properties, this 
sequence was chosen as the substrate portion for the designed PKC reporters. 
6.3.1.2 Selection of Protectides 
Based on the successful experience of the design of BCR-Abl reporters using 
protectides, the same strategy was used here for designing of reporters for PKC.  The results 
of the BCR-Abl degradation assay indicated that a larger and stabilized protectide provided 
better protection against degradation.  However, the crosslinking reaction and purification of 
reporters with stabilized protectides were both time consuming and expensive.  For the PKC 
reporters, an alternate series of WKWK protectides designed by the Waters lab were 
utilized.
20
 
The WKWK protectide sequence (Ac-RWVKVNGOWIKQ) contains an N-G beta 
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hairpin which provides the stable beta bend structure and orients the W-W pair diagonal to 
each other.  These W residues located on the two arms of the beta hairpin were selected on 
the basis of the NMR structure of the Trpzip peptide 
21
 in which the two W residues appear to 
form a cleft for the two K residues one position away from each W.   This provides a short-
range electrostatic interaction that further stabilizes the beta hairpin structure.  Additionally, 
this beta hairpin has a net charge of +3, making it more soluble and easier to synthesize and 
purify.  An unstructured version of this peptide with all the same residues in a scrambled 
sequence (Ac-KWVRWIKQVKNG) was designed to utilize as a control.   
 For the other two protectides utilized, several changes were made to the WKWK 
protectide to make the beta hairpin structure more stable.  First, a D-proline was added into 
the WKWK peptide to replace the N residue in beta turn i+1 position (called WKpG; Ac-
RWVKVpGOWIKQ-NH2).  This could potentially cause additional folding and possibly 
increase the cross strand interactions to make a more stable beta hairpin.  The other 
protectide, termed TrpK (Ac-RWVWVNGOKILQ-NH2) which has a K at position 4 and W 
at position 9, has been shown to create an aromatic pocket where the lysine side chain can 
participate in a cation-pi interaction.  Table 6.1 lists the percent folded values of these 
peptides based on one-dimensional NMR studies.
22
  These peptides are the most well-folded 
series of small beta hairpin peptides published to date. 
20
 
Additionally, for this specific application, the O residue for all protectides was 
replaced by K linked with 6-FAM for CE-LIF detection.   Compared to the protectides 
discussed in chapter 3, these structures are larger in size and do not require crosslinking 
reactions for stabilization because of their high degree of folding.  Based on these collective 
properties, they were chosen as a new generation of protectides for the PKC reporters (Figure 
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6.2-6.3) 
6.3.2 Selection of Separation Buffer  
The critical role the buffer plays in separations has been discussed in chapter 4.  In 
order to achieve full resolution of the PKC reporter and its phosphorylation product, a wide 
range of separation buffers (pH range 1.3-11) was tested.  First, the focus was on neutral or 
basic buffers (pH 6-11) since the FAM label on the peptides is pH sensitive.  In an acidic 
environment, the FAM tag is not as fluorescent making the detection limit worse.23 Buffers 
and additives tried are listed and described below.  No peak was detected when the following 
buffers were utilized: 50-100 mM Tris-HCl (pH 6-7); 100-150 mM tris/tricine buffer (pH 
7.2- 8.2); 50-200 mM borate (pH 8.2-8.7); and 10-150 mM CAPS (pH 11).  At these pH 
values, the capillary surface is negative and the peptides have a net positive charge.  It is 
likely that the peptides adhered to the capillary wall during the separation.   
In an attempt to prevent the adherence of the peptide to the capillary wall, detergents 
above and below the critical micelle concentration (CMC) were added to the buffers.  
Detergents utilized included the following: sodium dodecyl sulfate(SDS), sodium 
deoxycholate(SDC), cetyltrimethylammonium bromide(CTAB) and dodecyl trimethyl 
ammonium bromide (DTAB).  Buffer concentrations ranged from 50 – 300 mM in 10 mM 
increments and SDS or SDC was added to a final concentration of 1 – 10 mM (1 mM 
increments) or 10 – 150 mM (10 mM increments), respectively.  While some additives did 
seem to reduce wall interactions and yield sharper peaks, there were no separations with full 
resolution of the parent and phosphorylated pair.  Separations were attempted in both positive 
and negative polarity mode, yet no separation of the analytes was seen.  Figure 6.4 shows the 
separation result of Scram-PKC and its phosphorylated product in100 mM borate with 100 
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mM SDS (pH 8.5).  Other results not shown here demonstrated similar trends in migration 
time shifts yet no separations were observed.  These results demonstrated that these additives 
and buffers were not suitable for non-phosphorylated/phosphorylated pair separation. 
In addition, some polymers were utilized asdynamic coatings in an attempt to reduce 
or eliminate wall interactions.  Polymers tested include: EOTrol (described in chapter 4), 
Coating reagent 3 (proprietary formula), and different formulations of PVP and PEG.  These 
coatingsdid help in that they seemed to limitthe wall interactions and allowed for peptide 
elution, but yielded no separations, wide peaks and unacceptable electropherograms. 
Finally, even though the fluorescence of the analytes is decreased at low pH values, 
acidic buffers were tested for their effectiveness.  Sodium citrate (pH 3) and sodium 
phosphate (pH 2 – 3) at concentrations ranging from 20 – 300 mM (10 mM increments) were 
encouraging, yielding sharp peaks and in some cases, split peaks.  Based on these results, 
more acidic conditions were utilized in an attempt to further resolve the peaks from one 
another.  Phosphoric acid (pH 1.3 - 2) at concentrations ranging from 100 – 500 mM (50 mM 
increments) were tested and full resolution of the analytes was seen at a concentration of 250 
mM (Figure 6.5).  At this acidic pH, the charge on the capillary surface is positive.  However, 
the net charge on the peptides is also positive eliminating well interaction, giving them high 
electrophoretic motilities toward the outlet and resulting in good resolution. 
6.3.3 Fragment Generation by Trypsin and Pronase E 
The importance of generating degradation standards for CE analysis has been 
discussed in chapter 5.  For these peptide reporters, there are over than 100 different 
fluorescent fragments depending on sequence.  Normal SPPS methods to individually 
generate the standards would be labor intensive, time consuming and expensive.  To simplify 
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this process, a method utilizing the poteases trypsin and Pronase E was developed to generate 
a full repertoire of fragments standards.  The basic idea for using Pronase E to generate 
fragments for the peptides was discussed in chapter 4 and additional details for more 
applications was discussed in chapter 5.  As was mentioned in chapter 5, Pronase E is an 
inexpensive and fast method to generate fragments, but it is also non-specific.  For this set of 
PKC reporters, it can potentially generate more than 100 fragments.  However, as there are 
several K and R resides in the peptide sequences, the more specific protease trypsin could be 
utilized to cleave on the carboxy side of these positively charged residues to generate fewer 
peaks for testing of separation conditions.  For example, when the reporter Trpk-PCK was 
incubated with trypsin, 7 peptides (6 fragments plus the intact parent) were generated (Table 
6.4).  All 7 peptides were fully resolved in the 250 mM phosphoric acid buffer selected 
earlier (Figure 6.6).  On the timescales of this experiment, no evidence of the fragments 
generated by cleavage on the carboxy-terminus of the K residues in the protectide was seen.  
Ideally, separation of all fragments from the parent peptide and phosphorylated product 
would be achieved prior to the degradation assay utilized to determine reporter lifetime. 
The pronase E assay described in 6.2.3 was used for generating the fluorescent 
fragments of the peptide WKpG-PKC (Table 6.2).  MALDI results indicate that all fragments 
were generated by cleavage on residues not in the protectide were seen within the timescales 
of this experiment.  These fragments were used for standards in future experiments. 
6.3.4 Cell Lysate Degradation Assay 
The reason for testing the resistance to degradation using cell lysate has been 
discussed in Chapter 4.  Here the same cell lysate assay was used to screen the PKC reporters.  
OPM-2 cells were pre-incubated with PMA which is known as a PKC activator and lysate 
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was prepared as described in 6.2.6.1 and the degradation assay was performed as described in 
6.2.6.3.  The hydrolytic stability of all peptides was initially measured by incubation of the 
peptides in a cell lysate with 3 mg/mL total protein concentration, followed by analysis with 
CE-LIF.  The amount of breakdown was quantified by comparing the peak areas on the CE 
trace of the degradation products to that of the intact reporter at different time points (Figure 
6. 7).  According to these results, the control peptide Scram-PKC was 80% degraded within 
10 min and completely degraded within 20 min.  The WKWK-PKC and TrpK-PKC 
displayed increased lifetimes, with showing approximately 24% and 27% degradation seen 
after 10 min and 75% and 80% after 60 min respectively.  WKpG-PKC was particularly 
stable, with about 47% intact after 60 min.  These results show that the lifetime of the 
peptides with the protectide was increased compared with the linear control.  Also observed 
was that stabilization of the peptide by cross-linking of the beta hairpin protectide further 
increased the lifetime of the reporter, similar to what was seen with the Abl reporters (chapter 
4).  The highly folded protectides used for this work have a stable structure even they are not 
cross-linked, which leaves peptide reporters less likely to insert into the cleft where the active 
site is located.  Also, utilization of D-proline in the hairpin structure of the WKpG- protectide 
probably serves the dual purpose of being more stable due to folding and being less 
recognized by the peptidase, leading to the WKpG-PKC peptide’s longest lifetime in the 
lysate.  This result demonstrated that the incorporation of non-native amino acids in the 
protectide might be a viable alternative for increasing the hydrolytic stability overall. 
6.3.4 Kinase Assay  
In order to determine whether the designed reporters were phosphorylated with 
greater efficiency than the substrate peptide alone, the peptides Sub-PKC (substrate only) and 
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the other 3 designed reporters (WKWK-, WKpG- and TrpK-PKC) were 
incubated with PKC α kinase using the conditions described in 6.2.6.  At varying times, 
amount of phosphorylated peptide was measured using CE.  The peptide that showed the 
fastest phosphorylation was the Sub-PKC substrate, reaching about 90% phosphorylation 
within 20 min.  The other 3 peptides were phosphorylated slower than Sub-PKC yet similar 
to one another (Figure 6.8).  This result shows that it is likely that the protectide is blocking 
substrate recognition.  Here, (PEG)2 was used  in the design which might be too short, 
leading to a decrease in the interaction with the kinase.  In order to potentially increase 
substrate recognition, the optimal length of linker needs to be investigated in future studies. 
6.3.5 Cell Lysate Kinase Assay Utilizing OPM-2 Cells 
To determine if the peptides can be phosphorylated by an MM cell line OPM-2, a cell 
lysate kinase assay was performed for the control peptide (Sub-PKC) and the designed 
reporter WKpG-PKC which had the longest lifetime in the cell lysate studies. The assay was 
performed as described in 6.2.7 and the different time points of each sample were analyzed 
by CE.  Both peptides show both degradation and phosphorylation to varying degrees over 
time (Figure 6.9).  WKpG-PKC showed more resistance to degradation than Sub-PKC but 
slower phosphorylation at 10 min. The phosphorylation percentage increased and reached the 
peak (about 20%) at 40 min while the Sub-PKC and phosphorylation Sub-PKC was fully 
degraded at that time. The results show successful phosphorylation of the peptide by this 
PKC-activated OPM-2 cell lysate. 
6.3.6 Loading of PKC Reporters into OPM-2 Cells 
Toevaluate designed reporters in intact cells in future work, these reporters need to be 
loaded into a living cell.  See Chapter 4 for several loading methods utilized by the Allbritton 
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Lab and others in the past.  Microinjection was utilized in the Abl work described in Chapter 
4.  It is a reliable method that can be utilized to reproducibly deliver any compound into cells 
and it is compatible with instrumentation in the Allbritton Lab; however, it is extremely 
tedious, time consuming and expensive, so it alternatives were explored.  The TAT sequence 
(RKKRRQRRR) is a highly positively charged and derivate from the transduction domain 
from the HIV.24  It can be attached to substrates and act as a carrier to transfer the contents 
inside the cell.  The actual mechanism of this transfer is still unclear. The PKC reporters are 
highly positively charged, similar to TAT, so they may transverse the cell membrane using a 
similar mechanism.  To investigate this, the reporters in ECB were simply incubated with the 
intact cells for 20 min and imaged to determine reporter location.  It was found that the 
reporter was successfully loaded into the OPM-2 cells (Figure 6.10).  Further characterization 
of this loading strategy can be investigated in the future. 
6.4 Conclusion and Future Work 
The WKWK series peptides containing both a rigid beta-turn and strong side chain 
interactions were used as protectides for PKC reporters.  Incubation of the reporters in a 
cytosolic lysate indicated that these protectides provide resistance to reporter degradation 
without further cross-linking modifications.  Although these protectide-substrate conjugated 
reporters were phosphorylated less than the substrate only, further investigation could focus 
on optimizing the linker length to address this problem.  It was concluded that the use of a 
highly structured peptide, like those described herein, is a viable way to add resistance to 
proteolysis without using cyclic peptides.  Moreover, the combination of peptide structure 
with non-natural amino acids, such as D-proline, can possibly provide even greater resistance 
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to proteolysis.  This would be a good starting point for further modification of the protectide 
to resist proteolytic degradation. 
  
 181 
 
6.5 Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Schematic representation of the primary structure of conventional, 
novel, and atypical protein kinase Cs.  Indicated are the pseudosubstrate domain (pink), 
C1 domain comprising one or two Cys-rich motifs (purple), C2 domain (blue) in the 
regulatory domain, and catalytic region including the C3 (ATP binding region, orange) 
and C4 substrate-binding lobe (green).  nPKCs have a C2-like domain and aPKCs have 
only one Cysteine-rich motif. 
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Figure 6.4 The Scram-PKC and phosphorylated Scram-PKC showed no separation in 
100 mM Borate and 100 mM SDS buffer pH 8.2  
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Figure 6.5 The WKpG-PKC and phosphorylated WKpG-PKC (Pho- WKpG-PKC) are 
separated in 250 mM Phosphoric acid pH 1.5.  The Pho- WKpG-PKC peak increased 
over time when incubated with PKC α. 
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Figure 6.6 The Trpk-PKC and degradation fragments (Table 5.3) indicated by arrows 
are separated in 250 mM Phosphoric acid pH 1.5. 
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Figure 6.7 Degradation of the designed PKC reporters in OPM-2 cell lysate. 
The substrate with the fastest degradation was Scram-PKC while WKpG-PKC 
processed the longest life time in this lysate 
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Figure 6.8 Phosphorylation of the designed PKC reporters by PKC α kinase. 
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Figure 6.9 Phosphorylation of the designed PKC reporters in OPM-2 cell lysate. 
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Figure 6.10 PKC reporter WKpG-PKC loading into OPM-2 cells.  Control cells 
incubated without reporters (A-B) and experimental cells incubated with Scram-PKC 
for 20 min (C-D).  (A) and (C) are transmitted light images and (B) and (D) are 
fluorescent images. 
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Table 6.1 Average percentage of folded peptide
20
 
Peptide name Sequence Percent Folded 
Scram WKWK 
Ac-KWVRWIKQVONG-NH2 
0% 
WKWK 
Ac-RWVKVNGOWIKQ-NH2 
95% 
WKpG 
Ac-RWVKVpGOWIKQ-NH2 
Not determined 
TrpK 
Ac-RWVWVNGOKILQ-NH2 
100% 
 
 
 
Table 6.2 Designed peptide reporters for protein kinase C 
 
Name  Sequence 
Sub-PKC (control 1) 
Scram -PKC(control 2):  
FAM- RFRRFQTLKIKAKA-NH2 
Ac-K(FAM)WVRWIKQVKNG-PEG2-RFRRFQTLKIKAKA-NH2 
WKWK-PKC  Ac-RWVKVNGK(FAM)WIKQ-PEG2-RFRRFQTLKIKAKA-NH2 
WKpG-PKC:  Ac-RWVKVpGK(FAM)WIKQ-PEG2-RFRRFQTLKIKAKA-NH2 
Trpk-PKC:  Ac-RWVWVNGK(FAM)KILQ-PEG2-RFRRFQTLKIKAKA-NH2 
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Table 6.3 PKCα and OPM-2 cell lysate kinase assay conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buffer 
HEPES 20 mM 
ATP 1 mM 
MgCl2 100 mM 
Substrate PKC reporters 400 nM-10 µM 
Kinase or cell lysate 
PKCα or OPM-2 cell 
lysate 
100 ng/assay 
or 3 mg/mL 
Cofactors 
PS 100 µg/ml 
DAG 10 µg/ml 
CaCl2 1 mM 
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Table 6.4 Fragments of TrpK-PKC generated by Trypsin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fragment Expected 
MW (Da) 
Observed 
MW 
(Da) 
Ac-RWVWVNGK(FAM)KILQ-PEG2-
RFRRFQTLKIKAKA 
3872 3873 
Ac-RWVWVNGK(FAM)KILQ-PEG2-
RFRRFQTLKIKAK 
3801 3804 
Ac-RWVWVNGK(FAM)KILQ-PEG2-
RFRRFQTLKIK 
3602 3604 
Ac-RWVWVNGK(FAM)KILQ-PEG2-
RFRRFQTLK 
3360 3362 
Ac-RWVWVNGK(FAM)KILQ-PEG2-RFRR 2742 2743 
Ac-RWVWVNGK(FAM)KILQ-PEG2-RFR 2586 2588 
Ac-RWVWVNGK(FAM)KILQ-PEG2-R 2283 2284 
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Chapter 7: Development of Protectide-degron Reporters to Measure 
Proteasome/Ubiquitination Activity 
7.1 Introduction 
7.1.1 Proteasome/Ubiquitination Degradation Pathway 
Intracellular proteolysis is a natural process that controls the turnover of proteins and 
regulates the amount of antigens (peptides) present.  This degradation process involvesthe 
ubiquitin-proteasome system (UPS) as well as several aminopeptidases and endopeptidases. 
Mature proteasome is also called 26S, which is a large multi-subunit complex (~24MD).   Its 
structure is a hollow cylinder with a lid and a base. This hollow cylinder, called 20S, is the 
catalytic core that possesses all proteolytic activity including caspase, trypsin, and 
chymotrypsin-like activities.  The lid and base include the 19S regulatory domain, in which 
the recognition sites for ubiquitinated proteins are located.
1-3
  In eukaryotic cells, a protein is 
first degraded by the 26S proteasome into oligopeptides that are either of the correct size or 
require further proteolytic degradation at the N terminus.  Aminopeptidases in the cytosol or 
endoplasmic reticulum (ER) trim the N-extended precursors to the correct length.  
Proteasome products and other oligopeptides undergo degradation by endo- and 
exopeptidases.  This intracellular degradation is shown in Figure 7.1.
4-8
 
7.1.2 Ubiquitination and Degrons  
For protein degradation by a proteasome to occur, the target protein is first 
covalently-modified with ubiquitin (76 amino acids) on a lysine side chain.  This covalent 
modification is termed ubiquitination.
5,9
  During this process, a series of enzymes participate 
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in the ubiquitination of a protein.  The initial step is ubiquitin activation involving ubiquitin-
activating enzyme (E1), the second step is ubiquitin conjugation by ubiquitin-conjugating 
enzyme (E2), and the third step is transfer of ubiquitin to the target protein by ligases (E3).  
The proteasome substrate proteins are poly-ubiquitinated after these steps and the 
polyubiquitinated proteins are recognized by 19S, unfolded by other enzymes, and then 
degraded by 20S. 
4-6,8
  In the degradation possess, specific degradation signals (degrons) are 
the minimal domain on the substrate proteins that are sufficient for both recognition and 
degradation by the proteasome.
10-12
  There are different degrons which have been found 
including N-degrons, phospho-degrons, oxygen-dependent degrons and hydrophobic degrons. 
12,13
 
N-degrons are the simplest degrons which are single N-terminal amino acids.  N-
terminus positive residues (K, R) or hydrophobic residues (L, I, Y, F, W) on the proteins 
induce rapid degradation of the protein by the proteasome.  These residues process a higher 
affinity for E3 ligase than other residues. The degradation of β-galactosidase in cytosol is an 
example of this behavior.  The half-life of β-galactosidase in cytosol was 3 minutes with 
these N-terminal residues while the half-life was over 20 hours with other residues at the N-
terminus.
14,15
 
Phospho-degrons may contain one or more phosphorylated residues in certain 
sequence motifs.  Proteins such as cyclin E, c-myc, and notch1 possess a phospho-degron 
with a sequence motif of φ-X-φ-φ-φ-pT/S-P-P-X-pS/T where φ represents a hydrophobic 
residue, X represents any amino acid and pT/S represents phosphorylated T or S.  These 
degron sequences are recognized and bind to the binding partner in the E3 ligase complex.
13
  
There is a double phosphorylated degron [D(pS)GφX(pS)] which is derived fromβ-catenin.  
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It has been demonstrated that this degron is recognized widely by cullen-dependent E3 
ligases.
16
 
 Hydroxylated prolines can also act as degrons as they are one of the oxygen-
dependent degrons.  For example, a specific prolyl hydroxylase uses molecular oxygen to 
hydroxylate one or two specific prolyl residues on protein HIF-1 and form the oxygen-
dependent degrons on it.  This process leads the HIF-1α protein to be ubiquitinated by an E3 
ligase complex and leads to rapid subsequent proteasomal degradation.
17
  Additional studies 
show that the sequence LA(HyP)YIP, which is derived from hydroxylated HIF-1, binds to 
its partner in the E3 ligase complex at even higher affinity. 
18
 
Proteins possessing an exposed hydrophobic region are often not folded or assembled 
properly.  These hydrophobic regions could be ubiquitinated and then rapid degradation of 
these proteins by the proteasome was observed.  Therefore these hydrophobic regions are 
thought to act as degrons.
19
 
7.1.2 Targeting theProteasome in Multiple Myeloma (MM) 
The proteasome handles the degradation of various intracellular proteins including the 
proteins essential for cell cycle progression, inflammation, transcription, DNA replication, 
and apoptosis as well as misfolded and oxidized proteins.
20
  Not surprisingly, abnormal  
proteolytic activity of the proteasome has been associated with different diseases.
21
  The 
increased proteasome activity has been found in malignant transformation in a number of 
diseases including chronic lymphocytic leukemia,
22
 colon cancer,
23
 mantle cell lymphoma,
24
 
and multiple myeloma (MM).
25
 
Currently, the ubiquitin-proteasome pathway is an attractive therapeutic target in 
MM
25
  and initial studies showed remarkable anti-tumor activity due to the proteasome 
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inhibitor Bortezomib.  Moreover, the anti-MM activity of Bortezomib has been detected in in 
vivo studies, which led Bortezomib to be the first inhibitor of proteasome to be tested in 
humans and be approved for MM treatment by the FDA.
26-28
  Result of current investigations 
demonstrates that the plasma cells in MM are selectively sensitive to inhibitors of 
proteasome; however, the treatment of MM cell lines also showed resistance to 
Bortezomib.
29-32
  Thus, a method which has the ability to measure relevant proteasome 
activity in primary tumor samples would provide important information on treatment 
responsiveness and resistance in patients.  Development of proposed intracellular proteasome 
activity reporters will allow novel measurements of proteasome activity in clinical samples. 
7.2 Experimental 
7.2.1 Material 
All peptides listing in Table 6.1 were purchased from Anaspec (Fremont, CA) or 
synthesized by SPPS. 
Peptide Suc-LLVY-AMC, Ada-Y-(Ahx)
3
-L
3
-Vinyl sulfone, 20S proteasome, 
ubiquitin-conjugate specific antibody and Hela S100 kit were ordered form Biomol 
(Farmingdale, NY).  Proteasome inhibiter Bortezomib was courtesy of collaborator 
(Voorhee’s lab, UNC).  Ready gels and tricine sample loading buffer were purchased from 
Biorad (Hercules, CA), polyvinylidene fluoride (PVDF) membrane and pre-stained protein 
weight marker from Invitrogen (Carlsbad, CA) and fluorescent peptide weight marker, 
Phototope®-HRP Western Blot Detection System from cell signaling (Boston, MA). 
7.2.2 20S Assay 
Peptide Suc-LLVY-AMC, Trpzip2, UXBB1 and UXBB2 were used for 20s 
proteasome degradation assay.  The assay was modified based on the protocols from Biomol 
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(Farmingdale, NY).
33
 The assay was performed in assay buffer (50 mM Tris.HCl, 25mM 
KCl 10mM NaCl and 1mM MgCl2).  The assay conditions are listed in the Table 7.3. 
The substrate Suc-LLVY-AMC were incubated with purified 20S proteasome (2 
μg/mL,) in assay buffer described above at 30°C in the absence or presence of  20S inhibitors 
i.e. bortezomib (100 nM) or Ada-Y-(Ahx)
3
-L
3
-Vinyl sulfone (2 μM).  For the control 
experiment using inhibitors, 20s were pre-incubated with inhibitors for 10 min at 30
o
C to 
allow inhibitor/enzyme interaction.
33
  The 40 µl reaction mixture was added into microplate 
(Molecular devise, CA) and incubated at 30
o
C for 60 minutes. The fluorescence intensity was 
monitored by M5 at spectrum mode (Ex.: 380nm; Em: 460nm) during the assay.
34
 
The assay using Trpzip2, UXbb2 and UXBB2 peptides, the peptide (75 μM ), 20s 
proteaome (10 µg/mL) and inhibitors were mixed together and incubated at 37° C in the 
absence or presence of  20S inhibitor i.e. bortezomib (100 nM) or Ada-Y-(Ahx)
3
-L
3
-Vinyl 
sulfone (2 μM).  The assay buffer is same as above.  The reaction mixtures were removed at 
different time point and heated to 95
o
C for 4 minute to stop the reaction.  Degradation was 
quantified by CE analysis of aliquots taken from the reaction mix after various times of 
incubation. 
7.2.3 Ubiqutination (S100 lysate-based) Assay 
The HeLa S100 cytosolic lysate based assay was modified from the protocol provided 
by Biomol.
35
   Peptides ( Table 7.1) (10 µM) was incubated with a Hela S100 cell lysate (1 
mg/ml protein concentration) in the presence of DTT (2 mM) with the following reagents in 
the reaction mixture:  ubiquitin (100 μg/ml) or methylated ubiquitin (MeUb, 100 μg/ml), 
ubiquitin aldehyde (20 μg/ml), and ATP (5 mM).  In addition, all reaction mixtures possessed 
a cocktail of peptidase inhibiter cocktails (1x) and proteosome inhibitors Bortezomib (2 
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μg/ml) to minimize peptidase and proteasome activity.  Detail of reaction condition is listed 
in Table 7.3.  Reaction mixtures were incubated at 37°C from 0 minutes to 2 hours and were 
stoppedby heating at 95°C for 5 minutes.  
7.2.4 Gel Electrophoresis  
The reaction mixtures with FAM labeled peptide were analyzed by gel 
electrophoresis.  A 16.5% Tris/Tricine gel were used for analysis and the buffer 
Tris/Tricine100mM with 0.1% SDS was used as electrophoretic buffer.  5 μL reaction 
mixture quenched with 5 μL tricine sample loading buffer were loaded into the gel.  The pre-
stained SDS-PAGE molecular weight markers (Cell signaling, MA) and fluorescent gel 
molecular weight marker (Biorad, Hercules, CA) were loaded into the same gel.  The 
constant current mode (35 μA) was used for separation.   After the separation, the gels were 
ready to use for fluorescent imaging and Western blot analysis.  Fluorescent imaging of the 
gels were obtained by Typhoon imager (GE, MA) at excitation 488 nm and emission 530 nm.   
7.3 Results and Discussion 
7.3.1 Design of Proteasome Reporter 
The proteasome reporter was designed to have five components.  The first part was a 
degron which could be recognized by ubiquitinaton related enzymes (E1, E2 and E3).   The 
second portion was a protectide composed of a beta hairpin sequence designed for physically 
hindering the peptidase catalytic activity (see Chapter 2 for details on protectide design).The 
third part was a linker designed to minimize interference and to connect the protectide to the 
degron sequence.  The fourth unit was a fluorophore used for detection and quantification.  
Finally, at minimum, a single lysine must exist for linking of the structure to ubiquitin.  The 
general structure design can be seen in Figure 7.2.  The details for each component are 
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discussed below. 
7.3.1.1 Selection of Degrons 
Critical to reporter development is the ability to design peptide-based molecules that 
can be ubiquitinated; these peptides are called degrons.   A reporter of proteasome activity 
has to possess the ability to act as a substrate for the E3 ligase complex, and thus must be 
ubiquitinated first.  The proposed design for this work utilizes a degron appended to a 
protectide.  After screening the literature for existing degrons, the simplest one was an N-
degron.  An N-degron including the preferred sequence FIFSTDTGPGG, which has been 
shown to be recognized by some E3 ligases, was used for one design of the 
reporter.
36
However, since not all proteins or peptides have E3 ligase‐binding activity when 
an N‐degron is present,15,36 a phospho-degron D-pS-GIH-pS sequence was utilized as well.  
This sequence containing the double phosphorylated serine residues was derived from the 
proteins β-catenin and Iκ-B and showed good ability to be recognized by different E3 ligases.  
Therefore, it was chosen as a degron for one of the designed proteasome reporters.
16
 
7.3.1.2 Selection of Protectide 
In the reporter design, the protectide portion is intended to shield the reporter from 
intracellular proteases other than the proteasome as described in Chapters 3 and 6.  The 
protectide was expected to prevent rapid degradation due to proteases so that the degron-
protectide may be long-lived enough to be de-ubiquitinated and serve as a proteasome 
substrate.  For initial reporter design, the protectide termed Trpk pocket was chosen because 
of its outstanding resistance to degradation.
37
 
7.3.1.3 Details of the Design of Proteasome Reporters 
Two versions of reporters were designed for the experiments: BC-4 (the phospho-
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degron only) and BC-4-Trpk (the phosphodegron-protectide complex).  Both are shown in 
Table 6.3.   First, the phospho-degron D-pS-GIH-pS sequence was utilized for both designs. 
The peptide sequence AWQQQSYL was used as a linker located between the N-terminal 
lysine and the phospho-degron.  Previous results have shown that different distances between 
the degron and the ubiquitinated lysine can yield differences in ubiquitination.
16
  The linker 
AWQQQSYL leads to the maximal ubiquitination when this peptide was incubated with 
purified E1, 2, and 3 ligase mixtures.
16
  Additionally, two lysines were added to the C-
terminal end of the BC-4 peptide.  Therefore, the whole structure included more lysines on 
the N and C termini that could act as potential ubiquitination sites.BC-4-TrpK possesses a 
short and flexible polyethyleneglycol (PEG) linker connected the phospho-degron sequence 
to the C-terminal protectide.  Again, two lysines were added to the end of the structure at the 
C-terminus.  Both designed peptides are linked to 6-FAM for detection on the side chain of a 
lysine located on the protectide domain.  These designed peptides were custom made from 
Anaspec with purity greater than 75%.   
7.3.2 20S Assay 
The 26S proteasome is the central protease in the ubiquitin pathway of protein 
degradation.
5
  The actual proteolytic reactions are performed at the core of this enzyme 
complex, i.e. the 20S proteasome. The 20S core is a cylindrical-shaped protease of 
approximately 700kDa.   The 20S proteasome is predominantly degrades entirely unfolded 
polypeptides. 
38
 
In order to test the 20S proteolysis ability, the known substrate peptide Suc-LLVY-
AMC was used to test the assay conditions.  The peptide Suc-LLVY-AMC is a 7-amino-4-
methylcoumarin (AMC) labeled peptide that acts as a substrate for 20S chymotrypsin-like 
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hydrolysis.39  The intact peptide is non-fluorescent.  However, cleavage of AMC from the 
peptide by the 20S proteasome generates strongly fluorescent AMC that was monitored 
fluorimetrically at excitation 353 nm and emission 442 nm.39  The reaction mixture showed 
increasing of fluorescence over the time; however, for the control (buffer and substrate only) 
assay and the assay with different inhibitors, no obviously change of fluorescence was 
detected (Figure 7.3). The result also showed 1µM Bortezimib could fully inhibit the 20S 
degradation activity. 
The non‐cyclized protectide conjugates UXBB1 and UXBB2 were tested in an in 
vitro assay as 20S proteasome substrates.  In addition, another well-folded peptide, Trpzip 2, 
was also tested in a 20S proteasome degradation assay.  Trpzip 2 contained a PEG linker to 
the FAM and was utilized as the control since it was both well-folded and readily available.   
 Both non-cyclized peptides were found to be 20S proteasome substrates, with 27% of 
UXBB1 and 21% of UXBB2 degraded within 60 minutes under the conditions described 
above.  In the presence of bortezomib, a 20S proteasome inhibitor, only 2% of UXBBI and 1% 
of UXBB2were degraded (Table 6.3). These data indicate that the uncrosslinked protectide 
conjugates can serve as substrates for the catalytic core of the proteasome.  During identical 
degradation experiments, Trpzip 2 was undegraded bothin the presence and absence of the 
inhibitor.  This data indicates that well-folded peptides like Trpzip 2 were more stable the in 
20S proteasome assay and can therefore serve as a protectides. 
7.3.3 Ubiquitination assay and Characterization 
HeLa S100 cytosolic lysates were utilized to measure degron‐protectide 
ubiquitination.  HeLa S100 lysates provide the full cell compliment of E1, E2s, 20S and 26S 
proteasome, deubiquitinylating, and E3 enzymes and are ideal for demonstrating ubiquitin-
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proteasome mediated conjugation/degradation.  Therefore, this is a widely used assay for 
studies of the ubiquitin/proteasome system.  For this work, commercially available HeLa 
S100 lysates were purchased from Enzo Life Sciences (Farmingdale, NY).   
To determine whether the phosphodegron-protectide could be ubiquitinated by an E3 
ligase complex within the S100 cell lysate, the peptides Trpzip 2 (control 1), BC-4 (control 2) 
and BC-4-TrpK at concentrations of 10 nM to 10 μM were tested as substrates for the E3 
ligase complexes by incubation with the S100 lysate, ATP, protease inhibitors cocktail (1X) 
and ubiquitin/methylated ubiquitin (MeUb) for varying times (1 minute to 2 hours).  The 
details of the assay conditions are listed in Table 6.4. MeUb possesses a methyl group on 
every lysine side chain so that ubiquitin chain extension cannot occur and only a single 
ubiquitin can be added to a lysine on the targeted substrate. Ubiquitin aldehyde blocks 
enzymes that act to deconjugate ubiquitin from lysines.  Protease inhibitor cocktail blocks  
the proteases responsible for hydrolyzing the peptides.  Ubiquitinated peptides were  
accumulated in the reaction mixture over time.  The amount of peptide, degron‐protectide 
and ubiquitinated degron‐protectide were assayed by SDS-PAGE gel electrophoresis. 
The aliquots removed at different time points were separated utilizing SDS-PAGE.  
The fluorescence of the labeled peptides was detected using a Typhoon fluorescence imager 
(General Electric). When BC-4-Trpk (MW: 4776.2 Da) was incubated with the HeLa cell 
lysate containing MeUb, a fluorescence band not present at time zero was detected near 14 
kDa (Figure7.4).  The expected molecular weight of MeUb-BC-4-Trpk is 13.6 kDa.  This 
new fluorescent band increased in intensity over time.  A faint second band can be seen at a 
higher molecular weight (approximately 21 kDa) in Figure 7.4.  Since the addition of two 
MeUb is expected to increase the molecular weight to 22 kDa, this band was most likely due 
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to the addition of a MeUb on two different lysines of BC-4-Trpk.  No fluorescent bands were 
detected when BC-4-Trpk peptide was not added to the reaction mixture.  This result 
suggests that BC-4-Trpk was ubiquitinated by ligase complexes in the S100 cell lysate. 
An identical experiment was performed incubating the peptide BC-4 (degron 
sequence only (MW: 3250.4 Da) with the HeLa cell lysate and MeUb for varying times 
(Figure 7.5).  Mulitple band sat a higher molecular weights were detected and increased over 
time.  These new bands possessed a molecular weight consistent with that expected for 
MeUb-BC-4.  These bands were most likely due to the addition of a MeUb or endogous 
ubiquitin on different lysines of BC-4.  These results suggest that the degron alone was 
ubiquitinated in the cell lysate. 
In order to confirm ubiquntination of the designed peptides, additional experiments 
were performed using BC-4-Trpk and Trpzip2 peptides (Figure 7.6).  The BC-4-Trpk 
reaction mixture incubated for 0 hours (lane 3) did not possess the higher molecular weight 
band while that incubated for 2 hours (lane 4) possessed a band at the expected migration 
time of MeUb-BC-4-Trpk. In addition to these bands, there is a band appearing at a lower 
molecular weight than the BC-4-Trpkband.  This result suggests that breakdown of this 
peptide has begun to occur. This degradation can be due to either the proteasome or 
peptidases present in the lysate mixture. Incubation of BC-4-Trpk with the lysate in the 
absence of MeUb (lane 5) yielded a very faint band at the higher molecular weight. This faint 
band was most likely due to addition of endogenous ubiquitin from the lysate to BC-4-Trpk. 
Trpzip 2 was used simultaneously as a negative control for this assay.  Recall that Trpzip 2 is 
a readily available and well-folded peptide that is not supposed to be an ubiquitination 
substrate.  An S100 lysate assay of Trpzip 2 with MeUb (lane 6) did not yield higher 
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molecular weight products.  This result suggested that Trpzip2 was not ubiquitinated, which 
was expected because Trpzip 2 possesses no degron and should not be ubiquntinated. The 
BC-4-Trpk assay using non-methylated ubiquitin (Ub) (lanes 7 and 8) also showed higher 
molecular weight bands.  Finally when hexokinase and glucose were added to the HeLa 
lysate containing MeUb, the assay result of BC-4-Trpk(lane 9) yielded a small amount of 
product at the higher molecular weight. Hexokinase in the presence of glucose consumes 
endogenous lysate ATP, making the ATP-dependent ubiquitination of BC-4-Trpk by the E 
ligases less likely due to the decreased concentration of ATP in the reaction mixture.  
7.4 Conclusion and Future Works 
The above results show that peptides with phospho-degrons are ubiquitinated in a 
HeLa S100 cell lysate assay system.   All these results strongly suggest that these peptides 
were ubiquitinated.   Furthermore, the data support the feasibility of developing degron-
protectides as reporters for proteasome activity based on the successful ubiquntination of the 
degron-containing peptides.   The S100 cell lysate assay could be a fast and low cost method 
utilized for screening ubiquntination and usefulness of different substrates.  In the future, the 
different components of the designed proteasome reporter peptides could be optimized.  
Peptides with different degrons could be tested for their ability to be ubiquntinated and for 
their rate of ubiquitination in this S100 lysate assay system.   Also, the distance between the 
target lysine and the degron could be investigated and optimized.  Finally, these optimized 
proteasome reporters have the potential to be utilized for measuring proteasome activity in 
intact cells. 
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7.5 Figures and Tables  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Intracellular protein degradation pathways.  The majority of intracellular 
protein is ubiquitinated and degraded into peptides by the proteasome. These peptides 
are degraded further by peptidases into amino acids which can be used for protein 
synthesis by the ribosome. 
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Figure 7.2 General design of the degron-protectide peptide reporters for proteasome 
activity. There are five key parts: degron, linker, protectide, fluorophore and lysine 
residues (K). 
 
 
 
 
 
 
 
 
Degron Beta hairpin 
(protectide) 
 
Fluorophore 
Linker 
K 
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Figure 7.3 20S assay of known substrate Suc-LLVY-AMC with inhibitors at different 
concentrations.  Inhibitor1 is Ada-Y-(Ahx)3-L3-Vinyl sulfone and Inhibitor 2 is 
Bortezimib.  
 
 
A
FU
 
Time (min) 
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Figure 7.4 Fluorescence image of gel electrophoresis of peptide BC-4-TrpK 
uiquntination assay using S100 cell lysate and methylated ubiquitin (MeUb).  The band 
above BC-TrpK (13.6 kD) is a single MeUb-linked peptide (MeUb-BC-4-TrpK).  The 
other two bands could be multi-ubiquitinated peptide due to ubiquitination from 
endogenous ubiquitin. The bands below the BC-TrpK are probably peptide degradation 
products. 
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Figure 7.5 Fluorescence image of gel electrophoresis of peptide BC-4 ubiquitination 
assay using S100 cell lysate.  The bands above the BC-4 (3.6 kD) could be mono-, di- 
and tri-ubiquitinated products with methylated ubiquitin (MeUb).  The bands below 
the BC-4 are probably peptide degradation products. 
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Figure 7.6 Fluorescence image of gel electrophoresis of peptide Tripzip and BC-4-TrpK 
in aubiquitination assay using S100 cell lysate.  Tripzip 2 shows no ubiquitination (6) 
while the BC-4-Trpk showed successful ubiquitination after 1 (7) and 2 hours (8).  The 
control lysate (2), peptide only (5) and –ATP (9) samples shows none or very little 
ubiquitination. Lane 1 is fluorescent protein molecular weight ladder.  Lane 3 and 4 are 
the ubiquitination assay utilizing MeUb at 0 (3) and 2 hours (4). 
 
 
 
                 1       2         3         4         5        6         7        8        9 
BC-4-Trpk           -          +         +         +        -          +        +        + 
Trpzip2               -          -          -          -        +          -         -         - 
ATP                    +         +         +         +        +         +         +        - 
MeUb                 +         +         +          -        +          -         -        + 
Ub                      -          -          -          -         -          +        +        - 
Time(hr)                2           0           2           2          2           1          2         2 
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63 
32 
 
21 
 
 
11 
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Table 7.1 Peptides for 20S assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide Sequence 
Trpzip 2 FAM-PEG6-SWTWENGKWTWK-NH2 
UXBB1 K(FAM)WpGR-(PEG2)2-EAIYAAPFAKKK-NH2 
UXBB2 K(FAM)WpGRE-(PEG2)2-EAIYAAPFAKKK-NH2 
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Table 7.2 Designed peptide reporters of proteasome and degron. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
peptide Sequence 
BC-4 KAWQQQSYLD-pS-GIH-pS-GATTTAP-K(5-FAM)-KK-NH2 
BC-4-Trpk 
KAWQQQSYLD-pS-GIH-pS-GATTTAP-(PEG2)-RWVWVNG-
K(5-FAM)-KILQ-KK-NH2 
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Table 7.3 20S assay condition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assay Buffer 
50mM Tris.HCl 
25mM KCl 10mM 
NaCl 
1mM MgCl
2
 
20s Proteasome 2 µg/mL 
Substrate: SUC-LLVY-AMC 75 µM 
Inhibitor: 
Ada-Y-(Ahx)
3
-L
3
-Vinyl sulfone 
2 µM 
SDS 0.03% 
T 30
o
C 
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Table 7.4 20S degradation result of different peptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitor 1: Ada-Y-(Ahx)3-L3-Vinyl sulfone     
Inhibitor 2: Bortezimib 
 
 %  left ( 30mins) 
 
%  left ( 60mins) 
 
Trpzip2 100 100 
Trpzip2 (+inhibitor1) 100 100 
Trpzip2(+inhibitor2) 100 NA 
UXBB1 91 63 
UXBB1(+inhibitor1) 100 98 
UXBB1(+inhibitor2) NA 98 
UXBB2 89 69 
UXBB2(+inhibitor1) 100 98 
UXBB2(+inhibitor2) NA 98 
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Table 7.5  S100 lysate assay (ubiquntination assay) condition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HeLa S100 1 mg/mL 
Ubiquitin (or methylated 
ubiquitin) 
100 µg/mL 
DTT 2 mM 
20s Inhibiter 200 µg 
Ubiquitin aldehyde 20 µg/mL 
Protease Inhibitor 100 dilution 
Substrate 10 µM 
ATP 5 mM 
Reaction buffer 1 X 
Temperature 
37
o
C 
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